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ABSTRACT 
 
It is recommended that infants are breast fed exclusively for the first six months of life; 
however, less than 15% of infants in the United States are meeting this recommendation and only 
44% of infants receive human milk to any extent at six months of age (Gartner et al., 2005; Li et 
al., 2005; Eidelman et al., 2012).  Nearly 40% of infants receive formula as their sole source of 
nutrition by one month of age (Li et al., 2005).   Probiotics and/or prebiotics are increasingly 
supplemented in infant formulae and are generally regarded as safe in healthy infants without 
concern for growth or adverse effects (Holscher et al., 2012a; Holscher et al., 2012b).  
Additionally, human milk oligosaccharides have been shown to enhance intestinal maturation in 
vitro.  Thus, we aimed to assess 1) the effects of the probiotic Bifidobacterium animalis 
subspecies lactis, 2) the prebiotics galacto- and fructo-oligosaccharides, and 3) the individual and 
combined effects of specific human milk oligosaccharides as means to narrow the compositional 
gap between human milk and infant formula.  The central hypothesis of this research was that 
specific ingredients would enhance gastrointestinal health and development.   
Addition of probiotics to infant formula may positively affect immune function in non-
exclusively breastfed infants. Probiotics are live microorganisms that, when administered orally 
in adequate amounts, survive the digestion process and confer a benefit to the host (FAO/WHO, 
2001).  Our first study investigated the effects of an infant formula containing the probiotic 
Bifidobacterium animalis subspecies lactis (B. lactis) on intestinal immunity and inflammation 
(Holscher et al., 2012a).  Six-week-old healthy, full-term infants (n=172) were enrolled in a 
prospective, randomized, double-blind, controlled clinical trial with 2 groups studied in parallel 
to a breastfed comparison group.  Formula-fed (FF) infants were randomized to partially 
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hydrolyzed whey formula (CON), or the same formula containing 10
6
 CFU B.lactis/g (PRO) for 
6 weeks.  Fecal secretory IgA (sIgA), calprotectin, lactate, and stool pH were assessed at 
baseline, 2, and 6 weeks.  Anti-poliovirus-specific IgA and anti-rotavirus-specific IgA in stool 
were assessed at 2 and 6 weeks.  Among vaginally-delivered FF infants (n=39), PRO 
consumption increased (p<0.05) fecal sIgA, compared to CON.  Anti-poliovirus-specific IgA 
concentration increased (p<0.05) in all infants consuming PRO; whereas anti-rotavirus-specific 
IgA tended to increase (p=0.056) with PRO consumption in cesarean-delivered infants (n=14).  
Anthropometrics and tolerance did not differ significantly between FF infants.  In conclusion, 
infants consuming formula with B. lactis produced feces with detectable presence of B. lactis and 
augmented sIgA concentration.  Furthermore, cesarean-delivered infants consuming B. lactis had 
heightened immune response, as evidenced by increased anti-rotavirus- and anti-poliovirus-
specific IgA following immunization. These results demonstrate that negative immune-related 
effects of not breast feeding and cesarean delivery can be mitigated by including B. lactis in 
infant formula and thereby provide infants a safe, dietary, immune-modulating bacterial 
introduction. 
As infant formula containing prebiotics may beneficially impact gastrointestinal tolerance 
and composition of the commensal microbiota, we assessed gastrointestinal tolerance and fecal 
microbiota, pH, and short-chain fatty acid (SCFA) concentrations of infants consuming formula 
with or without prebiotics in a second trial utilizing the a similar model as that discussed above 
(Holscher et al., 2012b).  Prebiotics are selectively fermented ingredients that result in specific 
changes, in the composition and/or activity of the GI microbiota, thus conferring benefit(s) to the 
host (Gibson et al., 2010).  FF were randomized to consume a partially hydrolyzed whey formula 
with (PRE) or without (CON) 4g/L of galacto-oligosaccharides and fructo-oligosaccharides (9:1) 
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for 6 weeks.  Fecal bacteria, pH, and SCFA were assessed at baseline, 3, and 6 weeks.  
Caregivers of subjects recorded stool characteristics and behavior for 2 days before the 3- and 6-
week visits.  Feces from infants fed PRE had a higher absolute number (p=0.0083) and 
proportion (p=0.0219) of bifidobacteria than feces of CON-fed infants and did not differ from 
feces of BF.  BF had a higher proportion of bifidobacteria than CON (p=0.0219) and a lower 
number of Clostridium difficile than FF (p=0.0087).  Feces from FF infants had higher 
concentrations of acetate (p<0.001), butyrate (p<0.001), propionate (p<0.001) and total SCFAs 
(p=0.0230) than BF; however, fecal pH was lower (p=0.0161) in PRE and BF than CON. 
Prebiotic supplementation did not alter stool patterns, tolerance, or growth.  To conclude, infant 
formula containing the studied oligosaccharides is well-tolerated, increased abundance and 
proportion of bifidobacteria, and reduced fecal pH in healthy infants. 
Human milk oligosaccharides (HMOs) are abundant in human milk (> 15 g/L) and 
associated with enhanced intestinal maturation in vitro (Kuntz et al., 2008; Kuntz et al., 2009).   
Therefore, we aimed to: 1) determine the time course of impact of a model HMO, and; 2) assess 
the induction of ‘epithelial differentiation’ by three individual HMOs using an in vitro epithelial 
model of the crypt-villus axis.  In study 1, pre-confluent HT-29, pre-confluent Caco-2Bbe, 
confluent Caco-2Bbe, and post-confluent Caco-2Bbe cells were cultured individually and  
randomized to 1 of 5 treatments:  lacto-N-neotatraose (LNnT) at 0, 100, 200 or 400 mg/L or 
energy control (0 mg/L plus lactose + N-acetylglucosamine) for 24, 48 or 72 hours of incubation 
to assess effects on proliferation and differentiation.  In study 2, pre-confluent HT-29, pre-
confluent Caco-2Bbe, and post-confluent Caco-2Bbe cells were randomized to treatments with 
one of three HMOs at the following levels for 72 hours of incubation: a) LNnT at 0, 20, 200 or 
2000 mg/L or energy control (0 mg /L plus lactose + N-acetyllactosamine); b) 2'-fucosyllactose 
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(2'FL) at 0, 20, 200 or 2000 mg/L or energy control (0 mg/L plus lactose + fucose); c) 
6'sialyllactose (6'SL) at 0, 40, 400, 4000 mg/L or energy control (0 mg/L plus lactose + sialic 
acid). Dependent variables in study 2 included proliferation, differentiation, cell cycle analysis, 
apoptosis, disaccharidase activity, and absorption and barrier function via modified Ussing 
chambers.  In study 1, compared to 0 mg/L control, LNnT decreased cell proliferation in pre-
confluent HT-29 cells at 48 (p<0.05) and 72 hours (p<0.01) and pre-confluent CaCo-2Bbe at 72 
hours (p < 0.01). Alkaline phosphatase (AP) activity increased over time and was highest in post-
confluent CaCo-2Bbe cells (p<0.001); however, was not affected by treatment at any time point.  
In study 2, HT-29 cell proliferation was reduced (p<0.05) with 200 and 2000 mg/L LNnT, 2000 
mg/L 2'FL, and 400 and 4000 mg/L 6'SL. CaCo-2Bbe cell proliferation was reduced (p<0.05) 
with 2000 mg/L LNnT, 2000 mg/L 2'FL and 4000 mg/L 6'SL.  Reduced proliferation was 
associated with cell cycle arrest in the G2/M phase in pre-confluent HT-29 cells treated with 200 
(p=0.027) and 2000 mg/L (p=0.0033) of LNnT or 2000 mg/L 2'FL (p=0.021) and pre-confluent 
Caco-2Bbe cells treated with 4000 mg/L 6'SL. Interestingly, in pre-confluent HT-29 cells, 
treatment with 4000 mg/L 6'SL resulted in S phase arrest (p<0.001), whereas there was a trend 
(p=0.058) for cell cycle arrest in the G2/M phase with 400 mg/L 6'SL. Differentiation was 
increased 31% (p=0.030) in HT-29 cells and sucrase activity increased 54% (p=0.036) in post-
confluent CaCo-2Bbe cells with 2000 mg/L 2'FL.  Transepithelial resistance increased 21% 
(p=0.002) in post-confluent Caco-2Bbe cells with 200 mg/L LNnT.  In summary, inhibition of 
proliferation was associated with enhanced epithelial differentiation.  Well-differentiated cells 
had greater digestive and barrier function when treated with 2'FL and LNnT, respectively. 
Further study is needed to assess whether synergist effects occur following concomitant 
administration of HMOs.      
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Thus, we evaluated the effects of concomitant administration of 3'-sialyllactose (3'SL), 
2'FL, and 6'SL utilizing the same model of the crypt-villus axis discussed above.  Cells were 
randomized to 1 of 18 treatments for 72 hours of incubation:  individual HMO treatments at low 
and high doses (3'SL at 0.2 and 1.0 g/L, 6'SL at 0.4 and 1.0 g/L, 2'FL at 0.2 and 2.0 g/L), 
concomitant treatments of the previous HMOs at both low and high doses, and controls (0 g/L, 
media, 4 g/L total HMO, and lipopolysaccharide (LPS)).   Pre-confluent HT-29 cells had reduced 
proliferation (p<0.05) with individual high dose treatments of 6'SL and 2'FL, concomitant 
administration of the high doses of the HMOs (p<0.05), and total HMO (p<0.001).  Pre-
confluent CaCo-2Bbe cells were less sensitive to reduction in proliferation where only high dose 
concomitant treatments containing 2'FL (p<0.01) significantly reduced proliferation in addition 
to the total HMO (p<0.001).  Interestingly, 2'FL did not enhance differentiation in HT-29 cells as 
we had previously shown; however, it did increase (p<0.05) differentiation in pre-confluent 
Caco-2Bbe cells.  HMO treatments did not enhance AP activity, a general marker of 
differentiation, nor did it increase disaccharidase activity in post-confluent Caco-2Bbe cells.  
Disaccharidase activity was only affected by time (p<0.001) in that lactase activity was higher at 
12 days as compared to 21 days and the opposite was found for sucrase activity.  Apoptosis and 
necrosis were both significantly decreased (p<0.001) in post-confluent CaCo-2Bbe cells treated 
with 4.0 g/L HMO as compared to 0 g/L control.  In summary, HMO treatment consistently 
inhibits proliferation with some associated enhancement of epithelial differentiation.  Although 
total pooled HMO reduced apoptosis and necrosis, it is less clear if this is associated with 
functional outcomes.  Further study is needed to determine if these effects translate in vivo; 
however, results of our in vitro model of the crypt-villus axis suggest addition of HMOs may 
promote intestinal maturation.   
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CHAPTER 1 
 
LITERATURE REVIEW 
 
 
INTRODUCTION 
 
Exclusive breastfeeding is recommended for infants until six months of age; however, 
less than 15% of infants in the United States receive human milk exclusively during this time 
period and less than half of infants (44.3%) are breast fed to any extent at six months of age 
(Gartner et al., 2005; Li et al., 2005; Eidelman et al., 2012).  By one month of age, nearly 40% of 
infants are receiving formula as their only source of nutrition (Li et al., 2005).    
The gastrointestinal (GI) tract undergoes numerous structural and functional changes 
after birth as it adapts to extrauterine life (Catassi et al., 1995; Carver and  Barness, 1996).  In 
addition to these changes, colonization of the infant’s GI tract is also occurring, with the mode of 
delivery and feeding method impacting the types and numbers of bacteria that will initially take 
residence (Bettelheim et al., 1974; Weng and  Walker, 2006).  Human milk is considered the 
gold standard of nutrition for infants as it contains a number of functional nutritive and non-
nutritive components which aid in the maturation and protection of the neonatal GI tract, as well 
as the composition of the microbiota (Carver and  Barness, 1996; Walker, 2000).  Furthermore, 
breastfed infants have been shown to have decreased risk for a number of diseases including 
diarrhea, lower respiratory tract infections, urinary tract infections, bacteremia, and necrotizing 
enterocolitis (NEC) (Istre et al., 1985; Lucas and  Cole, 1990; Dewey et al., 1995; Lopez-
Alarcon et al., 1997; Schanler et al., 1999; Bachrach et al., 2003; Marild et al., 2004; Morrow et 
al., 2004; Newburg et al., 2005; Sisk et al., 2007).      
The health benefits associated with human milk are numerous.   However, as a large 
proportion of U.S. infants lack exposure to human milk during the neonatal developmental 
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period, it is essential that further research is done to narrow the compositional gap between 
human milk and infant formula and identify ingredients which can be added to formulae to 
impart some of the benefits of breast feeding on to formula-fed infants.   
Probiotics and/or prebiotics are increasingly supplemented in infant formulae and are 
generally regarded as safe in healthy infants without concern for growth or adverse effects 
(Braegger et al., 2011).  The most commonly studied probiotics include bifidobacteria and 
lactobacillus.  Our research investigating the effects of Bifidobacterium animalis subspecies 
lactis within infant formula can be found in Chapter 3.  Combinations of galacto-
oligosaccharides (GOS) and fructo-oligosaccharides (FOS) are among the most commonly 
studied prebiotics.  Our work, detailed in Chapter 4, also contributes to this body of literature.  
Benefits associated with supplementation of infant formula with either probiotics or prebiotics 
include increased fecal bifidobacteria, enhanced immunity, and decreased incidence of some 
infections and allergies.   
Recently, human milk oligosaccharides (HMOs) have been added to the list of human 
milk components that may contribute to neonatal intestinal development (Kuntz et al., 2008; 
Kuntz et al., 2009).  Additionally, HMOs have been associated with the enhancement of 
commensal bacteria within the GI microbiota as well as decreased incidence of several infectious 
diseases in infants (Newburg et al., 2005; Sela and  Mills, 2010).  As such, HMOs have become 
an obvious choice for potential ingredients worthy of investigation for addition to infant 
formulae.  Chapters 5 and 6 will detail our work on the effects of HMOs on intestinal cell 
maturation in vitro.  
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PROBIOTICS 
Probiotics are live microorganisms that, when consumed in adequate amounts survive 
digestion and provide benefit to the host (FAO/WHO, 2001).  Supplementation of infant formula 
with probiotics has been suggested as a means to modify the intestinal microbiota in ways that 
may benefit the health of the developing infant (Saavedra, 2001).  Specifically, the establishment 
of the infant’s microbiota is thought to have an integral role in immune development.  It is well 
established that bifidobacteria dominate the microbiota of breastfed infants (Yoshioka et al., 
1983; Matsuki et al., 1999; Harmsen et al., 2000).  Further, the dominance of bifidobacteria is 
thought to contribute to some of the health benefits breastfed infants possess as compared to 
formula-fed infants including lower incidence of infection and gastrointestinal disturbances 
(Weizman et al., 2005).  
Of particular interest with regard to immunomodulatory effects of probiotics is the 
stimulatory effect bifidobacteria have been shown to have on the production of secretory 
immunoglobulin A (sIgA) (Fukushima et al., 1998; Mullie et al., 2004; Rautava et al., 2006).  
SIgA is the predominant mucosal immunoglobulin within the GI tract and plays an integral role 
in the innate mucosal response to microbial and dietary antigens.  Human milk provides 
exogenous sIgA to infants, and significantly higher concentrations of fecal sIgA have been 
reported in breastfed versus formula-fed infants during the first six months of life (Koutras and  
Vigorita, 1989; Kohler et al., 2002).   
One of the most commonly studied probiotic bacteria is Bifidobacterium animalis 
subspecies lactis (B. lactis).  Supplementation of infant formula with B. lactis has been shown in 
a number of studies to support normal growth in infants (Langhendries et al., 1995; Ziegler et al., 
2003; Saavedra et al., 2004; Braegger et al., 2011).   Further, supplementation with B. lactis has 
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also been associated with a number of positive clinical outcomes including reduction in 
antibiotic use, febrile episodes, number of severe illness days, otitis media infection, and GI 
infections (Phuapradit et al., 1999; Saavedra et al., 2004; Weizman et al., 2005; Rautava et al., 
2009).  Additionally, consumption of B. lactis has been reported to improve allergy-related skin 
conditions (Isolauri et al., 2000; Sistek et al., 2006). 
Research has shown that supplementation of B. lactis also beneficially impacts immune 
defense by increasing fecal sIgA levels (Fukushima et al., 1998; Mohan et al., 2008; Holscher et 
al., 2012a) In a small clinical trial by Fukushima and colleagues, toddlers ages 15 to 31 months 
receiving formula containing B. lactis for three weeks had significantly higher levels of fecal 
sIgA and anti-poliovirus specific IgA (Fukushima et al., 1998).  Preterm infants were reported to 
have increased fecal sIgA concentrations following B. lactis supplementation during the first 
three weeks of life (Mohan et al., 2008).  Fecal sIgA levels have also been investigated in healthy 
full-term infants with conflicting results.  A trial by Bakker-Zierikzee and colleagues (2006) in 
which B. lactis containing formula was initiated soon after birth did not find an effect of 
supplementation on fecal sIgA levels through 32 weeks of life.  In contrast, our laboratory group 
found that supplementation of B. lactis over a six-week period beginning at 6 weeks of age 
resulted in a greater increase in fecal sIgA concentrations when compared to control infants.  
Furthermore, infants in the probiotic group also had greater concentrations of vaccine specific 
antibodies following rotavirus and poliovirus immunizations (Holscher et al., 2012a).  These 
results suggest that one benefit of a balanced GI microbiota influenced by probiotic 
supplementation is to provide stimulatory support to the mucosal immune system.      
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PREBIOTICS 
Prebiotics are selectively fermented food ingredients that promote specific changes in 
composition and/or activity of bacteria already present within the GI microbiota thus promoting 
host health and well-being (Gibson et al., 2010).  Oligosaccharides which are resistant to 
digestion by human enzymes arrive intact to the colon and stimulate both the number and 
concentration of fecal bifidobacteria (Moro et al., 2002).  It is hypothesized that this 
predominance of bifidobacteria in the microbiota contributes to some of the health benefits 
associated with breastfeeding. 
Infant formulae are commonly supplemented with the prebiotics GOS and FOS which are 
derived from plants or produced by technological means (Kunz and  Rudloff, 2006).  These 
prebiotic oligosaccharides are composed of the monosaccharides fructose, galactose, and glucose 
(Kunz and  Rudloff, 2006).  GOS consist of galactose chains linked by β1-6 linkages bound to a 
terminal glucose by α 1-4 linkage  and fructose monosaccharides are linked in FOS via β1-2 
linkages (Figure 1.1 and 1.2) (Tungland and  Meyer, 2002; Kunz and  Rudloff, 2006). 
GOS and FOS have been reported in a number of trials in healthy infants to be safe 
without concern for adequate growth or adverse effects (Moro et al., 2002; Schmelzle et al., 
2003; Haarman and  Knol, 2005; Knol et al., 2005a; Knol et al., 2005b; Waligora-Dupriet et al., 
2007; Ziegler et al., 2007; Costalos et al., 2008; Braegger et al., 2011; Holscher et al., 2012b).  
Additionally, supplementation of infant formula with varying blends and concentrations of GOS 
and FOS has been shown to increase fecal bifidobacteria in healthy term infants (Moro et al., 
2002; Schmelzle et al., 2003; Boehm et al., 2004; Bakker-Zierikzee et al., 2005; Haarman and  
Knol, 2005; Knol et al., 2005a; Knol et al., 2005b; Holscher et al., 2012b).  Further, infant trials 
have found outcomes such as decreased incidence of infection and atopic dermatitis to be 
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associated with infants receiving formula supplemented with GOS/FOS (Moro et al., 2006; 
Arslanoglu et al., 2008; Gruber et al., 2010). 
Additional benefits of supplementation of the non-digestible prebiotic oligosaccharides 
GOS/FOS include fermentation by the GI microbiota which results in production of short chain 
fatty acids (SCFA).  SCFA have a number of functions including energy salvage, stimulation of 
sodium and water absorption, reduction of colonic pH, and inhibition of overgrowth of 
pathogenic bacteria within the GI microbiota (Wang and  Gibson, 1993).  Supplementation of 
GOS/FOS to infant formula has been reported in several clinical trials to increase fecal SCFA 
and decrease fecal pH (Bakker-Zierikzee et al., 2005; Knol et al., 2005b; Bakker-Zierikzee et al., 
2006; Holscher et al., 2012b). 
In summary, the growing literature supports the safety and tolerance of infant formula 
containing prebiotics and suggests that supplementation of GOS/FOS results in an increased 
proportion of bifidobacteria and an associated lower fecal pH and enhanced fermentation profile. 
 
HUMAN MILK OLIGOSACCHARIDES 
Human milk plays an integral role in the development of the GI tract of infants.  
Composed of a magnitude of nutrients and bioactive components which are uniquely adapted to 
meet the needs of the growing infant, human milk stimulates structural and functional maturation 
of the GI tract (Donovan, 2006).   HMOs are one such abundant component of human milk 
which contributes to the maturation of the neonatal intestine (Kuntz et al., 2008; Donovan, 
2009).  Human milk contains nearly 200 unique oligosaccharides, a proportion of up to 15 grams 
per liter which varies between women and temporally (Coppa et al., 1999; Ninonuevo et al., 
2006; Wu et al., 2010).  Moreover, HMOs are the third most abundant solid component 
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following lactose (70 g/L) and lipids (40 g/L) and narrowing surpassing protein (8g/L) (Coppa et 
al., 1999; Chaturvedi et al., 2001a; Ninonuevo et al., 2006; German et al., 2008b; Thurl et al., 
2010; Wu et al., 2010).   Human milk is unique in its oligosaccharide composition and 
complexity.  Milk from animals is almost completely lacking in free complex oligosaccharides 
(Kunz et al., 2000).  Infant formula is devoid of HMOs, only plant derived or synthetic FOS and 
GOS are currently supplemented (Tungland and  Meyer, 2002; Kunz and  Rudloff, 2006).  
A number of functions have been associated with HMOs including enhanced immunity 
and prebiotic effects (Newburg et al., 2005; LoCascio et al., 2007).  Additionally, recent studies 
have shown that HMO may impact maturation of the neonatal GI tract (Kuntz et al., 2008; Kuntz 
et al., 2009).  
 
Human Milk Oligosaccharide Structures 
HMOs, synthesized in the mammary gland, range in length from simple three sugar units 
up to more complex thirty-two sugar units (Ninonuevo et al., 2006; Wu et al., 2010).  They are 
composed of the five monosaccharides:  D-glucose, D-galactose, N-acetylglucosamine, L-
fucose, and sialic acid (N-acetylneuraminic acid) (Figure 1.3) (Kunz et al., 2000).  HMOs 
consist of neutral and acidic fractions which are determined primarily by the presence of sialic 
acid groups which produce an anionic charge.  The core structures of HMOs consist of N-
acetylglucosamine monomers linked to galactose monomers via β1-3 or β1-6 linkages creating 
the backbone with lactose at the reducing end (Kunz et al., 2000).  Attachment of fucose and/or 
sialic acid further diversify the oligosaccharides by their linkages at varying positions within the 
core region and along the core elongation chain (Kunz et al., 2000).  Sialic acid added to 
galactose on the reducing end lactose by α2-3 and/or α-2-6 linkages forms 3'-sialyllactoase and 
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6'-sialyllactoase (Figure 1.4), respectively; additionally, fucose added to lactose in α1-2 or α 1-3 
linkages forms 2’-fucosyllactose (Figure 1.5) and 3'-fucosyllactose, respectively (Bode, 2009; 
Wu et al., 2010).  These short-chain oligosaccharides are termed trisaccharides (Bode, 2009).  
Lacto-N-neotetraose, a type II tetrasaccharide, is made up galactose β1-4 linked to N-
acetylglucosamine linked to the galactose of the lactose molecule by a β1-3 linkage (Figure 1.6) 
(Kunz et al., 2000).  In the more complex milk oligosaccharides, up to 15 N-acetyllactosamine 
repeating units are added to lactose to elongate the oligosaccharide; sialic acid may be added to 
the lactose or polylactosamine backbone in α 2-3 and/or α 2-6 linkages or fucose may be added 
in α1-2, α 1-3 and/or α1-4 linkages (Kunz et al., 2000; Bode, 2006). 
Genetic differences also influence oligosaccharide structures and variation within 
populations.  The addition of fucose monosaccharides is related to the varying levels of structural 
complexity because of the presence of three different fucosyltransferases that are genetically 
determined (Thurl et al., 1997).  The oligosaccharides present in human milk vary between 
women based on genetics.  Oligosaccharides closely follow the Lewis blood group classification 
which is based off of a Lewis gene coding for an α1-3/4 fucosyltransferase and a secretor gene 
coding for an α1-2 fucosyltransferase (Thurl et al., 1997; Stahl et al., 2001).   The most 
prevalent, α1-2-fucosyltransferase, is found in approximately 70% of the population who are 
Lewis blood group Le(a-b+) while the second most prominent transferase,  α1-4-
fucosyltransferase, is present in approximately 20% of the population who are classified as 
Le(a+b-) and attaches fucose to a subterminal N-acetylglucosamine of type 1 chains through α1-
4 linkages (Thurl et al., 1997; Stahl et al., 2001).  Women who possess the α1-2 
fucosyltransferase have 2'fucosyllactose present in their breast milk and are classified as 
secretors; women possessing the α1-4 fucosyltransferase lack 2'fucosyllacatose and are classified 
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as nonsecretors (Thurl et al., 1997; Stahl et al., 2001).  The remaining 10% of the population 
have milk samples which are void of α1-4 linked fucose residues and are classified as Lewis 
blood types Le(a-b-) (Thurl et al., 1997; Stahl et al., 2001).     
Several different sialyltransferases, which add sialic acid residues to the lactose 
backbone, are also present in addition to the different fucosyltransferase thus adding to the 
complexity of oligosaccharide structures within human milk (Kunz et al., 2000).  The varying 
degrees and combinations of fucosylation and/or sialylation result in approximately 200 distant 
HMOs, with the majority being fucosylated or neutral oligosaccharide (Ninonuevo et al., 2006).  
The two major groups of HMOs are classified as neutral oligosaccharides and anionic 
oligosaccharides (Ninonuevo et al., 2006; Wu et al., 2010).   Neutral oligosaccharides are made 
up of galactose, n-acetylglucosamine, lactose and fucose, while anionic oligosaccharides are 
made up of the same oligosaccharides with the addition of sialic acid (Ninonuevo et al., 2006).   
 
Variations in Human Milk Oligosaccharides  
HMOs vary among individuals and over the course of lactation with the general temporal 
trend being a gradual decline in oligosaccharide concentrations (Miller et al., 1994; Coppa et al., 
1999; Chaturvedi et al., 2001a; Thurl et al., 2010).  The variation among individuals can be 
categorized into four groups based on associated with the Lewis blood type and secretor status 
genes and thus the resulting structure of the terminal group of the oligosaccharides and 
oligosaccharide patterns (Thurl et al., 1997).  As most studies quantifying HMO focus on either 
neutral or acidic fractions but not both, it has been difficult to gain a true understanding of 
oligosaccharide composition and trends.  However, a recent study by Thurl and colleagues 
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provided analysis of both fractions thus providing a more complete picture of the total 
oligosaccharide content of human milk (Thurl et al., 2010).  
Thurl and co-workers (2010) investigated the concentrations of major neutral and acidic 
oligosaccharides in 30 German women from postpartum days 3 to 90.  They reported that the 
neutral and acidic oligosaccharide fractions of human milk are primarily made up of fourteen 
neutral oligosaccharides, of which concentrations vary significantly between secretors and non-
secretors, and six major acidic oligosaccharides which do not significantly differ based on 
secretor categorization (Thurl et al., 2010).  Table 1.1 and Table 1.2 summarize the average 
concentrations (g/L) of the most prevalent neutral and acidic oligosaccharide fractions present in 
each of the three groups.  The sum of the 14 neutral oligosaccharides and 6 acidic 
oligosaccharides quantified in this study are reflective of the total neutral and total acidic 
oligosaccharide fractions that have been individually reported in other trials (Miller et al., 1994; 
Coppa et al., 1999; Ninonuevo et al., 2008). 
Women in the study conducted by Thurl et al. (2010) were categorized based on their 
Lewis blood groups which were reflective of overall European populations proportions:  Le(a-
b+) represented 73% of the subjects (group 1), Le(a+b-) represented 17% of the subjects (group 
2), 10% were Le(a-b-) (group 3), and none of the subjects were Le(a+b+).  As predicted by the 
Lewis blood group classifications, milk samples from Le(a-b+) donors (secretors) contained all 
fourteen of the neutral oligosaccharides which included the presence of α1,2-, α 1,3-, and α1,4-
fucosylated oligosaccharides.  Milk samples from the non-secretors (Lea+b-) lacked α1-2-
fucosyloligosaccharides.  Women in group 3, secretors with Le(a-b-), had milk samples that 
contained α1,2- and  α1,3- fucosylated oligosaccharides but lacked α1,4- fucosylated 
oligosaccharides.  The six major acidic oligosaccharides did not significantly vary between the 
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three groups.    In assessing the temporal trend in oligosaccharide concentrations from day 3 to 
90 postpartum, they found that acidic oligosaccharides decreased from approximately 3 g/L to 1 
g/L in all groups while neutral oligosaccharides decreased in both secretor group, from 
approximately 11 g/L to 9 g/L but remained relatively constant at approximately 5 g/L in the 
non-secretor group (Figure 1.7) (Thurl et al., 2010).   
 
Milk Oligosaccharides 
Human milk and animal milk is generally quite different in terms of oligosaccharide 
composition, concentration, and complexity.  In domestic animal milk, compositional differences 
exist in both the neutral and acidic fractions.  Neutral oligosaccharide fractions of animal milk 
rarely contain fucosylated oligosaccharides which are the most dominate type in human milk.  
Instead linkages to galactose or N-acetylglucosamine are dominant in animals.  Sialic acid is 
present in animal milk as both N-acetylneuraminic acid and N-glycolylneuraminic acid while 
human milk only contains N-acetylneuraminic acid (Boehm and  Stahl, 2007).  In bovine milk, 
sialyllactose is the dominate oligosaccharide, most notably 3'sialyllactose (Kunz et al., 2000).  
Concentrations of oligosaccharides in animal milk are also much lower than the 5-15 g/L found 
in human milk.  The oligosaccharide concentrations of the most relevant domestic animals are 
10- to 100- fold less than human milk (Boehm and  Stahl, 2007).  Bovine milk contains only 
eight neutral and ten sialylated oligosaccharides as compared to approximately 200 total HMOs 
(Gopal and  Gill, 2000; Wu et al., 2010).  Milk from common experimental animals such as mice 
and pigs, as well as milk from farm animals such as goats, sheep and cows is nearly completely 
lacking in free complex oligosaccharides; only milk from elephants is comparable to human milk 
in terms of complex oligosaccharides content (Kunz et al., 2000; Kelder et al., 2001; Osthoff et 
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al., 2008).  Although not identical, one notable structural similarity between human and animal 
milk oligosaccharide cores structures is the β -glycosidically bound galactose which protects the 
molecule from digestion as it passes through the infant GI tract (Chaturvedi et al., 2001b; Boehm 
and  Stahl, 2007).  
 
Oligosaccharides in Infant Formulae  
As the majority of infant formula is composed primarily of bovine milk, it contains only 
trace amounts of less complex milk oligosaccharides.  To mimic the prebiotic effects of HMOs, 
infant formulae are commonly supplemented with the prebiotic oligosaccharides (PBOs) GOS 
and FOS which are derived from plants or produced by technological means (Kunz and  Rudloff, 
2006).  PBOs are composed of the monosaccharides galactose, fructose, glucose, xylose and 
arabinose of which only glucose and galactose are found in HMOs (Kunz and  Rudloff, 2006).  
In addition to the differences in monosaccharides which compose the oligosaccharide chains, the 
linkage specificity also varies between HMOs and PBOs.  Fructose monosaccharides are linked 
in FOS via β1-2 linkages and GOS consist of galactose chains linked by β1-6 linkages bound to a 
terminal glucose by α 1-4 linkage.  Monosaccharide linkages in HMOs consist of a variety of α 
linkages as well as and β1-3 and β1-4 linkages (Tungland and  Meyer, 2002; Kunz and  Rudloff, 
2006).    
 
Prebiotic Effects of Human Milk Oligosaccharides  
 HMOs are resistant to digestion and arrive intact to the infant colon where they provide 
fermentation substrates to the commensal microbiota and aid in selective colonization and 
development of a protective microbiota (Chaturvedi et al., 2001b; Zivkovic et al., 2011).  
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Bifidobacteria make up a large portion of the microbiota of the breastfed infant, as compared to 
their formula fed counterparts, with prominent species including Bifidobacterium longum, 
Bifidobacterium breve, and/or Bifidobacterium bifidum (Matsuki et al., 1999; Harmsen et al., 
2000).  A number of health benefits have been associated with bifidobacteria in the developing 
infant including reduced incidence of NEC, reduced rotavirus infections, reduced susceptibility 
to antibiotic related GI disturbances, and modulation of the immune system (Arunachalam et al., 
2000; Picard et al., 2005).  
B. bifidum and B. longum subsp. infantis have been shown to thrive on HMOs as an 
energy source while B. longum subsp. longum and B. breve grow moderately well (Table 1.3) 
(LoCascio et al., 2007). The modes of utilization of HMOs as an energy source vary between 
these bacteria.  B. longum subsp. infantis ATCC15697 has been shown to prefer HMOs with 
chain lengths less than seven while B. longum subsp. longum DJO10A selectively consumes 
Lacto-N-neotetraose (LNnT) (LoCascio et al., 2007; Ward et al., 2007; Zivkovic et al., 2011).  B. 
breve ATCC15700 consumes LNnT as well as monosaccharides which suggest that cross-
feeding may be occurring between these bacteria within the GI tract.  The consumption of HMOs 
by these bacterium seems to be selective of the major HMOs produced by the lactating 
mammary gland as the majority of oligosaccharides have chain lengths less than 7 
monosaccharides and LNnT is also abundantly available (LoCascio et al., 2007; Ward et al., 
2007; Zivkovic et al., 2011). 
Bacterial fucosidase and sialidase activities relevant to fucosylated and sialylated 
oligosaccharide catabolism provides further insight to the potential activities related to HMO 
fermentation within the GI tract.  B. longum subsp. infantis has high sialidase activity as well as 
fucosidase activity, likely internalizing the HMO molecules prior to catabolizing them (LoCascio 
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et al., 2007).   B. bifidum, on the other hand, has been shown to export fucosidases which cleave 
the fucose molecule prior to the bacterium internalizing the remaining oligosaccharide (LoCascio 
et al., 2007; Ward et al., 2007).  B. breve is also thought to internalize LNnT, a HMO lacking 
fucose or sialic residues, for catabolism as well as utilize free monosaccharides cleaved from 
HMOs(LoCascio et al., 2007; Ward et al., 2007; Zivkovic et al., 2011).  
Interestingly, from these data it seems likely that HMOs do not directly nourish the 
growing neonate, but instead enrich the GI microbiota providing substrates for bacterial 
fermentation and subsequently benefiting the growth of commensals while hindering the growth 
of pathogens. 
     
Anti-adhesion Effects of Human Milk Oligosaccharides 
 A lower incidence of diseases in breastfed infants was documented as early as the 1930s, 
when several fold reductions in diarrheal diseases and respiratory infections were seen in 
breastfed infants as compared to their formula-fed counterparts (Grulee et al., 1934).  A number 
of enteric pathogens including Escherichia coli, Campylobacter jejuni and Helicibacter pylori, 
Noroviruses, and Rotavirus target specific intestinal epithelial cell surface glycan epitopes for 
adherence during the first stage of pathogenesis.  HMOs, which also possess common intestinal 
epithelia epitopes, have become an area of interest for deducing the mechanisms behind lower 
incidences of disease in breastfed infants (Morrow et al., 2004; Newburg et al., 2004; Newburg 
et al., 2005).  Decoy binding of oligosaccharide epitopes in place of binding of intestinal 
epithelia epitopes by pathogens is a potential mechanism by which infection and diarrheal 
diseases are reduced in human milk fed infants as compared to formula-fed infants (Newburg et 
al., 2004; Morrow et al., 2005; Newburg et al., 2005) 
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 Human milk which contains α1,2-fucosylated oligosaccharides has been associated with 
anti-adhesive effects in several in vivo and in vitro studies (Morrow et al., 2004).  An in vivo 
study of 2- to 4-day-old suckling mice infected with E. coli stable toxin (STa) showed that mice 
fed the STa with human milk had increased survival time as compared to control; additional  
analyses revealed that the separated neutral oligosaccharide fraction contained α1,2-fucosylated 
oligosaccharides (Crane et al., 1994; Newburg et al., 2004).  An in vitro study using T84 cells 
was conducted to determine the mechanism by which ST infection was inhibited—results of the 
trial showed that the fucosylated oligosaccharide bound the extracellular guanylate cylcase 
domain and thus prevented binding of the ST and the associated infection (Crane et al., 1994). 
The oligosaccharide 2'fucosyllactose (2'FL) has also demonstrated anti-adhesive effects 
in vivo.  A reduced incidence of campylobacter infection has been shown in mice fed milk from 
dams transfected with the human fucosyltransferase I gene.  The transfected dams’ milk 
contained increased H-2 epitopes, the known target epitope of campylobacter. Pups receiving the 
enhanced dam milk had enhanced protection from infection as compared to control (Ruiz-
Palacios et al., 1990).   
In breastfed infants, an inverse correlation has been found between risk of campylobacter 
diarrhea and 2'FL breast milk sample concentrations suggesting a protective effect of 2'FL 
against campylobacter in human infants (Morrow et al., 2004).  Morrow and colleagues (2004) 
also reported an inverse correlation between another fucosylated human milk oligosaccharide, 
lactodiffucohexaose-1 (LDFH-1) and norovirus associated diarrhea in breastfed infants, likely 
linked to the presence of a Lewis b moiety, as well as an overall inverse correlation between total 
concentration of α1,2-linked fucosyloligosaccharides in breast milk samples and moderate-to 
severe diarrhea from all causes (Morrow et al., 2004).   
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 In summary, a number of different anti-adhesive mechanisms are associated with 
fucosylated oligosaccharides allowing them to inhibit attachment of E. coli, Campylobacter and 
Norvirus thus providing a potential benefit of reduced diarrheal illness in infants.     
  
 Glycome-modifying Effects of Human Milk Oligosaccharides 
 In addition to HMOs anti-adhesive effects on diarrheal pathogens, milk oligosaccharides 
have also been associated with glycome-modifying effects in vitro, suggesting that modifications 
in adhesion of pathogens and commensal bacteria may result due to the changes in expression of 
intestinal epithelial cell surface glycans (Figure 1.8) (Bode, 2009).  An in vitro study conducted 
in CaCo-2 cells showed that incubation with 3’sialyllactose reduced adhesion of 
enteropathogenic E. coli (EPEC) by 90% as compared to controls (Angeloni et al., 2005).  These 
glycan modifying effects are hypothesized to be an additional means by which HMOs provide 
protective effects to the breastfed infant.     
 
Intestinal Epithelial Cell Effects of Human Milk Oligosaccharides         
Kuntz and colleagues (2008) hypothesized that neutral and acidic HMO fractions or 
individual oligosaccharides would affect cell dynamics in non-transformed fetal intestinal crypt 
cell line, HIEC, and in transformed human intestinal cell lines, HT-29 and CaCo-2.  The in vitro 
model consisted of HIEC cells to model undifferentiated intestinal stem-like crypt cells, HT-29 
cells to model normal crypt colonocytes, and CaCo-2 cells to model intestinal epithelial cells.  
Under pre-confluent conditions, these cells types create a model of the proliferating cells of the 
crypt/villus axis and thus simulate the development within the fetal and neonatal intestine (Kuntz 
et al., 2008).   
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They reported that neutral and acid HMO fractions induced growth inhibition in all cell 
types in a dose dependent manner after 72 hours of incubation with the most sensitivity in HT-29 
and CaCo-2 cells.  HT-29 cells experienced growth inhibition by several individual neutral and 
acidic HMOs including lacto-N-tetraose (LNT) at 1.4 mg/ml and 6’SL at 1.5 mg/ml, however 
2'FL at 2 mg/ml did not significantly affect proliferation.  CaCo-2 and HEIC cells were not affect 
by LNT or 2'FL but showed a significant decrease with 6'SL as compared to control.  Alkaline 
phosphatase (AP) activity, a marker of cellular differentiation, was assessed following a 72 hour 
incubation with neutral or acidic fractions and it was found that AP activity significantly 
increased as compared to controls in HT-29 and HEIC cells treated with 15 mg/L of the neutral 
fraction as well as with 7.5 mg/L and 15 mg/L of the acidic fraction.  CaCo-2 cells, a more 
differentiated cell type, were not significantly affected by neutral or acidic HMO fractions or 
individual HMOs.  Treatment with individual HMOs at 1 mg/ml resulted in an increase in AP 
activity as compared to control in HT-29 and HIEC cells treated with 6'SL.  Cellular caspase-3 
activity, a measure of apoptosis, increased in both HT-29 cells and HEIC cells in the 15 mg/L 
neutral HMO fraction group, however the acidic fraction did not significantly affect any of the 
cell types at any level of treatment as compared to control.   In summary, this trial by Kuntz and 
coworkers demonstrated that neutral and acidic HMO fractions induce growth inhibition in 
intestinal cell lines by two different mechanism 1) suppression of cell cycle progression through 
induction of differentiation and/or 2) induction of apoptosis (Kuntz et al., 2008).   
To determine potential mechanisms behind the growth inhibition of the intestinal cell 
lines exposed to neutral and acid HMO fractions in the study discussed above, Kuntz and 
colleagues used flow cytometry to asses cell cycle events and quantitative real-time RT-PCR to 
examine effects on cell cycle genes (Kuntz et al., 2009).  They found that both neutral and acidic 
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fractions induced G2/M arrest in a dose dependent manner in all cell types (HT-29, CaCo-2, and 
HEIC).  RT-PCR results showed an increase in mRNA expression levels of the cell cycle gene 
cyclin B/GAP-DH as compared to control in all three cell types after 72 hours of incubation with 
both neutral and acidic HMO fractions at a concentration of 15 mg/L.  Additionally, cyclin 
A/GAP-DH increased in HT-29 and HIEC cells following incubation with the acidic fraction but 
not with the neutral fraction, while there was no effect in CaCo-2 cells.  Further, it was found 
that the block in cell cycle progression was related to CDKI levels, specifically an increase in 
p21
cip1
 and p27
kip1
 in both neutral and acidic HMO treatment groups for HT-29 and HEIC cells.  
CaCo-2 cells had increased levels of    p21
cip1
 but not p27
kip1
.  These differences were 
independent of p53 levels, as no differences were detected for any cell type within any treatment 
group.  Lastly, it was found that both acidic and neutral HMOs induced phosphorylation of the 
epidermal growth factor receptor (EGFR) and increased extracellular signal-regulated kinase 1/2 
(ERK1/2) and p38 phosphorylation.  These results suggest that HMO associated growth 
inhibition is related to altered cell cycle progression with concurrent effects on regulator gens 
and stimulation of mitogen-activated protein kinase (MAP-kinase) signaling (Kuntz et al., 2009).   
 
SUMMARY 
 In summary, the beneficial attributes of probiotics, prebiotics, and human milk 
oligosaccharides make them attractive ingredients for infant formula supplementation.  As 
previously discussed, each has been shown to enhance commensal bacteria within the GI 
microbiota.  Further, the enhancement of the commensal resident bacteria stimulates immune 
factors such as sIgA, as well as provides colonization resistance against pathogens.  In addition 
to all these effects, HMOs may also have a role in maturation of the GI tract.  Thus, additional 
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research examining the effects of probiotics, prebiotics, and HMOs in vivo and in vitro becomes 
increasingly important.  The information gained would provide a greater understanding of the 
role of each in GI health and development.   
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Figure 1.1.  Galacto-oligosaccharide 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Fructo-oligosaccharide  
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Figure 1.3.  Monosaccharides used to synthesize human milk oligosaccharides.  Adapted 
from Kunz, 2006.   
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Figure 1.4. 6’-Sialyllactoase (6’SL) 
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Figure 1.5. 2’-Fucosyllactose (2’FL) 
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Figure 1.6. Lacto-N-neotraose (LNnT) 
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Table 1.1.  Average neutral human milk oligosaccharide concentration (g/L) over the course of 90 days of lactation.  Adapted from 
Thurl 2010. 
 
 
 
Table 1.2.  Average acidic human milk oligosaccharide concentration (g/L) over the course of 90 days of lactation.  Adapted from 
Thurl, 2010.
 2'FL 3-FL LDFT LNFP I LNFP II 
LNFP 
III 
LNDFH I LNDFH II 2'-F-LNH 3'-F'LNH 
2',3'-DF-
LNH 
Group 
One 
3.13 0.42 0.41 1.58 0.22 0.38 1.28 0.2 0.21 0.16 0.33 
Group 
Two 
ND 1.79 ND ND 1.25 0.38 ND 0.45 ND 0.35 ND 
Group 
Three 
4.57 0.15 0.17 3.18 ND 0.31 ND ND 0.26 0.13 0.58 
 3'-SL LSTa DSLNT LSTb 6'SL LSTc 
Group One 0.27 0.04 0.34 0.08 1.22 0.29 
Group Two 0.24 0.04 0.42 0.11 1.14 0.21 
Group Three 0.31 0.06 0.41 0.08 1.31 0.31 
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Figure 1.7.  Average total oligosaccharide content over course of 90 days.  Average 
concentration of oligosaccharide fractions vary between groups of women classified based on 
Lewis blood groups and the presence or absence of the secretor gene.  Figure adapted from 
Thurl, 2010. 
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  B. bifidum 
 
B. longum 
subsp. infantis 
B. longum subsp. 
longum 
B. breve 
HMO growth High High Moderate moderate 
HMOs degraded 
LNT, LNnT  LNT, chains < 7 LNnT LNT, LNnT and 
monosaccharides 
HMO units & 
monosaccharide 
growth 
Lacto-N-biose 
(LNB), Glc, Gal 
LNB, Glc, Gal, 
Glucosamine, 
Fucose, sialic 
acid 
LNB, glucose, 
galactose 
LNB, Glc, Gal, 
Glucosamine, 
Fucose, sialic acid 
Extracellular 
activities & 
enzymes 
•β-galactosidase(s)   
•lacto-N-biosidase 
•1,2a- & 1-3/4a-  
fucosidases  
 •endo-a-N-acetyl-
galactosaminase 
  •lacto-N-biosidase 
 •endo-a-N-acetyl-
galactosaminase 
  
•lacks sialidase 
and fucosidases  
  
Intracellular 
activities & 
enzymes 
Internalizes free 
LNB after fucose 
cleaved 
Internalizes 
HMO, 
intracellular 
glycosidase, 
sialidases & 
fucosidases 
  Internalizes LNnT 
and free 
monosaccharides 
from HMO 
 
Table 1.3.  Prebiotic Effects of HMOs. (LoCascio et al., 2007; Ward et al., 2007; Zivkovic et 
al., 2011)  
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Figure 1.8.  Human milk oligosaccharides provide anti-adhesive and glycome modifying 
effects.  A) Bacteria bind lectins, glycan-binding proteins, during the initial stages of 
pathogenesis.  B) HMOs may provide decoy binding sites and prevent adhesion of pathogens.    
C)  HMOs may also alter epithelial glycans preventing recognition of pathogen binding sites. 
(Bode, 2009).  Figure reprinted with permission from John Wiley and Sons. 
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CHAPTER 2 
RATIONALE AND OBJECTIVES OF RESEARCH 
 
RATIONALE OF RESEARCH 
 Although human milk is recommended to be fed exclusively to developing infants for the 
first six months of life, less than half of infants are meeting this recommendation (Eidelman et 
al., 2012).  As health outcomes are generally better in infants receiving human milk, further 
research is necessary to identify key ingredients that will aid in narrowing the compositional gap 
between human milk and infant formula and thus provide benefit to formula-fed infants.  
Ingredients of interest include probiotics, prebiotics, and human milk oligosaccharides (HMOs).  
The information gained from additional study of these ingredients may allow for a narrowing of 
this compositional gap and improvements to formula-fed infants health outcomes.   
 
AIMS AND SCOPE OF RESEARCH 
The overall objective of this thesis research is to examine the effects of probiotics, 
prebiotics, and human milk oligosaccharides as means to narrow the compositional gap between 
human milk and infant formula.  Thus, we aimed to assess 1) the effects of the probiotic 
Bifidobacterium animalis subspecies lactis (B.lactis), 2) the prebiotics galacto- and fructo-
oligosaccharides, and 3) the individual and combined effects of human milk oligosaccharides 
within in vivo and in vitro models.  The central hypothesis of this research is that specific 
ingredients will enhance gastrointestinal health and development.  The specific aim will be 
investigated using the following hypotheses: 
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 Hypothesis 1:  Consumption of an infant formula containing B. lactis for 6 weeks will 
positively impact the intestinal-associated immune system and resident microbiota of formula-
fed infants.  Chapter 3 establishes that infant formula containing B. lactis is well tolerated and 
stimulates intestinal immunity as evidenced by enhanced fecal secretory immunoglobulins A 
(sIgA) and vaccine-specific IgA following immunization.  Furthermore, it demonstrates that 
some of the negative immune-related effects of not breast feeding and cesarean delivery can be 
mitigated by supplementing infant formula with B. lactis thereby providing a safe, dietary, 
immune-modulating bacterial introduction to infants. 
 Hypothesis 2:  Consumption of the galacto- and fructo-oligosaccharide-containing 
formula for six weeks will be well-tolerated and increase the proportion of fecal bifidobacteria to 
total bacteria in formula-fed infants.  Chapter 4 establishes that infant formula containing 
galacto- and fructo-oligosaccharides is well-tolerated by formula fed infants, increases the 
abundance and proportion of fecal bifidobacteria, and reduces fecal pH. 
 Hypothesis 3:  Three individual HMOs, 2'-fucosyllactose (2'FL), lacto-N-neotetraose 
(LNnT), and 6'-sialyllactose (6'SL), will induce epithelial differentiation in an in vitro epithelial 
model of the crypt-villus axis consisting of pre-confluent HT-29 cells, pre-confluent CaCo-2Bbe 
cells, and post-confluent CaCo-2Bbe cells. Chapter 5 investigates the interaction between 
individual HMOs and the transformed intestinal epithelial cell lines, HT-29 and Caco-2Bbe.  
Using an in vitro model, it establishes that all three HMOs inhibit cellular proliferation, with 
2'FL also providing stimulation for enhancement of epithelial cell differentiation.  Furthermore, 
it demonstrates that well differentiated cells have greater digestive and barrier function when 
treated with 2'FL and LNnT, respectively.    
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 Hypothesis 4:  Concomitant administration of the HMOs, 2'-fucosyllactose (2'FL), 3'-
sialyllactose (3'SL) , and 6'-sialyllactose (6'SL), will induce epithelial differentiation and enhance 
maturation of the small intestine in vitro in an epithelial model of the crypt-villus axis consisting 
of pre-confluent HT-29 cells, pre-confluent CaCo-2Bbe cells, and post-confluent CaCo-2Bbe 
cells.  Chapter 6 explores the effects of administration of concomitant HMOs on transformed 
intestinal epithelial cell lines, HT-29 and Caco-2Bbe.  Within the in vitro model, it establishes 
that there is an additive effect of HMO on cellular proliferation and an associated enhancement 
of differentiation in pre-confluent Caco-2Bbe cells.   
   Chapter 7 summarizes the results of these studies and discusses the insights gained 
from the research.  It also explores future directions of the research with particular emphasis on 
the need to investigate the physiological relevance of the in vitro effects of HMOs within 
preclinical animal models so that we may better understand their effects on intestinal maturation, 
digestive and absorption capabilities, and barrier function within the gastrointestinal tract.      
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CHAPTER 3 
 
BIFIDOBACTERIUM LACTIS ENHANCES INTESTINAL ANTIBODY RESPONSE IN 
FORMULA-FED INFANTS:  A RANDOMIZED, DOUBLE-BLIND, CONTROLLED 
TRIAL
1
 
 
 
ABSTRACT 
Background:  Addition of probiotics to infant formula may positively affect immune function in 
non-exclusively breastfed infants. This study aimed to investigate the effect of infant starter 
formula containing the probiotic Bifidobacterium animalis subspecies lactis (B. lactis) on 
intestinal immunity and inflammation. Methods: Six-week-old healthy, full-term infants (n=172) 
were enrolled in a prospective, randomized, double-blind, controlled clinical trial with 2 groups 
studied in parallel to a breastfed comparison group.  Formula-fed (FF) infants were randomized 
to partially hydrolyzed whey formula (CON), or the same formula containing 10
6
 CFU B. 
lactis/g (PRO) for 6 weeks.  Fecal secretory IgA (sIgA), calprotectin, lactate, and stool pH were 
assessed at baseline, 2, and 6 weeks.  Anti-poliovirus-specific IgA and anti-rotavirus-specific 
IgA were assessed at 2 and 6 weeks.  Results: Among vaginally-delivered FF infants, PRO 
consumption increased (p<0.05) fecal sIgA, compared to CON.  Anti-poliovirus-specific IgA 
concentration increased (p<0.05) in all infants consuming PRO; whereas anti-rotavirus-specific 
IgA tended to increase (p=0.056) with PRO consumption in cesarean-delivered infants.  
Anthropometrics and tolerance did not differ significantly between FF infants.  Conclusions: 
Infants consuming formula with B. lactis produced feces with detectable presence of B. lactis 
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and augmented sIgA concentration.  Further, cesarean-delivered infants consuming B. lactis had 
heightened immune response, as evidenced by increased anti-rotavirus- and anti-poliovirus-
specific IgA following immunization. These results demonstrate that negative immune-related 
effects of not breast feeding and cesarean delivery can be mitigated by including Bb12 in infant 
formula and thereby providing infants a safe, dietary, immune-modulating bacterial introduction. 
 
CLINICAL RELEVANCY STATEMENT 
Breast milk, the ideal source of nutrition for infants, is also a source of secretory 
immunoglobulin (Ig) A, as well as bacteria, which enhance both passive and active infant 
immunity. These benefits are not provided by routine use infant formula. The addition of 
probiotics to infant formula is reported to increase fecal secretory IgA.  This study demonstrates 
that supplementation of infant formula with Bifidobacterium animalis subspecies lactis (B. 
lactis) results in detectable fecal levels of B. lactis and increased concentrations of secretory-, 
anti-rotavirus-specific, and anti-poliovirus-specific IgA. Therefore, including B. lactis in infant 
formula provides infants a safe, dietary, immune-modulating bacterial experience. 
 
INTRODUCTION 
While it is known that breastfeeding is best, infant formulas are often used to supplement 
breast milk, and mothers of some infants may choose not to breastfeed. Attempts to optimize 
infant formula have been undertaken to impart some of the benefits of breast milk to the formula-
fed infant. One such strategy is to positively influence the composition and activity of the 
intestinal microbiota of the formula-fed infant to more closely reflect that of the breastfed infant. 
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An infant starter formula containing the probiotic Bifidobacterium lactis is currently being 
marketed in the US and is available in many other parts of the world. 
Probiotics are live microorganisms that, when administered orally in adequate amounts 
survive the digestion process and confer a beneficial effect on the host (FAO/WHO, 2001).  
Saavedra proposed probiotics as a concept by which the use of these nonpathogenic agents 
“constitutes a purposeful attempt to modify the relation with our immediate microbial 
environment in ways that may benefit our health” (Saavedra, 2001). The microbial environment 
of the intestinal microbiota is an integral part of the immune system.  In particular, it has been 
established that the microbiota of the breastfed infant is dominated by bifidobacteria early in life, 
and this has been thought to contribute to the many health benefits breastfed infants possess 
(Yoshioka et al., 1983).  The lower incidence of infection and gastrointestinal disturbances 
observed in breastfed infants compared to their formula-fed counterparts may be related to 
differences in their respective microbiota. One such benefit of a balanced intestinal microbiota 
influenced by probiotics is to provide stimulatory support to the mucosal immune system. 
Non-pathogenic bacteria are not considered to be a probiotic until a clinical benefit to the 
host has been demonstrated. Amongst those probiotic bacteria that have been better studied is B. 
lactis.  Safe administration of B. lactis to pediatric populations has been reported widely in the 
literature, with no adverse effects on growth noted (Langhendries et al., 1995; Ziegler et al., 
2003; Saavedra et al., 2004; Braegger et al., 2011).  Further, B. lactis consumption is reported to 
beneficially impact immune function, by increasing fecal IgA levels (Fukushima et al., 1998; 
Mohan et al., 2008). Associated outcomes including reduction in antibiotic use, reduction in 
febrile episodes, reduction in number of severe illness days, reduction in otitis media infection, 
and improvements in allergy-related skin conditions have also been seen (Isolauri et al., 2000; 
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Saavedra et al., 2004; Weizman et al., 2005; Sistek et al., 2006; Rautava et al., 2009).  In a small 
group of toddlers (15-31 months) fed a B. lactis-containing formula, significantly higher levels 
of fecal sIgA and anti-poliovirus IgA were observed after 3 weeks of feeding (Fukushima et al., 
1998).  Separately, Mohan demonstrated increased fecal sIgA concentration in a study of 
premature infants fed a B. lactis-containing formula for the first 3 weeks of life (Mohan et al., 
2008).  Fecal IgA levels of full-term infants exclusively fed a B. lactis-containing formula has 
only been reported in one other study to date, however the current trial differs in the timing of 
probiotic initiation and the composition of the formula vehicle (Bakker-Zierikzee et al., 2006).  
Secretory immunoglobulin A (sIgA) is the predominant immunoglobulin in mucosal 
surfaces and provides key protection in the innate mucosal immune response to dietary and 
microbial antigens.  While breast milk contains sIgA, infant formula does not. Significantly 
higher levels of fecal sIgA in samples from breastfed infants compared to formula-fed infants 
have been reported through the first 6 months of life (Koutras and  Vigorita, 1989; Kohler et al., 
2002).  Probiotics have been shown to increase fecal sIgA levels in a pediatric population after 3 
weeks of feeding (Fukushima et al., 1998).  Further investigations to determine ways to increase 
levels of fecal sIgA in formula-fed infants could lead to improvements in infant formula. 
The primary outcome of the this trial was to compare the fecal sIgA concentration of six-
week-old healthy infants following 6 weeks of feeding of a partially hydrolyzed whey-based 
starter formula (control) or the same formula containing Bifidobacterium animalis subspecies 
lactis (B. lactis).  Secondary outcomes, which quantified markers of immunity and inflammation, 
were fecal sIgA concentration at 8 weeks of age (following 2 weeks of feeding) and fecal 
abundance of B. lactis, anti-rotavirus-specific IgA, anti-poliovirus-specific IgA, calprotectin, 
lactate, and stool pH after 2 and 6 weeks of formula feeding.  We hypothesized that consumption 
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of an infant formula containing Bb12 for 6 weeks would positively impact the intestinal-
associated immune system and resident microbiota of formula-fed infants. 
 
METHODS 
Subjects and Study Design   
The study was conducted from September 2007 to March 2008 at 5 study sites (Pedia 
Research in KY/IN, Southwest Children’s Research Associates in San Antonio, Texas and Scott 
& White Memorial Hospital in Temple & Killeen, TX) within the United States.  Newborn 
infants (2–6 weeks of life) were recruited. All subjects were required to live within 45 minutes of 
a study center and have a working freezer in their home.  Infants receiving antibiotic therapy in 
the 30 days prior to enrollment, or breastfed subjects whose mothers had received antibiotic 
therapy within the same period, were not eligible for the study.  Other criteria for exclusion from 
the study were: known or suspected cow-milk allergy; congenital illness or malformation that 
affects infant feeding and/or growth; significant pre-natal and/or post-natal disease; 
immunocompromise; any readmission to hospital (except for hyperbilirubinemia) prior to 
enrollment; diarrhea requiring treatment in the 7 days prior to enrollment, or; receipt of 
medication other than multivitamin supplement.  Parents of all participants were required to sign 
a written informed consent prior to enrollment.  The studies were approved by the relevant IRB 
of each site recruiting subjects and the University of Illinois, where all laboratory analyses of 
samples occurred.  The procedures followed were in accordance with the ethical standards of the 
responsible institutional or regional committee on human experimentation. 
Formula-fed (FF) infants were randomized to receive either CON or PRO at 6 weeks of 
age and consume the assigned formula exclusively for the following 6 weeks.  The control 
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formula was a commercially available partially hydrolyzed whey infant formula (CON; Nestlé 
Good Start ®  Nestlé, Florham Park, NJ), whereas the test formula (PRO) was identical to CON 
with the exception of the addition of 10
6
 CFU B. lactis /g powder.  Both formulas provided 20 
kcal/oz with 2.2 g protein/100 kcal from 100% partially hydrolyzed whey. Randomization of FF 
subjects was stratified by delivery (vaginal versus cesarean-section).  The self-selected breastfed 
reference group was exclusively breastfed and followed for 6 weeks starting at 6 weeks of age.   
Weight of each subject was taken at baseline (V0) and after 2 (V1) and 6 weeks (V2) of 
feeding at study visits.  Caregivers were instructed to complete daily records for 2 days prior to 
the visits.  Using paper diaries, caregivers of all subjects recorded the same data regarding 
formula intake volumes, stool patterns and tolerance-related behavior.  Caregivers of breastfed 
subjects documented the length of each feeding or the amount of expressed breast milk given at 
each feeding, in addition to stool patterns and tolerance-related behavior.  All subjects were 
asked to receive immunizations according to the schedule outlined by the Department of Health 
and Human Services, which included receipt of rotavirus (Rotateq, Merck, Whitehouse Station, 
NJ) and inactivated poliovirus (Ipol, Sanofi Pasteur SA, Swiftwater, PA) vaccines at 8 weeks of 
age.  Stool sample for Visit 1 was collected prior to vaccinations.  
Within 72 hours of each study visit, stool samples were collected at home in 30 ml 
polypropylene fecal collection tubes (Globe Scientific, Paramus, NJ) within 30 minutes of 
passing.  Caregivers brought the fresh sample in a cooler with ice packs to the site within 30 
minutes of collection or the tube with the sample was placed in a home freezer for 2-72 hours 
prior to transporting the sample to a study site in the manner outlined above.  Upon arrival at the 
study site, samples were promptly placed at -20°C for a maximum of 2 weeks before shipment 
on ice to the University of Illinois were samples were stored at -80°C until analysis. 
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Fecal Homogenates   
Fecal homogenates were prepared by thawing frozen fecal samples on ice then creating a 
10% wt:vol mixture in PBS followed by homogenization with a homogenizer (Model PCU-11; 
Brinkman Instruments, Westbury, NY) for 1 minute.  Aliquots of fecal homogenates for 
quantification of sIgA, anti-polio-specific IgA and anti-rotavirus-specific IgA were stored at -
80
o
C until analysis.   
Secretory IgA 
Fecal secretory IgA (sIgA) was determined from the fecal samples that were collected at 
baseline, 2 and 6 weeks of feeding.  Analysis of sIgA was performed as described before by 
Scholtens and colleagues, with minor modifications (Bakker-Zierikzee et al., 2006; Scholtens et 
al., 2008).  Modifications included a decreased concentration of the secondary antibody, biotin-
conjugated mouse anti-human IgA1/IgA2 monoclonal antibody (BD Pharmingen 555884, 
Franklin Lakes, NJ), to a concentration of 200 ng/ml and use of 1-step Ultra TMB-ELISA 
(Pierce 34028, Rockford, IL) for 3 minutes prior to addition of 1.8 M H2SO4 to stop the 
enzymatic color development. The plates were read at 450 nm in a plate reader.  Fecal sIgA 
concentrations were determined using serially diluted purified human IgA isolated from 
colostrum (Sigma I-1010, St. Louis, MO) to generate a standard curve.  Results are expressed as 
change from baseline (mg/sIgA per gram feces).    
Anti-poliovirus- and Anti-rotavirus-Specific IgA 
Measurements of anti-poliovirus-specific IgA and anti-rotavirus-specific IgA from fecal 
samples collected prior to vaccination (V1) and following vaccination (V2) were conducted in a 
similar manner as the sIgA protocol with modifications in the original coating of the plate, 
preparation of the standard curve, sample dilutions and incubation with 1-Step Ultra TMB.  
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Plates were coated with 1:100 dilutions of either IPOL vaccine or oral Rotateq vaccine in a 
20mM NaHCO3 coating buffer (pH 9.5) for poliovirus-specific or rotavirus-specific IgA, 
respectively (Mullie et al., 2004).  As standards are not commercially available for either anti-
poliovirus- or anti-rotavirus-specific IgA, the respective standard curves were generated by 
pooling separately all V2 fecal samples from infants receiving the polio vaccine and/or the 
rotavirus vaccine to create a relative measurement of antibodies present.  The total pooled 
samples used to relatively quantify the amount of anti-poliovirus or anti-rotavirus-specific IgA 
were serially diluted and included on each plate.  Fecal homogenates were diluted between 10 
and 200 times.  Incubation time with 1-Step Ultra TMB (3,3′,5,5′-tetramethylbenzidine) was 
increased to 30 minutes at room temperature before stopping the enzymatic color reaction with 
stop solution.  Anti-polio-specific and anti-rotavirus-specific IgA concentrations were 
determined from their respective standard curves and expressed as change in units per gram feces 
from V1 to V2 as all vaccinations took place after collection of the V1 sample.   
Fecal Calprotectin, Lactate, and pH 
Fecal calprotectin and lactate were measured using commercial kits, PhiCal Fecal 
Calprotectin Immunoassay (Genova Diagnostic, Asheville, NC) and Lactate Assay Kit 
(BioVision K607, San Francisco, CA), respectively.   Fecal pH value was immediately obtained 
upon thawing sample by submerging the pH probe (Futura Refillable Probe, Beckman 
Instrument, Inc., Fullerton, California) into the fecal matter and waiting until the pH meter (UP-
5, Denver Instrument, Denver, Colorado) reading stabilized.     
Stool DNA Extraction and Quantitative Polymerase Chain Reaction of Bb12   
DNA from stool samples was isolated using the QIamp DNA stool mini kit (Qiagen, 
Valencia, CA) with minor modifications previously described by Solano-Aguilar and collegues 
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(Solano-Aguilar et al., 2008).  Briefly, 1.4 ml of lysis buffer was added to 180-220 mg of feces 
followed by immediate mixing for one minute.  Homogenate was then incubated at 95
o
C for 5 
minutes to facilitate increased DNA yield, followed by removal of inhibitors and proteinase K 
digestion.  DNA was then bound to a column, washed, and eluted.   
The amount of Bb12 copy numbers in fecal samples was determined using a primer-
probe set specific for the tuf gene as previously described by Solano-Aguilar and colleagues, 
2008.(Solano-Aguilar et al., 2008)  Primers and probes were purchased from Applied 
Biosystems (ABI, Foster City, CA) as follows: tuf Forward GTG TCG AGC GCG GCA A; 
Reverse CTC GCA CTC ATC CAT CTG CTT; BGB probe ATC AAC ACG AAC GTC GAG 
A.  Commercially-available Taqman Gene Expression assays (Applied Biosystems, Carlsbad, 
CA) supplied minor groove binding probes and primers for amplification and analysis of the tuf 
gene of Bb12.   
Dr. Gloria Solano-Aguilar (The Henry A. Wallace Beltsville Agricultural Research 
Center, Beltsville, MD) generously donated a genomic tuf gene fraction (136.52 nmoles/L; 8.21 
x 10
10
 copies/µl) for use to generate the standard curve.  The size of the fragment (120 bp) and 
its molecular mass were quantitatively determined on the DNAChip (Agilent, Waldbronn, 
Germany) using Bioanalyzer (Agilent Technologies, Wilmington, DE).    
Bb12 tuf gene abundance was measured with a Taqman ABI 7900 (Applied Biosystems). 
Data were analyzed with ABI Sequence Detection System software (Version 2.2.1, Applied 
Biosystems) using standard curve methodology. In this method, the threshold cycles from the 
Bb12 tuf gene were compared with a standard curve generated from a series of dilutions of the 
tuf gene standard. The calculated concentration of the Bb12 copy numbers was normalized to 
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fecal mass (mg). Each sample was assayed in triplicate.  Both positive (DNA extracted from the 
PRO formula) and negative controls were included on each plate. 
 Statistical Analysis 
The statistical power analysis and the number of study subjects were based on the 
primary outcome, level of fecal sIgA, to investigate whether infants consuming infant formula 
containing Bb12 have a higher level of fecal sIgA compared to infants receiving the control 
formula. The number of infants was determined by having sufficient statistical power to test the 
differences in changes in fecal IgA from baseline between the probiotic formula and the control 
formula, using two- tailed t tests at a level of significance of p=0.05, i.e., Type I error = 0.05.   
Fukushima and colleagues found that the mean fecal sIgA at baseline was 1.49±0.32 
mg/g and rose to 4.29±1.09 mg/g after 8 days of feeding with probiotic formula.(Fukushima et 
al., 1998)  We assumed that infants fed with control formula would not experience a change in 
level of fecal IgA from baseline values to values at 8 days of follow-up. Therefore, we calculated 
the sample size per group for a statistical power of 0.80 for detecting a difference of 2.8 mg/g or 
greater. The standard deviation of the fecal IgA was 0.8 mg/g at baseline in Fukushima’s study 
and increased to 2.88 mg/g after 8 days of exposure to probiotic-containing formula. To detect a 
group difference in changes from baseline, the sample size necessary to achieve a power of 0.80 
was at least 36 infants per group. As such, 90 subjects (45 for each formula group) were 
recruited to compensate for an anticipated attrition of 20% over the study period. A separate 
group of exclusively breastfed infants were included as a reference. In anticipation of a similar 
attrition in this group, 45 breastfed infants were recruited in the expectation that 36 of them 
would complete the study. 
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Data were analyzed using SAS (Version 9.1; SAS Institute). The generalized linear 
model included main effects for treatment and delivery and an interaction of treatment and 
delivery.  Treatment means were compared using Student’s t-test.   Significance of difference 
was set at P<0.05.  Change in fecal SIgA from baseline was assessed using per protocol and 
intent-to-treat approaches.  All other analyses were performed only on subjects completing the 
study per protocol.  Histograms and q-q plots were used to visually assess normality, log 
transformations were utilized as needed.  Values reported are means + standard error of the mean 
(SEM). 
The secondary outcomes of gastrointestinal tolerance, weight gain, and adverse events 
were analyzed according to per protocol (PP) and intention-to-treat (ITT) designs.  To compare 
the differences in tolerance data and body weight data between the two formula groups and a 
breastfed group, a general linear model analysis was performed followed by a Tukey-Kramer 
procedure to control the overall type 1 error rate (Tukey, 1953; Kramer, 1956).  Mixed effects 
models were applied to serial values at baseline (V0), 2 weeks of feeding (V1), and 6 weeks of 
feeding (V2).  The analysis was performed with route of delivery and study center as covariates.   
 
RESULTS  
Of 172 recruited infants, 21 FF infants and 6 breastfed infants did not complete the 
baseline visit at 6 weeks of age (Figure 3.1).  Infants included in the intent to treat analysis 
included fifty-two infants whose mothers selected to exclusively breastfed (39 vaginally 
delivered and 13 by cesarean-section), and 93 FF infants were randomized to CON (43 subjects; 
27 vaginally delivered and 16 by cesarean-section) or PRO (50 subjects; 34 vaginally delivered 
and 16 by cesarean-section).  Forty breastfed and 75 FF infants completed the study per protocol 
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(PP) with 41 randomized to PRO (25 vaginally-delivered and 16 by cesarean-section) and 34 to 
CON (19 vaginally-delivered and 15 by cesarean-section).  Nine subjects in each of the FF 
groups (18 total; 5 drop-out before study completion; 4 lost-to-follow-up; 6 received non-study 
formula; 1 received cereal; 1 investigator withdrew subject; 1 study formula unrelated serious 
adverse event (hospitalization for respiratory syncytial virus)) and 12 breastfed infants (6 not 
exclusively breastfed; 3 incorrect timing of stool collection; 1 false inclusion; 2 drop-out before 
study completion) were excluded from the per protocol analysis due to study withdrawal or non-
compliance.   
Measures of birth weight, length, gestational age, or route of delivery did not differ 
between feeding groups at baseline.  These data as well as subjects’ pre-study feeding regimen 
are presented in Table 3.1.  The average formula intake for infants assigned to the PRO was 24 
ounces per day (1.0 x 10
8
 CFU Bb12) at 8 weeks of age and 25.6 ounces (1.1 x 10
8
 CFU Bb12) 
per day at 12 weeks of age.  The average formula intake for infants assigned to the CON formula 
was 23 ounces per day at 8 weeks of age and 23.8 ounces per day at 12 weeks of age. There was 
no difference in intake between PRO and CON (p=0.2829).  Breastfed infants were fed an 
average of 7 times per day. 
Stool samples from 145 infants were analyzed as intent-to-treat (ITT; primary outcome 
only) while stool samples from 115 infants were included in PP analysis.    Tolerance outcomes 
and growth are reported for all recruited subjects on an ITT basis.  Data on fecal samples are 
reported on ITT and per protocol subjects for fecal sIgA and PP infants only for all other 
outcomes assessed on stool samples. 
Fecal Bb12 abundance was assessed by quantifying tuf gene copies and was found to be 
present in 93% and 88% of PRO fecal samples at V1 and V2, respectively.  There was no 
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difference (p=0.12) in Bb12 tuf gene copy numbers in PRO (26.6 ± 15.0), CON (1.5 ± 1.4), or 
BF (50.1 ± 22.3) samples at baseline, prior to study formula initiation (Figure 3.2).  As expected, 
Bb12 tuf gene copy number abundance was significantly greater (p=0.0095) in PRO vs CON at 
V1 (3290 ± 1210 vs. 26 ± 11 respectively) and V2 (5105 ± 1909 vs. 39 ± 18 respectively), 
thereby validating compliance regarding assigned formula intake within the study population.  
Breast fed infants were found to have 231.9 ± 46.3 Bb12 tuf gene copy numbers at V1 and 203.7 
± 63.3 at V2. 
Breast fed infants had significantly higher (p<0.001) concentrations of fecal sIgA in stool 
samples as compared to FF infants at all time points (Figure 3.3).  Vaginally-delivered PRO 
infants had increased (p=0.046; 1.053 ± 1.017mg/g) fecal sIgA concentration from baseline to 6 
weeks of feeding (V0 to V2) compared to CON (-1.809 ± 1.341mg/g change from baseline) in 
the ITT groups (Figure 3.4a).   Additionally, the change from V0 to V1 also tended (p=0.063) to 
be significant in PRO ITT-vaginally delivered infants (1.77 + 1.52 mg/g change from baseline) 
as compared to CON (-1.82 + 1.9 mg/g change from baseline) as shown in Figure 3.4a.  Fecal 
sIgA concentration was not affected by formula composition in the cesarean-delivered ITT 
(Figure 3.4b).  
Within per protocol (PP) infants, PP vaginally-delivered PRO infants demonstrated a 
trend toward increased fecal sIgA from baseline to visit 2 similar to the ITT-vaginally-delivered 
infants (p=0.052; PRO: 1.80 +1.9 mg/g change from baseline; CON: -2.58 +1.83 mg/g change 
from baseline).   There was no difference in fecal sIgA in PP-cesarean-delivered infants, data not 
shown.   
In cesarean-delivered infants, PRO (54.9 + 30.0 U/g change) tended to increase 
(p=0.056) anti-rotavirus-specific IgA concentrations from V1 to V2, however no change was 
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observed with CON (11.5 + 17.0 U/g change) (Figure 3.5).  There was also a trend (p=0.07) for 
probiotic supplementation to increase anti-rotavirus-specific IgA concentration from V1 to V2 
when all three groups were analyzed without stratification by delivery method (PRO: 20.2 + 20.5 
U/g change; CON: 6.0 + 23.1 U/g change; BF: -59.1 + 31.6 U/g change).   
From V1 to V2, the increase in anti-poliovirus-specific IgA concentration was higher in 
all PRO (48.2 + 40.2 U/g change) versus CON (-18.0 +20.0 U/g change) stool samples 
(p=0.031), including those from cesarean-delivered infants (p=0.026; PRO: 51.6 +26.2 U/g 
change; CON: 19.4 + 19 U/g change) as shown in Figure 3.6.  A similar trend (p=0.10) in 
poliovirus-specific IgA concentration is noted in vaginally-delivered infants consuming PRO; 
however, statistical significance was not achieved due to high variability (PRO:  45.9 + 66.6 U/g 
change; CON: -50.7 + 31.8 U/g change  (Figure 3.6).  Again, there was also a trend (p=0.075) 
for probiotic supplementation to increase anti-poliovirus-specific IgA concentration from V1 to 
V2 when all three groups were analyzed without stratification by delivery method (PRO: 48.2 + 
40.2 U/g change; CON: -18.0 + 20.0 U/g change; BF: -16.5 + 20.3 U/g change). 
Fecal calprotectin concentration increased from V0 to V1 in the all PRO group (P=0.043) 
as compared to CON (Figure 3.7).  This same difference was also seen in infants delivered by 
cesarean section (p=0.039) but not by those delivered vaginally (p=0.21).  At V2 there was no 
difference  (p=0.16) between PRO (177.9 ± 34.3 µg/g feces) and CON (149.9 ± 15.3 µg/g feces) 
infants fecal calprotectin levels regardless of delivery method  The change in fecal calprotectin 
from V0 to V1 and V2 to V0  did not differ between BF and FF (data not shown).  However, BF 
infants did have significantly higher calprotectin levels than CON and PRO infants at V0 
(p=0.0002; BF: 307.8 ± 34.9 µg/g; CON: 195.2 ±  19.4;  PRO: 165.6 ± 19.9), V1 (p=0.028; BF: 
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260.3 ± 36.7 µg/g; CON: 153.9 ± 17.2;  PRO: 202.3 ± 29.3), and V2 (p=0.0024 BF: 319.2 ± 52.3 
µg/g; CON: 149.9 ± 15.2;  PRO: 177.9 ± 34.3) as shown in Figure 3.7.   
Fecal pH was not affected by treatment. However, infants in the breastfed reference 
group had significantly lower fecal pH at all time points as shown in Figure 3.8  (V0 p=0.0155; 
PRO: 6.5 ±  0.09; CON: 6.5 ±  0.1; BF: 6.1 ±  0.1; V1 p=0.0135; PRO: 6.4 ±  0.07; CON: 6.4 ±  
0.1; BF: 6.1 ±  0.1; V2 p=0.0255; PRO: 6.2 ±  0.1; CON: 6.3 ±  0.08;BF: 5.9 ±  0.1.  
Additionally, there were not differences between formula groups when stratified by delivery 
method.  
Lactate concentration (Figure 3.9) was found to be significantly higher (p=0.013) in BF 
infants as compared to FF infants at V1 (PRO 4.7 ± 0.9; CON: 3.5 ± 0.6; BF: 8.4 ± 1.8).  When 
stratified for delivery method, vaginally delivered PRO infants had decreased (p=0.033) lactate 
concentrations from V0 to V2 (-0.40 + 0.1) as compared to CON (0.23 + 0.2).  The opposite 
trend (p=0.086) was seen in cesarean-delivered PRO infants, where lactate concentrations 
increased from V0 to V2 PRO (0.02 + 0.2) as compared to CON (-0.62 + 0.9).  Lactate 
concentrations did not differ between formula groups when left unstratified for delivery.           
There were no differences in stool frequency, color, or consistency between the two 
formula groups.  The breastfed group had a significantly greater average daily number of bowel 
movements (3.4 per day at V1 and 2.4 per day at V2) than each of the two formula groups (1.3 to 
1.4 per day at V1 and V2).  Breastfed infants had yellow stools 85% of the time, and these 
proportions were significantly higher than in either of the two formula groups (18.5% in PRO 
versus 9% in CON).  Approximately 84% of the time, infants assigned to formula had soft stool 
which was significantly higher than breastfed infants.  However, breastfed infants had 
significantly higher proportions of liquid stool than either formula group (p<0.0001).  There 
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were no differences among the groups in gas, spit-up, or vomiting.   Mean weight percentiles 
generated from the World Health Organization growth charts did not differ among PRE, CON, 
and BF.  Breastfed infant girls had significantly higher weight percentiles than infant girls fed 
with either formula. 
 
DISCUSSION 
B. lactis was detected within the collected stool samples following ingestion of the 
probiotic (B. lactis) containing study formula.  The use of a primer-probe specific for the tuf gene 
region allowed for highly sensitive and specific quantification of B. lactis.  The qPCR assay has 
been shown to have sensitivity to 10 copies of the tuf gene and specificity adequate to 
differentiate between even the most closely related B. animalis subspecies animalsis as well as B. 
breve, B. longum, B. suis (Solano-Aguilar et al., 2008).  Our results demonstrated that Bb12 was 
present in significantly greater levels in PRO infants as compared to CON and BF.  Although 
Bb12 was detected in the majority of fecal samples after 2 weeks (88%) and 6 weeks (93%) of 
probiotics feeding it was not detected in 100% of the fecal samples.  This likely relates to 
insufficient tuf gene copy numbers present in the tested fecal sample when quantities were 
limited.  Additionally, it is possible that unreactive samples were related to non-compliant use of 
study formula.   
Secretory IgA (sIgA) is a predominant mucosal immunoglobulin and plays an integral 
role in protection from antigens, toxins, and potential pathogens (Forchielli and  Walker, 2005).  
Fecal levels of sIgA are a good measure of levels of sIgA available in the colon and can be 
assessed non-invasively.  Not surprisingly, we observed a significantly higher concentration of 
total fecal sIgA in breast fed infants than formula fed infants due to the exogenous contribution 
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of sIgA through the mother’s breast milk.  Within the formula fed groups, we found that the 
probiotic formula containing Bb12 significantly increased fecal sIgA from baseline in vaginally 
delivered PRO infants by ITT analysis after 6 weeks of feeding and had a very strong trend 
toward increasing sIgA from baseline in vaginally delivered PRO per protocol infants after 6 
weeks of feeding.  No treatment effect of B. lactis was found on sIgA levels in cesarean-section 
delivered infants or when treatment groups were left unstratified for delivery method.  A 
potential explanation for the treatment effect within vaginally delivered infants PRO infants and 
not in cesarean delivered PRO infants may be related to the composition of the infants’ 
microbiota.  Microbiota varies based on delivery method, and it is well established that infants 
born by vaginal delivery have higher proportion of bifidobacteria than their cesarean delivered 
counterparts (Yoshioka et al., 1983; Harmsen et al., 2000; Penders et al., 2006; Biasucci et al., 
2008; Huurre et al., 2008).  Additionally, studies have found that bifidobacteria stimulate the 
production of sIgA (Fukushima et al., 1998; Mullie et al., 2004; Rautava et al., 2006).  Thus, the 
addition of B. lactis to an already bifidobacteria dominant microbiota in vaginally delivered 
infants may have enhanced the effects of the presence of the probiotic and thus resulted in larger 
change from baseline in secretory IgA during the treatment period.   
Alternatively, the addition of B. lactis may have contributed to further enhancement of 
bifidobacteria as was the case in preterm infants supplemented with B. lactis from the first day of 
birth until 21 days where a trend was found between bifidobacteria cell counts and fecal sIgA 
(r=0.344, p=0.08) (Mohan et al., 2006).   As these effects were only seen in vaginally delivered 
infants and not cesarean delivered infants, inadequate power may have been an issue within the 
smaller subsample of infants (14 infants in both PRO and CON in both the ITT and PP groups) 
stratified for cesarean section delivery.  As discussed above, this trial was powered to detect a 
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change in sIgA regardless of delivery method.  The effects of B. lactis supplementation on fecal 
SIgA in infants have only been investigated in a limited number of trials to date.   B. lactis 
supplementation in healthy children and preterm infants has been shown to enhance fecal SIgA 
(Fukushima et al., 1998; Mohan et al., 2008).  Bakker-Zierikzee and colleagues investigated 
Bb12 supplementation in healthy full-term infants; however, they did not detect a significant 
effect of Bb12 supplementation on fecal SIgA levels.  Our differing results may be due to 
inadequate power of the Bakker-Zierikzee and colleagues’ study as the post-hoc power analysis 
suggested a five-fold increase in each group was needed to reach adequate sensitivity (Bakker-
Zierikzee et al., 2006).  Additionally, statistical analysis on data in the Bakker-Zierikzee trial was 
done only on infants comprising the 10
th
 to 90
th
 percentile due to high variation between subjects 
instead of utilizing logarithmic transformations to normalize data, and delivery method was not 
accounted for in their statistical modeling.  In the present study, log transformations were utilized 
to normalize data due to high variation, and analysis was stratified by delivery method thus 
allowing for detection of the significant increase in fecal SIgA from baseline in PRO infants that 
were vaginally delivered.  
Similar to our findings, Bifidobacterium longum-infantis and Bifidobacterium breve have 
been shown to increase fecal SIgA and anti-poliovirus-specific IgA in healthy full term infants 
after 4 months of feeding (Mullie et al., 2004). To the best of our knowledge, this is the first trial 
to investigate the immune modulating effects of B. lactis, or any probiotic, on fecal anti-rotavirus 
or anti-polio-specific IgA in healthy full term infants.  Few studies have investigated immune 
effects related to the interaction of infant delivery method and probiotic feeding.  One trial found 
that probiotic supplementation consisting of 4 bacteria strains (Lactobacillus rhamnosus GG, L. 
rhamnosus LC705, Bifidobacterium breve Bb99, and Propionibacterium freudenreichii ssp. 
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Shermanii) provided protection from IgE-associated allergy in caesarean delivery children until 
age 5 while those born by vaginal delivery were not afforded the same protective effects 
(Kuitunen et al., 2009).  Our results similarly support enhanced protective effects of probiotics in 
infants born by caesarean delivery.  As our study contained B. lactis and the other two trials each 
included Bifidobacteria spp. it is possible that the microbiota’s of the infants in all three trails 
were afforded immunological benefits associated with an enriched Bifidobacterium population as 
an effect of the respective bifidobacteria added as probiotics.   As discussed above, it is well 
established that the dominant bacteria within vaginally delivered infants is bifidobacteria 
(Yoshioka et al., 1983; Harmsen et al., 2000; Penders et al., 2006; Biasucci et al., 2008; Huurre 
et al., 2008).  As shown in our trial and the trial by Kuitunen and colleagues, further 
immunological benefit may be gained by a Bifidobacterium probiotic to cesarean delivered 
infants as it may be contributing to a shift the commensal bacterial populations to be more 
similar to the vaginally-delivered infant (Kuitunen et al., 2009).        
At birth, the immune system of infants is skewed toward T-helper (Th)-2 responses 
(Prescott et al., 1998).  According to the “hygiene hypothesis”, exposure to bacteria is important 
in changing the immune response to be more skewed toward Th-1 responses, which in turn has 
been linked to reducing propensity to allergic diseases (Yazdanbakhsh et al., 2002; Bufford and  
Gern, 2005; Rook and  Brunet, 2005; Weng and  Walker, 2006).  As infants born by cesarean 
section have been shown to have increased incidences of allergic diseases such as allergic 
rhinoconjunctivitis and asthma one could speculate that this correlation may also be related to the 
hygiene hypothesis (Renz-Polster et al., 2005). By extension, the sterile delivery methods of 
cesarean section delivery may provide a lesser initial exposure to bacteria and hinder the infant’s 
progression toward a more skewed Th1 response.  In the present study, cesarean delivered PRO 
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infants saw a significant increase in both anti-poliovirus-specific and anti-rotavirus-specific- 
fecal IgA after 6 weeks of feeding.  Thus, it is possible that Bb12 provided immune-modulating 
bacterial exposure that was more pronounced in the cesarean-delivered infants.  Additionally, all 
per protocol PRO infants experienced an increase in anti-poliovirus-specific fecal IgA suggesting 
that the addition of Bb12 to infant formula may be helpful in mitigating some of the negative 
immune-related effects associated with formula feeding.      
Calprotectin, a zinc and calcium binding protein which constitutes over half of the 
soluble cytosolic protein within human neutrophil granulocytes, is a non-invasive marker of 
gastrointestinal inflammation (Steinbakk et al., 1990; Carroll et al., 2003; Kapel et al., 2010).   
Calprotectin has been measured in a number of studies to evaluate inflammation and immune 
status of the gastrointestinal tracts of infants (Golden et al., 2002; Olafsdottir et al., 2002; 
Rugtveit and  Fagerhol, 2002; Carroll et al., 2003; Campeotto et al., 2004; Mohan et al., 2006; 
Dorosko et al., 2008; Rhoads et al., 2009; Calabrese et al., 2010; Kapel et al., 2010).  Existing 
literature reports conflicting data regarding fecal calprotectin in breastfed and formula-fed 
infants.  Our findings are in agreement with some published studies in full term infants 
monitored during the pre-weaning period showing calprotectin concentrations were significantly 
higher in BF infants as compared to FF infants (Dorosko et al., 2008; Calabrese et al., 2010).   
Few studies have evaluated the effects of probiotic supplementation on calprotectin levels 
(Mohan et al., 2008; Kukkonen et al., 2010).  One study in healthy full-term infants assessed the 
effects of a probiotic capsule containing 4 bacteria strains (Lactobacillus rhamnosus GG, L. 
rhamnosus LC705, Bifidobacterium breve Bb99, and Propionibacterium freudenreichii ssp. 
Shermanii) on calprotectin and fecal SIgA levels at 3 and 6 months of age.  This trial found a 
positive correlation between fecal SIgA and calprotectin and reported a correlation between 
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higher fecal SIgA levels and lower IgE associated atopic diseases at 2 yrs of age (Kukkonen et 
al., 2010).  Kukkonen and colleagues concluded from this trial that these findings were indicative 
of immune maturation with associated reduction in risk for atopic diseases during the first two 
years of life.  Further, they proposed that this slight immune activation may be a potential 
mechanism by which probiotics stimulate immune maturation.   Another trial which investigated 
the effect of probiotic feeding (B. lactis) on preterm infant fecal calprotectin levels found the 
opposite effect in that calprotectin levels were attenuated in the infants consuming Bb12.  Our 
results suggest that the effect of probiotic supplementation varies over time, with an initial 
increase in calprotectin levels followed by a decrease to levels of non-supplemented infants by 6 
weeks of feeding.  The results of our trial and that of Kukkonen and colleagues support the 
hypothesis that B. lactis aids in priming of the gastrointestinal tract of full term infants to 
enhance maturation and attenuate the inflammatory responses to bacterial and dietary antigens. 
Clearly, more research is needed to investigate the effects of probiotic supplementation on 
calprotectin in infancy.   
Fecal pH was lower at each time point in BF versus FF infants; however there were no 
differences between FF groups even when stratified for delivery method.  In coordination with 
the lower pH, fecal lactate concentrations were higher in BF infants as compared to FF infants, 
but again no effect was seen as a result of the addition of Bb12 to infant formula when infants 
were not separated by delivery method.  When infants within the formula groups were stratified 
for delivery method, fecal lactate concentrations decreased from baseline to visit 2 (6 weeks of 
study formula) within the vaginally delivered infants with the opposite trend occurring within the 
cesarean-delivered infants.  As these small changes in fecal lactate concentration were not 
mirrored by a significant change in fecal pH, the biological relevance of this is likely minimal. 
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Our results differ from Mohan and colleagues where fecal pH was shown to decrease in preterm 
infants fed B. lactis and the decreased pH was mirrored by an increase in fecal lactate 
concentration (Mohan et al., 2008).  Trials in full-term infants have not investigated the effects of 
Bb12 supplementation on fecal lactate levels.   
 
CONCLUSIONS 
By virtue of containing bioactive substances such as SIgA, microbes and human milk 
oligosaccharides, breast feeding is superior to formula feeding in maintaining high intestinal 
levels of protection in infants during the first 3 months of life.  Breastfed infants’ total fecal SIgA 
levels decrease over time; however, they remain significantly higher than formula-fed infants at 
all time points. Infants fed formula supplemented with B. lactis had significantly higher levels of 
B. lactis and infants born by vaginal delivery had increased concentrations of SIgA.  
Additionally, infants born by cesarean-section who received the probiotic formula had enhanced 
immune response to poliovirus and rotavirus vaccines as evidenced by an increase in anti-
rotavirus- and anti-poliovirus-specific IgA. These results demonstrate that negative immune-
related effects from absence of breast feeding and cesarean-section delivery may be mitigated by 
including Bifidobacterium animalis subspecies lactis B. lactis in infant formula and thereby 
providing infants a safe, dietary, immune-modulating bacterial experience.  Anti-viral specific 
mucosal antibodies in this study were evident after only a single dose of vaccines. This 
enhancement in antibody responses could be of further clinical significance as related to levels of 
protection achieved from oral viral vaccines in non-breast fed infants. Further research is needed 
to investigate the degree and potential for immune-related benefits of probiotics, and their 
relation to infant microbiota, and mode of delivery.   
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TABLES AND FIGURES 
 
 
 
 
 
Table 3.1.  Baseline characteristics of Intention-To-Treat (ITT) Population.  BF: breastfed; CON: control infant formula group; PRO: 
probiotic infant formula group.   Data are expressed as means + SEM.   
  
 BF CON PRO 
 Vaginally 
Delivered 
(n=39) 
Delivery by C-
section (n=13) 
Vaginally 
Delivered 
(n=27) 
Delivery by C-
section (n=16) 
Vaginally 
Delivered 
(n=34) 
Delivery by C-
section (n=16) 
Birth weight (g) 3355±79 3552±126 3176±82 3379±78 3277±75 3278±149 
Birth length (cm) 50.8±0.5 50.4±0.6 50.3±0.6 48.6±0.4 50.3±0.5 49.5±0.5 
Gestational age 
(weeks) 
39±0.1 39±0.3 38±0.2 38±0.2 39±0.2 39±0.2 
Pre-study feeding 9 subjects 
received some 
formula for 1 
day 
4 subjects 
received some 
formula for 
1.3±0.3 days 
7 subjects 
received 
breastmilk for 
11.3±4.5 days 
6 subjects 
received 
breastmilk for 
10.3±5.3 days 
5 subjects 
received 
breastmilk for 
13.1±4.9 days 
3 subjects 
received 
breastmilk for 
9.3±4.0 days 
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Figure 3.1.  Schematic of subject retention and inclusion in stool per protocol analysis (PP).  BF: breastfed; CON: control infant 
formula group; PRO: probiotic infant formula group; SAE: serious adverse event.   
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Figure 3.2.  Effect of probiotic supplementation on fecal B. lactis copy numbers per gram feces in all infants.  There was no 
difference at baseline (V0) in copy numbers between groups (p=0.12).  Probiotics increase B. lactis copy numbers in formula-fed 
infants after 2 week and 6 weeks of study formula consumption.    PRO infants had significantly greater (p=0.0095) B. lactis at V1 and 
V2 as compared to CON at V1and V2. Data are expressed as means + SEM.  BF: breast-fed reference group; CON: control infant 
formula group; PRO: probiotic infant formula group.V0: baseline sample at 6 weeks of age; V1: 8 weeks of age; V2 12 weeks of age.    
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Figure 3.3.  Effect of probiotic supplementation on fecal sIgA concentration (in milligram per gram feces) of infants at baseline (V0), 
after 2 weeks (V1) and after 6 weeks (V2).  Breastfed infants have higher fecal sIgA (p<0.001) than formula-fed infants at all time 
points.  Data are expressed as means + SEM.  BF: breastfed CON: control infant formula group; PRO: probiotic infant formula group 
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Figure 3.4 a.          Figure 3.4 b.  
 
 
Figure 3.4.   Within the intent to treat design probiotics increased fecal sIgA in vaginally delivered formula-fed infants after 6 weeks 
of study formula consumption (3.4a).  Data are expressed as means + SEM.  CON: control infant formula group; PRO: probiotic infant 
formula group.  Vaginally-delivered PRO infants had a significantly greater (p=0.046) increase in fecal sIgA concentration from V0 
(baseline at 6 weeks of age) to V2 (12 weeks of age) compared to CON.  Bb12 supplementation also tended (p=0.063) to enhance the 
change of fecal sIgA at V1 (8 weeks of age) in PRO ITT-vaginally delivered infants as compared to CON.  There was no treatment 
effect in ITT-cesarean section infants in change from baseline at V1 (p=0.24) or V2 (p=0.26) (3.4b).  
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Figure 3.5.  Probiotics increase anti-rotavirus-specific IgA in infants delivered by C-section.   Data are expressed as means + SEM.  
CON: control infant formula group; PRO: probiotic infant formula group.  PRO infants delivered by cesarean-section had greater 
(p=0.056) changes in anti-rotavirus-specific IgA concentrations from V1 (8 weeks of age prior to receiving vaccination) to V2 (12 
weeks of age after receiving vaccination). 
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Figure 3.6.   Fecal anti-poliovirus-specific IgA concentration increased in infants consuming probiotic formula.   Data are expressed 
as means + SEM.  CON: control infant formula group; PRO: probiotic infant formula group.  From V1 (8 weeks of age prior to 
receiving vaccination) to V2 (12 weeks of age after receiving vaccination), the increase in anti-poliovirus-specific IgA concentration 
was higher (p=0.031) for PRO vs CON.  When looking at infants based on delivery method, PRO infants delivered by C-section had 
significantly greater (p=0.026) changes in fecal anti-poliovirus-specific IgA concentration as compared to CON infants delivered by 
C-section.  A similar numerical increase in change in anti-poliovirus-specific IgA concentration was noted in vaginally-delivered PRO 
infants as compared to CON infants; however, statistical significance was not achieved due to high variability. 
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Figure 3.7.  Effect of feeding method on fecal calprotectin concentration (in microgram per gram feces) in infants at baseline (V0), 
after 2 weeks (V1) and after 6 weeks (V2).  BF infants did have significantly higher calprotectin levels than CON and PRO infants at 
V0 (p=0.0002), V1 (p=0.028), and V2 (p=0.0024). Fecal calprotectin concentration also increased from V0 to V1 in PRO (P=0.043) 
vs. CON denoted with the #.  Data are expressed as means + SEM.  CON: control infant formula group; PRO: probiotic infant formula 
group. 
  
# 
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Figure 3.8.  Breast fed infants had significantly lower fecal pH at baseline (V0), after 2 weeks (V1) and after 6 weeks (V2) as 
compared to PRO and CON.  Data are expressed as means + SEM.  BF: breastfed CON: control infant formula group; PRO: probiotic 
infant formula group. *p<0.05.   
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Figure 3.9.  Breast fed infants had significantly higher fecal lactate concentration at after 2 weeks (V1) compared to PRO and CON. 
Data are expressed as means + SEM.  BF: breastfed CON: control infant formula group; PRO: probiotic infant formula group. 
*p<0.05. 
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CHAPTER 4 
 
EFFECTS OF PREBIOTIC-CONTAINING INFANT FORMULA ON 
GASTROINTESTINAL TOLERANCE AND FECAL MICROBIOTA IN A 
RANDOMIZED CONTROLLED TRIAL
2
  
 
 
ABSTRACT  
Background: Infant formula containing prebiotics may beneficially impact gastrointestinal 
tolerance and composition of the commensal microbiota.  Objective: Assess gastrointestinal 
tolerance and fecal microbiota, pH, and short-chain fatty acid (SCFA) concentrations of infants 
consuming formula with or without prebiotics.  Design: Healthy, full-term formula-fed infants 
were enrolled in a randomized, double-blind, controlled trial with 2 groups studied in parallel to 
a breastfed comparison group (BF). Formula-fed infants (FF) were randomized to consume a 
partially hydrolyzed whey formula with (PRE) or without (CON) 4g/L of galacto-
oligosaccharides and fructo-oligosaccharides (9:1) for 6 weeks.  Fecal bacteria, pH and SCFA 
were assessed at baseline, 3, and 6 weeks.  Caregivers of subjects recorded stool characteristics 
and behavior for 2 days before the 3- and 6-week visits.  Results: Feces from infants fed PRE 
had a higher absolute number (p=0.0083) and proportion (p=0.0219) of bifidobacteria than feces 
of CON-fed infants and did not differ from feces of BF.  BF had a higher proportion of 
bifidobacteria than CON (p=0.0219) and a lower number of Clostridium difficile than FF 
(p=0.0087).  Feces from formula-fed infants had higher concentrations of acetate (p<0.001), 
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butyrate (p<0.001), propionate (p<0.001) and total SCFAs (p=0.0230) than BF; however, fecal 
pH was lower (p=0.0161) in PRE and BF than CON. Prebiotic supplementation did not alter 
stool patterns, tolerance, or growth.  Compared to FF, BF had more frequent stools that were 
yellow (p<0.0001) and more often liquid (p<0.0001).  Conclusions:  Infant formula containing 
the studied oligosaccharides is well-tolerated, increased abundance and proportion of 
bifidobacteria, and reduced fecal pH in healthy infants. 
 
CLINICAL RELEVANCY STATEMENT  
Breast milk, the optimal source for infant nutrition, provides a source of prebiotics in the 
form of human milk oligosaccharides which in turn partially contribute to the distinct 
bifidobacteria-dominant microbiota of a breastfed infant as compared to the formula-fed 
infant.  Although the addition of oligosaccharides from human milk is not clinically feasible at 
this time, the addition of prebiotics in the form of galacto-oligosaccharides and fructo-
oligosaccharides to infant formula has been reported to facilitate development of a more 
desirable microbiota pattern in the formula-fed infant.  This study demonstrates that 
supplementation of infant formula with galacto-oligosaccharides and fructo-oligosaccharides is 
well-tolerated and modestly increased fecal bifidobacteria and lowered fecal pH. 
 
INTRODUCTION 
Breastfeeding promotes the establishment of intestinal microbiota typically characterized 
by predominance of bifidobacteria. This effect is not seen with infant formulas in routine use. 
One strategy to improve infant formula is to modify it in ways that can influence the composition 
and activity of the intestinal commensal microbiota of the formula-fed infant to better reflect that 
of the breastfed infant.  Altering the microbiota of the formula fed infant is thought to provide 
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benefits related to enhanced mucosal immunity.  Studies by Bakker-Zierikzee et al. and 
Scholtens et al. have demonstrated that supplementation of infant formulas with GOS/FOS is 
associated with enhanced fecal secretory IgA levels (Bakker-Zierikzee et al., 2005; Scholtens et 
al., 2008).  Secretory IgA is found within breast milk and provides an important benefit of 
decreased pathogen adherence within the gastrointestinal tract.  Additionally, other studies in 
infants have found that providing GOS/FOS can enhance immunity with outcomes such as 
decreased incidence of atopic dermatitis and infection (Moro et al., 2006; Arslanoglu et al., 2007; 
Gruber et al., 2010). 
Colonization of the infant’s gastrointestinal tract primarily begins at birth, with the mode 
of delivery impacting the types and numbers of bacteria present.  Vaginal delivery results in 
inoculation of bacteria from the mother’s cervix, vagina and feces while cesarean delivery, under 
more sterile conditions, provides the infant with bacterial exposure related to the hospital 
environment, tools, hospital personnel and other infants (Bettelheim et al., 1974; Lennox-King et 
al., 1976a; Lennox-King et al., 1976b; Brook et al., 1979).  However, after delivery the infant’s 
diet soon begins to impact the microbiota.  Breast milk provides both microbes (up to 
108microbes/L) and prebiotics for bacterial fermentation (human milk oligosaccharides in ranges 
of 7-12g/L) (Collins and Gibson, 1999; Heikkila and Saris, 2003; Martín et al., 2003; Boehm et 
al., 2004). 
Prebiotics are carbohydrates that are resistant to digestion by human enzymes and 
selectively stimulate the growth and activity of beneficial bacteria in the gastrointestinal tract 
(Gibson and  Roberfroid, 1995). Oligosaccharides have been shown to increase the number and 
concentration of bifidobacteria in the feces in a dose-dependent manner (Moro et al., 2002).  
Therefore, it has been postulated that the dominance of bifidobacteria in breastfed infants’ 
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microbiota may be responsible for some of the health benefits the breastfed infant possess in 
comparison to the formula-fed infant. 
A number of studies have shown that infant feeding with the prebiotics galacto-
oligosaccharides (GOS) and fructo-oligosaccharides (FOS) is safe for healthy term infants and 
promotes satisfactory growth (Moro et al., 2002; Schmelzle et al., 2003; Haarman and  Knol, 
2005; Knol et al., 2005a; Knol et al., 2005b; Waligora-Dupriet et al., 2007; Costalos et al., 2008; 
Braegger et al., 2011).  Additionally, a large number of clinical trials in term infants have shown 
that supplementation of infant formula with GOS and FOS at varying concentrations and blends 
increases bifidobacteria in feces as compared to control (Moro et al., 2002; Moro et al., 2003; 
Schmelzle et al., 2003; Ben et al., 2004; Boehm et al., 2004; Bakker-Zierikzee et al., 2005; 
Haarman and  Knol, 2005; Knol et al., 2005a; Knol et al., 2005b). 
The majority of studies in the literature of prebiotic-containing infant formulas have been 
conducted outside of the United States and in the context of several different formula matrices.  
The intent of the study described herein is to investigate the effects of a prebiotic-containing 
partially hydrolyzed whey infant formula on tolerance, stool characteristics, and commensal 
microbial populations in infants from the United States.  It is hypothesized that consumption of 
the prebiotic-containing formula would be well-tolerated and increase fecal bifidobacteria 
proportions as compared with the control formula. 
 
METHODS 
This randomized, controlled, double-blind prospective clinical trial of two formula-fed 
groups with an exclusively breastfed reference group was conducted from November 2005 to 
May 2006 in the United States at 4 study sites (Pediaresearch, Owensboro KY; University of 
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Iowa, Iowa City IA; Children’s Medical Group, Poughkeepsie NY; Carle Clinic, Urbana IL).  
The randomized trial included healthy, full-term (37-42 weeks gestation) infants who were 2-8 
weeks old and whose mothers had elected not to continue breastfeeding and who had not 
received solid foods.  All study infants were required to live within 45 minutes of a study center 
and have a working freezer in their home.  Infants with any of the following conditions were 
excluded from the study: known or suspected cow-milk allergy; major deformities and/or illness 
including cardiovascular, gastrointestinal, renal, neurological and/or metabolic; admission to 
intensive care or required readmission to hospital in first 14-28 days of life; diarrhea requiring 
treatment in the 7 days prior to enrollment; receiving therapeutic iron supplementation or 
medication other than multivitamin supplement.  In addition, infants receiving antibiotic therapy, 
or breastfed subjects whose mothers had received antibiotic therapy, within 30 days prior to 
enrollment were not eligible for the study. Parents of all participating infants provided written 
informed consent at the time of enrollment.  The study was approved by the relevant Institutional 
Review Board (IRB) of each study site and the University of Illinois IRB, where laboratory 
analyses occurred.  The procedures followed were in accordance with the ethical standards of the 
responsible institutional or regional committee on human experimentation. 
The primary objective of the study was to compare the proportions of fecal bifidobacteria 
in infants fed formula with or without prebiotics for 6 weeks.  Secondary outcomes were 
absolute and relative fecal lactobacilli, bacteroides, and C. difficile; fecal pH and short chain 
fatty acid (SCFA) concentrations; gastrointestinal (GI) tolerance; and body weight.  
Formula-fed (FF) infants were randomized to receive either the control formula (CON) or 
the prebiotic containing formula (PRE).  The control formula used was a commercially available 
partially hydrolyzed whey infant formula (Nestlé Good Start Supreme DHA/ARA, Florham 
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Park, NJ).  The test formula was nutritionally identical to the control formula with the exception 
of the addition of 4 g/L of GOS (Vivinal
®
 GOS; Domo, the Netherlands) and short-chain FOS 
(Beneo™ P95 ; Orafti N.V., Belgium) (9:1) (Table 4.1).  A dose of 4 g/L was chosen to 
conservatively mimic the neutral oligosaccharide content of human breast milk (Thurl et al., 
1993).  As the fermentability of GOS/FOS is higher than that of human milk oligosaccharides, 
provision of a lower concentration of prebiotic than that of breast milk was hypothesized to 
provide adequate substrate for enhancing commensal bacteria such as bifidobacteria (Chaturvedi 
et al., 2001a; Coppa et al., 2001; Smiricky-Tjardes et al., 2003).  Randomization for FF subjects 
was stratified according to route of delivery (vaginal versus cesarean-section).  Subjects received 
their assigned formula as exclusive feeding for a period of 6 weeks.  The self-selected breastfed 
reference group was exclusively breastfed and followed for a period of 6 weeks.  Weight of each 
subject was taken at baseline and after 3 and 6 weeks of feeding at study visits.   
The caregiver of each subject was responsible for keeping records for 2 days before the 
3- and 6-week visits to assess nutritional intake, stool assessment, and GI tolerance indicators.  
The amount of formula consumed at each feeding was recorded for formula fed infants whereas 
length of each feeding at the breast, or the amount of expressed breast milk given at each 
feeding, was documented for breastfed infants.  Stool color (green, yellow, brown, black), 
consistency (hard, formed, soft, liquid), odor (normal or unusual) and number of stools passed 
within each 24-hour period were recorded.  In addition, the frequency of gas, spitting up, 
vomiting, crying bouts lasting more than 10 minutes, fussing bouts lasting more than 30 minutes, 
“colic” as perceived by the caregivers as number of episodes of intense, unsoothable crying with 
painful facial expressions and pulling up of legs were documented. 
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  Within 72 hours of each study visit, stool samples were collected within 30 minutes of 
passing at home in 30 ml polypropylene fecal collection tubes (Globe Scientific, Paramus, NJ).  
Caregivers then brought the fresh sample in a cooler with ice packs to the study site within 30 
minutes of collection, or the sample was placed in a home freezer for 2-72 hours.  In the latter 
case, samples were then transported to a study site in a cooler with ice packs with a maximum 
transit time of 45 minutes.  At the study site, samples were stored at -20°C for a maximum of 2 
weeks prior to storage at -80°C until analysis. 
Enumeration of Fecal Microbiota by Fluorescent In Situ Hybridization (FISH) 
To study the gastrointestinal microbiota, enumeration was conducted using FISH to 
quantify bacteria present in fecal samples.  Specifically, Bifidobacteria spp., 
Bacteroides/Prevotella, C. difficile, and Lactobacillus spp. were quantified (Ribo Technologies 
Microbial Diagnostics, Groningen, The Netherlands) (Matteuzzi et al., 2004).   Briefly, fecal 
samples were homogenized vigorously with glass beads and centrifuged at 80 x g to remove 
debris.  One hundred microliters supernatant, which contained the bacteria, was removed and 
added to a clean microcentrifuge tube and incubated with 10 μl fixative at 4°C for 30 
minutes.  The bacterial cells were then dehydrated with 70% ethanol and hybridized with the 
species-specific rRNA probes at 50°C in the dark for 16 to 24 hours to quantify the number of 
each respective fluorescein isothiocyanate (FITC)-labeled bacterial target strain.  The bacterial 
cells were counted visually using 100 x magnification on an Axioskop 40 Carl Zeiss 
epifluorescence microscope (Goettingen, Germany) fitted with a 50 watt arc lamp and double 
filter for FITC (excitation 495 nm and emission 520 nm) and Cy3 (excitation 550 nm and 
emission 570 nm).  The quantitative value was then normalized to total bacterial counts using 
Eub 338, specific for the domain Bacteria.  Each fecal microbiota population was analyzed in 
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two ways: first, quantitatively, log
7-10 
cells per gram feces, as well as normalized to total bacteria 
as a percentage at each time point.   
Short Chain Fatty Acid Quantification 
Concentrations of SCFAs were determined using gas chromatography (GC)/mass 
spectrometry (MS) based on the method of Knol and colleagues (Knol et al., 2005b).  Three 
hundred and fifty milligrams of feces were vortexed with 350 μl 1.2 g/L 2-ethylbutyric acid, 350 
μl distilled sterile water, and 100 μl of formic acid for 2 minutes.  Samples were then centrifuged 
for 5 minutes at 16,000 x g to remove large particles and the supernatant was stored at -20°C in 
GC vials until analysis.   Acetate, butyrate, propionate, isobutanate and valerate were quantified 
using a GC/MS (Agilent 6890N Santa Clara, CA) equipped with an electron impact ionization 
and chemical ionization, flame ionization detector, thermal conductivity detector, 7683B 
autosampler, and 5973N mass selective detector.  Five microliters of sample were injected at 
80°C into the column (Zebron-wax Plus, 30 m x 250 μm, film thickness 0.25 μm, Phenomenex, 
Torrance, California) using helium as a gas carrier (11.61 psi).  After injection of the sample into 
a splitless inlet, the oven was heated to 230°C where it was transferred to the MS at the same 
temperature with a scan range of 25 to 800.  Commercial Wiley and National Institute of 
Standards and Technology (NIST) libraries were used to interpret the mass spectra. The levels of 
SCFAs were determined using 2-ethylbutyric acid as an internal standard in combination with an 
external standard curve.   SCFAs were expressed as absolute quantity (μmol per gram feces) and 
on a relative basis (normalized to total concentration of SCFAs) at each time point.   
Fecal pH 
Fecal pH was used as a surrogate marker for the acidity of the colonic contents, altered 
primarily by the degree of fermentation occurring in the colon.  Fecal pH value was obtained by 
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submerging the pH probe (Futura Refillable Probe, Beckman Instrument, Inc., Fullerton, CA) 
into the sample immediately upon thawing and waiting until the pH meter (UP-5, Denver 
Instrument, Denver, CO) reading stabilized.   
 Dry Matter Determination 
Dry matter concentrations of fecal samples were used to normalize bacterial and SCFA 
measurements.  Dry matter concentrations of fecal samples were determined by AOAC methods 
by obtaining the dry weight of crucibles by baking them overnight in a 105
o
C oven, then 
allowing the crucibles to reach room temperature within desiccators.  Once the dry weight of the 
crucible was obtained, an aliquot of 0.025-1.0 g feces was treated in the same manner so that the 
dry matter proportion of the fecal sample could be determined (Association of Ofﬁcial Analytical 
Chemists, 1984).  
Statistical Methods 
Statistical analyses were carried out using an analysis of variance (ANOVA) for a 2 x 3 
factorial design for fecal bacterial populations, pH and SCFAs.  The random and fixed effects 
were visit (visit = 3) and treatment (treatment = 3).  Sources of variation were the visit, 
treatment, and visit by treatment interaction.  The random effect for route of delivery and study 
site were included in the model.  If a significant visit by treatment interaction existed, the 
interaction was broken down into its component parts.  In addition, a longitudinal analysis for 
repeated measurements of fecal bacterial and SCFA data at baseline, visits 1, and visit 2 using a 
mixed effects model was also done.  Normality was tested using the Shapiro-Wilk statistic.  Log 
transformations were utilized as needed.  To compare the differences in tolerance and body 
weight data between the two formula groups and the breastfed group, a general linear model 
analysis was performed followed by a Tukey-Kramer procedure to control overall type 1 error 
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rate (Tukey, 1954; Kramer, 1956).  Computations were conducted using SAS (Version 9.1; SAS 
Institute, Cary, NC).  Statistical significance was defined as p≤0.05.  All values are shown as 
mean ± SEM. 
 
RESULTS  
  Of 146 recruited infants, 139 gave a baseline stool sample and continued in the study 
(Figure 4.1).  At the baseline visit, 50 breastfed infants were enrolled, and 89 formula-fed 
infants were randomized to PRE (43 subjects) or CON (46 subjects).  123 infants completed all 
visits (attrition rate of 12%).  Three subjects in PRE, 10 subjects in CON, and 3 BF subjects did 
not complete the study.  While CON group had a higher attrition rate, there were no differences 
in tolerance or occurrence of adverse events during the study.  Birth weight, length, gestational 
age, or route of delivery did not differ between feeding groups.  Average formula intake was 798 
± 30 milliliters per day for both formula groups.  Breastfed infants were fed an average of 7.0 ± 
0.1 times per day. 
Stool samples from 102 infants were analyzed.  Reasons for excluding samples in stool 
analyses include false inclusion (3), incorrect timing of stool collection (1), non-compliance (4), 
and antibiotic use (13).  Tolerance outcomes and growth are reported for all recruited subjects on 
an intention-to-treat basis.  Data on fecal samples are reported on per protocol subjects only. 
Both statistical approaches employed in analyzing fecal bacteria and SCFA gave similar results 
whether looking at data for dry or wet fecal matter.  Unless otherwise indicated, for these 
measures, the ANOVA model results are reported for wet weight of stools. 
Absolute and relative bacterial abundance in fecal samples at all time points are reported 
in Table 4.2.  Dependent variables impacted by visit and/or treatment are outlined on the figure 
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specified in the following text.  Stool of subjects consuming PRE had a higher absolute number 
(p=0.0083) and proportion (p=0.0219) of bifidobacteria than CON for all visits combined (Table 
4.2 and Figure 4.2).   Neither the absolute number, nor proportion of fecal bifidobacteria 
differed between PRE and BF.  BF had a higher proportion of bifidobacteria than CON 
(p=0.0218), though the absolute number of bifidobacteria did not differ between BF and CON.   
BF had a lower number of C. difficile in feces than FF (p=0.0087; Table 4.2, Figure 4.3).  
Formula type did not alter fecal total bacteria abundance, nor the absolute and relative abundance 
of Bacteroides/Prevotella, C. difficile, or Lactobacillus spp (Table 4.2).  On a dry matter basis, 
number of Bacteroides/Prevotella was higher in PRE than BF though there was no difference 
between PRE and CON (Table 4.2). 
Fecal pH was significantly lower (p=0.0161) in PRE (6.59 ± 0.11) and BF (6.41 ± 0.11) 
than CON (6.69 ± 0.11) for all visits combined.   Fecal SCFA concentrations are reported at all 
time points in Table 4.3.  FF infants (PRE and CON combined) had significantly higher 
concentrations of acetate, butyrate, propionate (p<0.0001), and total SCFAs (p=0.0230) than BF 
infants.  Comparing PRE and CON to each other, PRE had lower concentrations of propionate 
(p<0.0001) and butyrate (p<0.0001) than CON.  PRE infants also had a lower proportion of 
propionate (p=0.0026) and a higher proportion of acetate (p=0.0007) compared to CON.   Fecal 
valerate or isobutanate were not altered by visit or treatment. 
Formula differences did not alter fecal attributes (frequency, consistency, color, or odor).  
BF had significantly more frequent stools (p<0.0001) compared to FF (3.0/day versus 1.4/day).  
FF subjects had soft stools 83% of the time.  BF had a higher (p<0.0001) proportion of liquid 
and lower (p<0.0001) proportion of soft stools than FF.  Confirming this subjective information 
recorded by caregivers, the objective measurements taken by weighing actual fecal matter 
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showed FF had a significantly higher (p<0.001) proportion of dry matter in their stools compared 
to BF.  In formula-fed subjects, stool color was green 70% of the time.  Parents of BF infants 
reported yellow stools 80% of the time.  These differences in color were statistically significant 
(p<0.0001). 
Formula type did not impact care-giver perceived incidence of crying, fussing, parent-
perceived “colic”/cramps, spitting up, vomiting, and flatulence frequency.  Nor did formula type 
alter body weight.  Mean weight percentiles generated from the World Health Organization 
growth charts did not differ among PRE, CON, and BF.  A trend was seen for BF girls to be 
heavier than girls fed either formula (p=0.067).    
 
DISCUSSION  
A combination of GOS and FOS has demonstrated potential health promoting 
characteristics in numerous human studies by preferentially targeting specific bacteria, such as 
bifidobacteria, which have been associated with enhanced mucosal immunity.  Although the 
prebiotic source utilized in this study is different from others that have been studied in previous 
literature, results of this study add to this body of evidence as indicated by positive alterations in 
fecal microbial populations.   
Infants recruited into this study were between 2 and 8 weeks of age and therefore 
received either human milk or infant formula prior to enrollment.  The demographics of the pre-
study feeding method regarding type of formula and any amount of breast milk formula-fed 
infants received prior to study enrollment were similar between PRE and CON. The age of 
infants at enrollment into the study was also similar within each treatment group.  Although both 
of these factors likely play a role in the initial composition of the microbiota, it is interesting that 
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they did not prevent the detection of a statistically significant increase in fecal bifidobacteria 
numbers.  However, this variation may have attributed to the lack of detection in differences in 
C. difficile numbers between formula groups.  It is clinically noteworthy that consumption of 
GOS/FOS resulted in a positive shift within the commensal microbiota population even among a 
group of diverse infants.   
Prebiotic consumption increased the number of Bifidobacterium spp. when combining 
data for all visits.  The enhanced colonization of bifidobacteria in the PRE group was 
accompanied by suppressed growth of the pathogenic bacteria C. difficile in comparison to CON. 
However this was not statistically significant, possibly due to the significant variability of C. 
difficile at baseline among treatment groups.  Despite this variation at baseline, formula type 
impacted the C. difficile response over time wherein PRE decreased fecal C. difficile 
concentration 39%, whereas CON increased it 80%.   This observation is similar to the results 
from in vivo and in vitro studies that showed stimulation of bifidobacteria and suppression of 
potential pathogen, such as clostridia associated with prebiotic consumption and inoculation, 
respectively (Wang and  Gibson, 1993; Gibson and  Roberfroid, 1995; Penders et al., 2006).  In 
healthy, term infants (0-14 days), Costalos and colleagues reported that consumption of a 
prebiotic formula for 6-weeks reduced fecal clostridia and increased fecal bifidobacteria 
(Costalos et al., 2008).  The carbohydrate portion of oligosaccharides is largely indigestible and 
may be acting as a receptor analog to preclude pathogen colonization by prevention of epithelial 
adherence (Schroten et al., 1992; Schwertmann et al., 1999; Kunz et al., 2000).     
Overall, while statistically significant, the differences in fecal microbiota studied herein 
were relatively small when considering the magnitude of the resident microbiota of the human 
infant.  Increases in bifidobacteria were observed, however the changes that occurred were no 
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greater than 1 log of CFU.  In comparison, Moro and colleagues reported bifodobacteria 
increases > 1 log of CFU in infants fed for the first 28 days of live with an intact whey and 
casein-containing formula with 4g/L of a prebiotic mixture similar to that used in this study 
(Moro et al., 2002).  Several aspects of the current study should be considered in light of this.  
First, the studied population was healthy, full-term infants at the ages of 2-8 weeks with a more 
diverse microbiota established, as discussed above.  In this context, a dose > 4g/L of a prebiotic 
mixture may be more effective.  Second, the GOS:FOS combination used in the bulk of other 
prebiotic-containing infant formula literature is referred to as long-chain FOS and short-chain 
GOS; whereas, the combination utilized in this study had short-chain FOS with degree of 
polymerization of 2-7 and GOS containing typically between 1-7 galactose units in comparison 
(Moro et al., 2002; Moro et al., 2003; Schmelzle et al., 2003; Boehm et al., 2004).  Therefore, 
differences in fermentability of these combinations could affect various outcomes and explain 
inconsistencies seen between the current study and previous literature.  Third, the formula matrix 
studied herein was a whey-based, lower phosphate, lactose-containing formula, with and without 
prebiotics.  These attributes may already beneficially support a healthy microbiota as compared 
to a casein-dominant, higher phosphate, lactose-free formula (Balmer et al., 1989; Petschow and  
Talbott, 1990; Langhendries et al., 1995).  Finally, the low protein content of human milk is an 
attribute postulated to enhance its bifidogenicity within the infant intestine (Willis et al., 1973; 
Bullen et al., 1977).  It is possible that the use of an infant formula with hydrolyzed whey may 
reduce the amount of undigested protein reaching the colon and thus available for fermentation, 
as compared to an infant formula with intact protein.  Addition of this prebiotic combination of 
GOS/FOS to a healthy microbiota-supportive formula based on hydrolyzed whey may have 
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limited the magnitude of effect of the prebiotic studied in the current trial albeit statistically 
significant and presumably clinically-relevant changes were indeed observed.     
Microbial composition and its associated metabolic activity in response to diet impacts 
the abundance of SCFA produced.  Hence, a change in the composition of the intestinal 
microbiota may result in changes in levels of SCFA present in feces (Midtvedt and  Midtvedt, 
1992; Knol et al., 2005b).  In the present study, propionate and butyrate concentrations were 
lower in feces of infants consuming breast milk.  These data agree with Flickinger and co-
workers who reported that breastfed infants produced a lower proportion of propionate and 
butyrate compared with proportions produced by formula-fed infants (Flickinger et al., 2002).  
Acetate has been reported as the major acid in feces of breastfed infants, however, we found a 
higher concentration of acetate in our formula-fed infants in comparison to the breastfed infants 
(Flickinger et al., 2002; Bakker-Zierikzee et al., 2005).  Lack of consistent data in fecal SCFA in 
the published literature reflects the difficulties of obtaining this information in a healthy 
population of infants as effects of oxidation in fecal matter are great with these highly volatile 
materials.  Consideration of the relevance of such data is also under debate as concentrations of 
SCFAs in fecal matter may not accurately reflect those present at the epithelial interface.  
Similarly, measurement of intestinal fermentation using pH is difficult because it is an indirect 
measure and numerous other factors can also impact fecal pH such as mucosal bicarbonate 
secretion.   
The current study adds to the mounting body of evidence that prebiotic-containing infant 
formulae are well-tolerated and affect the microbiota of the formula-fed infant.  Future studies 
could concentrate on how these alterations in the microbiota may lead to clinical effects and 
optimal dosing.   Recent studies have looked at potential effects of prebiotics on immune-related 
80 
 
outcomes such as primary prevention of allergy and atopic dermatitis and infection rates 
(Arslanoglu et al., 2007; Arslanoglu et al., 2008; Bruzzese et al., 2009; Gruber et al., 2010).  In 
addition, greater effects of prebiotics could be seen in a potentially less bifidogenic formula 
matrix within a population who may already have a suboptimal intestinal microbiota due to 
underlying etiologies.  The use of prebiotics in such cases could render greater realization of 
their benefits in at-risk populations.  Such knowledge would help change the composition of 
infant formula to simulate the health advantages currently achieved in the breastfed infant 
population. 
In conclusion, feeding healthy full-term infants a partially hydrolyzed whey formula with 
4g/L of GOS/FOS results in a modification of the established microbiota that more closely 
resembles the breastfed infant as assessed by an increase proportion of bifidobacteria in the stool.  
Additionally, this remodeled microbiota was associated with lower fecal pH and changes in the 
fermentation profile.  This randomized controlled trial contributes further to the growing 
literature supporting the safety and tolerance of infant formula containing prebiotics.  More study 
is needed to clarify the clinical relevance of these fecal alterations and if such shifts persist after 
cessation of prebiotic use.   
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TABLES AND FIGURES 
 
 
 
Table 4.1. Composition of Infant Diets 
1
Typical composition of mature breast milk (Jensen, 1995). 
2
Casein and whey protein. 
3
Enzymatically hydrolyzed whey protein concentrate. 
4
Lactose. 
5
Lactose and corn maltodextrin. 
6
Oligosaccaride content is predominantly lactose-N-tetraose and its monofucosylated derivatives, 
representing about 10% of total milk carbohydrate (Kunz et al., 2000). 
7
Galactooligosaccharides:short-chain fructooligosaccarides (9:1); Vivinal
®
 GOS (Domo, the 
Netherlands);  FOS (Beneo™ P95 ; Orafti N.V., Belgium). 
8
Triglycerides and polyunsaturated fatty acids.  
9
Vegetable oils (Palm Olein, Soy, Coconut, and High-Oleic Sunflower), DHA and ARA 
represents about 3.2% and 0.64% of total fat content, respectively.  
 
 Breast milk
1
 
(BF) 
Control Formula 
(CON) 
Prebiotic Formula 
(PRE) 
Energy (kcal/L)       640-670                                                                   670 670 
Protein (g/L)   11
2  
 14.7
3
 14.7
3
 
Carbohydrate (g/L) 75
4
        75
5
            75
5
 
  Prebiotic (g/L)  7-12
6
      ----              4
7
 
Fat (g/L) 42
8
         34.2
9
               34.2
9
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  BF CON PRE 
  W0 W3 W6 W0 W3 W6 W0 W3 W6 
Absolute Abundance 
CFU/g wet weight 
stool 
    
  
  
   
Bifidobacterium spp3 
2.04x10^9 ± 
7.04x10^8 
2.85x10^9 ± 
8.24x10^8 
3.02x10^9 ± 
8.47x10^8 
1.91x10^9 ± 
7.08x10^8 
1.90x10^9 ± 
6.81x10^8 
2.05x10^9 ± 
7.00x10^8 
2.61x10^9 ± 
8.04x10^8 
4.60x10^9 ± 
1.02x10^9 
3.72x10^9 ± 
9.27x10^8 
Bacteroides/Prevotella  
6.08x10^7 ± 
2.41x10^7 
7.19x10^7 ± 
2.74x10^7 
8.91x10^7 ± 
3.23x10^7 
7.06x10^7 
± 2.63x10^7 
7.18x10^7 ± 
2.54x10^7 
8.50x10^7 ± 
3.18x10^7 
6.29x10^7 
± 2.14x10^7 
1.24x10^8 ± 
4.27x10^7 
1.02x10^8 ± 
3.79x10^7 
Clostridium difficile4 
6.55x10^6 ± 
2.58x10^6 
1.85x10^7 ± 
6.30x10^6 
1.93x10^7 ± 
5.88x10^6 
2.56x10^7 
± 6.84x10^6 
2.69x10^7 ± 
5.40x10^6 
2.51x10^7 ± 
5.40x10^6 
3.32x10^7 
± 7.13x10^6 
2.49x10^7 ± 
5.10x10^6 
1.79x10^7 ± 
4.06x10^6 
Lactobacillus spp5 
4.80x10^7 ± 
1.62x10^7 
8.21x10^7 ± 
2.68x10^7 
1.36x10^8 ± 
4.35x10^7 
1.19x10^8 
± 3.28x10^7 
2.07x10^8 ± 
5.79x10^7 
1.39x10^8 ± 
3.98x10^7 
1.36x10^8 
± 3.68x10^7 
1.34x10^8 ± 
3.55x10^7 
1.94x10^8 ± 
5.66x10^7 
Total bacteria6 
4.40x10^9 ± 
7.14x10^8 
5.30x10^9 ± 
8.59x10^8 
5.65x10^9 ± 
9.01x10^8 
5.65x10^9 ± 
9.02x10^8 
7.35x10^9 ± 
1.17x10^9 
7.04x10^9 ± 
1.14x10^9 
6.64x10^9 ± 
1.69x10^9 
1.06x10^10 
± 1.62x10^9 
8.12x10^9 ± 
1.28x10^9 
Relative Abundance 
(% of total) 
         
Bifidobacterium spp7 36.38 ± 6.73 48.77 ± 7.33 43.48 ± 6.77 36.70 ± 6.68 30.85 ± 5.87 32.62 ± 8.09 45.59 ± 7.35 49.46 ±7.12 44.10±6.74 
Bacteroides/Prevotella  1.54 ± 0.62 1.29 ± 0.49 1.29 ± 0.46 1.26 ± 0.47 0.90 ±0.32 1.27± 0.48 0.86± 0.28 1.08± 0.36 1.19± 0.44 
Clostridium difficile 0.16 ± 0.08 0.32 ± 0.13 0.34 ± 0.12 0.45 ±0.14 0.34 ±0.08 0.37 ±0.07 0.42 ±0.10 0.21 ±0.05 0.18 ±0.05 
Lactobacillus spp 0.98 ± 0.30 1.68 ± 0.51 2.20± 0.66 2.10 0.54 2.76 ±0.72 2.16 ±0.57 2.20 ±0.55 1.36 ±0.34 2.82 ±0.84 
 
Table 4.2.  Absolute and Relative Bacterial Abundance in Fecal Samples
1, 2  
 
1
Data are expressed as means ± SEM. 
2
BF: breastfed; CON: control infant formula group; PRE: prebiotic infant formula group; W0: week 0; W3: week 3; W6: week 6; CFU: colony 
forming units; spp: species. 
3
For means pooled for diet, PRE>CON; PRE=BF; CON=BF (p=0.0083).  Refer to Figure 4.2a. 
 4
A significant interaction between diet and time was seen (p=0.0414).  Refer to Figure 4.3. 
5
For means pooled for diet, PRE=CON>BF (p=0.0104). 
6 
For means pooled for diet, PRE=CON>BF (p=0.0007). 
7
For means pooled for diet, PRE=BF; PRE>CON; BF>CON (p=0.0218).  Refer to Figure 4.2b. 
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  BF CON PRE 
  W0 W3 W6 W0 W3 W6 W0 W3 W6 
Absolute Abundance 
Units(µmol/g wet 
feces) 
    
  
  
   
Acetate 3 17.87 ± 2.80 17.10 ± 2.68 19.91 ± 3.12 33.22 ± 5.22 31.04± 4.88 33.92 ± 5.38 26.33± 4.07 34.76 ± 5.38 35.21 ± 5.38 
Propionate4 3.58 ± 0.93 3.63 ± 1.02 4.83 ± 1.26 12.07 ± 2.35 9.39 ± 1.76 9.96 ± 1.88 7.58 ± 1.28 7.03 ± 1.28 7.42 ± 1.38 
Butyrate5 1.66 ± 0.52 1.85 ± 0.64 1.40 ± 0.44 5.26 ± 1.30 3.43 ± 0.81 4.45 ± 1.04 2.96 ± 0.68 3.25 ± 0.77 2.87 ± 0.68 
Valerate 2.06 ± 1.74 1.41 ± 1.37 0.97 ± 0.87 2.38 ± 1.91 1.46 ± 1.13 1.23 ± 0.98 1.71± 1.36 1.18 ± 0.94 1.09 ± 0.90 
Isobutanoic 5.59 ± 3.76 5.30± 8.59 4.10 ± 4.40 1.92 ± 0.39 1.38 ± 0.46 1.52 ± 0.49 1.12 ± 0.39 1.47 ± 0.64 1.36 ± 0.63 
Total6 35.29 ± 8.48 30.22 ± 8.37 37.20 ± 9.01 57.92 ± 9.03 45.99 ± 6.63 50.49 ± 7.15 40.95 ± 5.77 51.36 ±7.40 45.73±6.62 
          
Relative Abundance 
(% of total)          
Acetate7 67.76 ± 3.53 76.67 ± 3.99 77.82 ± 3.51 65.45 ± 2.31 67.89 ± 2.14 70.08 ± 2.12 68.73 ± 2.03 74.61±2.08 75.62±2.13 
Propionate8 20.30 ± 3.96 12.14 ± 2.71 11.53 ± 2.24 21.43 ± 2.62 20.83 ± 2.33 20.01 ± 2.19 19.60 ± 2.08 15.34 ± 1.67 15.68 ± 1.73 
Butyrate 9.16 ± 2.09 7.09 ± 1.95 6.46 ± 1.66 10.59 ± 1.43 8.27 ± 1.16 9.57 ± 1.22 8.62 ± 1.15 7.49 ± 1.10 7.27 ± 1.10 
 
Table 4.3.  Absolute and Relative Short Chain-Fatty Acid Abundance in Fecal Samples
1,2
   
1
Data are expressed as means ± SEM. 
2
BF: breastfed; CON: control infant formula group; PRE: prebiotic infant formula group; W0: week 0; W3: week 3; W6: week 6; CFU: colony 
forming units; spp: species. 
3
For means pooled for diet, CON=PRE>BF (p<0.0001). 
 4
For means pooled for diet, BF<PRE<CON (p<0.0001). 
5
For means pooled for diet, BF<PRE<CON (p<0.0001). 
6 
For means pooled for diet, CON=PRE>BF (p=0.0230). 
7
For means pooled for diet, PRE=BF; PRE>CON; BF>CON (p=0.0007). 
8
For means pooled for diet, PRE=BF; CON >PRE; CON>BF (p=0.0026). 
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Figure 4.1.  Experimental Design and Subject Completion 
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 Figure 4.2a        Figure 4.2b        
 
Figure 4.2.  Subjects consuming prebiotic formula had more fecal bifidobacteria than those consuming the control formula.  Bars with 
different superscripts indicate a statistically significant difference.  Data are expressed as means (pooled for time) ± SEM.  Table 4.2 
contains data for each group at each time point.  BF: breastfed; CON: control infant formula group; PRE: prebiotic infant formula 
group; CFU: colony forming units.  Figure 4.2a.  Absolute abundance (CFU/g) of fecal bifidobacteria was significantly higher 
(p=0.0083) in subjects consuming prebiotic formula as compared to the control formula.  Figure 4.2b.  Relative abundance 
(percentage of total) of fecal bifidobacteria was significantly higher (p=0.0219) in subjects consuming prebiotic formula as compared 
to the control formula.  
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Figure 4.3.  Subjects consuming prebiotic formula had significantly less C. difficile abundance over time.  Bars with different 
superscripts indicate a statistically significant difference.  Data are expressed as means ± SEM.  Table 4.2 contains data for each group 
at each time point.  BF: breastfed; CON: control infant formula group; PRE: prebiotic infant formula group. 
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CHAPTER 5 
 
 
HUMAN MILK OLIGOSACCHARIDES INFLUENCE INTESTINAL MATURATION 
IN VITRO 
 
 
ABSTRACT 
 
Human milk is considered the gold standard of infant nutrition and recommended 
exclusively until 6 months of age; however, by one month of age nearly 40% of infants are 
receiving infant formula as their sole source of nutrition (Li et al., 2005; Eidelman et al., 2012). 
Formula-fed infants are at increased risk of morbidity and mortality compared to their breastfed 
counterparts (Grulee et al., 1934; Lopez-Alarcon et al., 1997; Sisk et al., 2007).  As such, 
research is needed to identify infant formula ingredients that impart some of the benefits of 
breast feeding onto formula-fed infants. Human milk oligosaccharides (HMOs) are abundant in 
breast milk (>15 g/L) and associated with decreased disease risk and enhanced intestinal 
maturation in vitro (Newburg et al., 2004; Kuntz et al., 2008; Kuntz et al., 2009).   Therefore, we 
aimed: 1) to determine the time course of impact of a model HMO; and 2) to assess the induction 
of epithelial differentiation by three individual HMOs using an in vitro epithelial model of the 
crypt-villus axis.  In study 1, pre-confluent HT-29, pre-confluent Caco-2Bbe, confluent Caco-
2Bbe, and post-confluent Caco-2Bbe cells were cultured individually and  randomized to 1 of 5 
treatments:  lacto-N-neotetrose (LNnT) at 0, 100, 200 or 400 mg/L or energy control (0 mg/L 
plus lactose + N-acetylglucosamine) for 24, 48 or 72 hours of incubation to assess effects on 
proliferation and differentiation.  In study 2, pre-confluent HT-29, pre-confluent Caco-2Bbe, and 
post-confluent Caco-2Bbe cells were randomized to treatments with one of three HMOs at the 
following levels for 72 hours: a) LNnT at 0, 20, 200 or 2000 mg/L or energy control (0 mg /L 
plus lactose + N-acetyllactosamine); b) 2'-fucosyllactose (2'FL) at 0, 20, 200 or 2000 mg/L or 
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energy control (0 mg/L plus lactose + fucose); c) 6'-sialyllactose (6'SL) at 0, 40, 400, 4000 mg/L 
or energy control (0 mg/L plus lactose + sialic acid). Dependent variables included proliferation, 
differentiation, cell cycle analysis, apoptosis, disaccharidase activity, and absorption and barrier 
function via modified Ussing chambers. Treatment effects of individual HMO treatments were 
assessed by one-way ANOVA and paired-comparisons.  Statistical significance was set at 
p<0.05.  In study 1, compared to 0 mg/L control, LNnT decreased cell proliferation in pre-
confluent HT-29 cells at 48 hours (p<0.05) and 72 hours (p<0.01) and pre-confluent CaCo-2Bbe 
at 72 hours (p< 0.01). AP activity increased over time and was highest in post-confluent CaCo-
2Bbe cells (p<0.001) but was not affected by treatment.  In study 2, pre-confluent HT-29 cell 
proliferation was reduced (p<0.05) with 200 and 2000 mg/L LNnT, 2000 mg/L 2'FL, and 400 
and 4000 mg/L 6'SL. Pre-confluent CaCo-2Bbe cell proliferation was reduced (p<0.05) with 
2000 mg/L LnNT, 4000 mg/L 6'SL, and 2000 mg/L 2'FL.  Reduced proliferation was associated 
with cell cycle arrest in the G2/M phase in pre-confluent HT-29 cells treated with 200 (p=0.027) 
and 2000 mg/L (p=0.003) of LNnT or 2000 mg/L 2'FL (p=0.021), and pre-confluent Caco-2Bbe 
cells treated with 4000 mg/L 6’SL. Interestingly, in pre-confluent HT-29 cells, treatment with 
4000 mg/L 6'SL resulted in S phase arrest (p<0.001), whereas there was a trend (p=0.058) for 
cell cycle arrest in the G2/M phase with 400 mg/L 6'SL.  AP activity increased 31% (p=0.030) in 
pre-confluent HT-29 cells and tended (p=0.071) to increase by 33% in post-confluent Caco-2Bbe 
treated with 2000 2'FL.  Further, post-confluent CaCo-2Bbe cell sucrase activity increased 54% 
(p=0.036) compared to control when treated with 2000 mg/L 2'FL. Transepithelial resistance 
increased 21% (p=0.002) in post-confluent Caco-2Bbe cells with 200 mg/L LNnT, and tended 
(p=0.059) to increase by 12% with 2000 mg/L LNnT, compared to control.  In summary, study 1 
identified 72 hours as the most sensitive incubation period to measure treatment effects.  In study 
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2, individual HMOs were found to inhibit proliferation in transformed small intestinal cell lines 
with associated cell cycle arrest, primarily within the G2/M phase.  More importantly, the 
inhibition of proliferation was associated with enhanced differentiation.  Well differentiated 
enterocytes, modeled by post-confluent CaCo-2Bbe cells, expressed greater digestive capabilities 
and barrier function, following treatment with physiologically relevant doses of 2'FL and LNnT, 
respectively. Further study is needed to determine if these effects translate in vivo, however, 
these results suggest addition of HMO may promote intestinal maturation in vitro.   
 
INTRODUCTION 
 
Human milk is regarded as the gold standard of infant nutrition because of the magnitude 
of functional nutritive and non-nutritive components it contains that aid in the maturation and 
protection of the neonatal gastrointestinal (GI) tract (Carver and  Barness, 1996).  The American 
Academy of Pediatrics recommends that infants be provided human milk exclusively for about 
six months followed by continued breastfeeding during the first year or longer as complementary 
foods are introduced (Eidelman et al., 2012).  Nevertheless, by one month of age over one-third 
of infants are receiving formula as their sole source of nutrition (Li et al., 2005). As a large 
proportion of infants are lacking exposure to human milk during infancy, research is needed to 
identify formula ingredients that may be able impart some of the benefits of human milk to 
formula-fed infants.   
Human milk contains nearly 200 unique oligosaccharides, a concentration >f 15 grams 
per liter which varies between women and also over time; moreover, human milk 
oligosaccharides (HMOs) are the third most abundant solid component following lactose (70 
g/L) and lipids (40 g/L) and narrowly surpassing protein (8g/L) (Coppa et al., 1999; Chaturvedi 
et al., 2001a; Ninonuevo et al., 2006; German et al., 2008b; Thurl et al., 2010; Wu et al., 2010).   
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Human milk is unique in its oligosaccharide composition and complexity, as milk from animals 
is nearly completely lacking in free complex oligosaccharides (Kunz et al., 2000).  Infant 
formula is completely lacking in HMOs, only plant derived or synthetic fructo- and galacto-
oligosaccharides are currently supplemented (Tungland and  Meyer, 2002; Kunz and  Rudloff, 
2006).  
Interestingly, recent studies have reported that HMOs may have an effect on intestinal 
maturation.  Kuntz and colleagues showed that neutral and acidic HMO fractions in pre-
confluent HT-29 and CaCo-2 transformed intestinal cell lines induced growth inhibition by two 
different mechanism 1) suppression of cell cycle progression through induction of differentiation 
and/or 2) induction of apoptosis (Kuntz et al., 2008).  To expand on these research findings we 
aimed: 1) to determine the time course of impact of a model HMO on proliferation and 
differentiation in transformed intestinal cell lines (HT-29 and CaCo-2Bbe cells); and 2) to assess 
the induction of epithelial differentiation by three individual HMO, 2'-fucosyllactose (2'FL), 
lacto-N-neotetraose (LNnT), and 6'-sialyllactose (6'SL), using an in vitro epithelial model of the 
crypt-villus axis consisting of pre-confluent HT-29 cells, pre-confluent CaCo-2Bbe cells, and 
post-confluent CaCo-2Bbe cells.    
 
MATERIALS AND METHODS 
Study Design 
 Our model consisted of pre-confluent HT-29 cells, pre-confluent CaCo-2Bbe cells, 
confluent CaCo-2Bbe, and post-confluent CaCo-2Bbe cells cultured individually to provide an in 
vitro model of the small intestinal crypt-villus axis and simulate the varying levels of 
differentiation within the constantly renewing villus in vivo (Figure 5.1).  HT-29 cells are a low 
91 
 
differentiated phenotype reflective of crypt colonocytes—these cells are not able to differentiate 
even in post-confluent states under normal culture conditions (Lesuffleur et al., 1990).   HT-29 
cells have properties of chloride secreting cells related to a chloride channel that can also be 
found within human intestinal epithelial cells (Kreusel et al., 1991).   CaCo-2Bbe cells, a well 
characterized model of absorptive intestinal epithelium, exhibit moderate differentiation in a pre-
confluent state and in a post-confluent state exhibit a process of differentiation similar to that 
seen in a villus enterocyte (Peterson and  Mooseker, 1992).  CaCo-2Bbe cells will grow as a 
monolayer, continuing to differentiate and form cylindrical polarized morphology with tight 
junctions between cells (Peterson and  Mooseker, 1992).  Additionally, CaCo-2Bbe cells have 
apical microvilli with associated brush-border enzymes (sucrase and lactase) in post-confluent 
states which are similar to human fetal enterocytes (Peterson and  Mooseker, 1992).   
Furthermore, CaCo-2 cells grown as a monolayer are also a well-established model of intestinal 
absorptive function and provide an avenue by which transepithelial resistance and nutrient 
transport can be assessed (Delie and  Rubas, 1997).       
Overall, our model allowed us to assess relevant outcomes along the length of the crypt-
villus axis in vitro as pre-confluent HT-29 cells model secretory crypt cells, pre-confluent CaCo-
2Bbe cells model proliferating absorptive enterocytes as they migrate up the villus, and post-
confluent CaCo-2Bbe cells model well differentiated functional absorptive villus cells.  The in 
vitro model as a whole simulates the neonatal infant’s maturing gastrointestinal epithelial.  
Furthermore, incubation of the cells with HMO provides a simulation of the suckling infant’s 
nearly continuous enteral feedings of human milk.   As such, our model proved an avenue for 
novel insight into the effects of HMO administration on small intestinal cellular dynamics and 
function in vitro.      
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Cell Culture 
To model the crypt-villus axis and investigate the effects of incubation with HMO, pre-
confluent HT-29, pre-confluent CaCo-2Bbe, confluent CaCo-2Bbe and post-confluent CaCo-
2Bbe cells were utilized.  The CaCo-2Bbe cell line was obtained from American Type Culture 
Collection (CRL-2102, ATCC, Manassas, VA) clone of CaCo-2 (ATCC: ATB-37).  They were 
used between passages 55 and 65.  The transformed human intestinal cells, HT-29 cells, were 
obtained from American Type Culture Collection (ATCC, Manassas, VA).  They were used 
between passages 5 and 15.  Both cell lines were separately maintained in 75 cm
2 
tissue culture 
flasks (TP90075, Midwest Scientific, St. Louis, MO) and maintained in a humidified atmosphere 
of 37
o
C and 5% CO2.     HT-29 cells were maintained in McCoy’s 5A media (pH 7.4) 
supplemented with 10% fetal bovine serum (Atlanta Biological, Lawrenceville, GA).  CaCo-
2Bbe cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) (pH 7.4) 
supplemented with 10% fetal bovine serum (Atlanta Biological, Lawrenceville, GA) and 0.01 
mg/ml human apotransferrin (Sigma, St. Louis, MO).  Growth medium was replaced as needed, 
but no fewer than twice per week. Cell lines were subcultured weekly at pre-confluent densities 
with 0.25% trypsin-EDTA (25200, Invitrogen, Carlsbad, CA).   
HMO Treatments 
Study 1 and 2 
Prior to treatment, each of the HMOs (provided by Abbott Nutrition, Columbus, OH)and 
energy controls were added to either DMEM or McCoy’s 5A cell culture media at a 
concentration of 20 mg/mL, passed through a Detoxi-Gel endotoxin removing column (Pierce), 
and stored at -80
o
C until use.  The columns utilize immobilized polymixin B to remove pyrogens 
by binding their lipid A domains. 
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Study 1 
Treatments included LNnT at 0, 100, 200 or 400 mg/L or energy control (0 mg/L plus 
lactose + N-acetylglucosamine) for 24, 48 or 72 hours of incubation.  The LNnT treatment doses 
centered on the physiologically relevant level of 200 mg/L in human milk.  
Study 2 
Pre-confluent HT-29, pre-confluent Caco-2Bbe, and post-confluent Caco-2Bbe cells were 
randomized to treatments with one of three HMOs at the following levels for 72 hours of 
incubation: a) LNnT at 0, 20, 200 or 2000 mg/L or energy control (0 mg /L plus lactose + N-
acetyllactosamine); b) 2'FL at 0, 20, 200 or 2000 mg/L or energy control (0 mg/L plus lactose + 
fucose); c) 6'SL at 0, 40, 400, 4000 mg/L or energy control (0 mg/L plus lactose + sialic acid) 
(Table 5.1).  Final treatment solutions maintained a pH of 7.4.  LNnT and 6'SL treatments 
centered on their physiologically relevant doses of 200 and 400 mg/L, respectively. The highest 
treatment dose of 2'FL at 2000 mg/L is the physiologically relevant level found in human milk.            
Cell Proliferation  
In study 1, cell proliferation was measured using the BrdU & Ki-67 Assay (HCS213, 
Millipore) according to manufacture directions.  Prior to assay, 96 well plates were seeded with 
HT-29 or CaCo-2Bbe cells at a density of 1500 cells/well and allowed to adhere for 48 hours in 
the case of pre-confluent cells, 7 days for confluent cell types, and 21 days for post-confluent 
cells.  Thereafter, the medium was replaced with treatment medium containing LNnT at variable 
concentrations for 24, 48, or 72 hours.  At the end of the incubation period, 20 µM BrdU was 
added to cell culture wells for 1 hour at 37
o
C prior to a one hour fixation period at room 
temperature.  After removing the fixation solution, wells were washed two times with wash 
buffer.  Next, the primary antibody solution containing mouse anti-BrdU and rabbit Anti-Ki-76 
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was allowed to incubate for 1 hour at room temperature.  Following a second wash step, the 
secondary antibodies (FITC-Donkey Anti-Mouse, Cy3-Donkey Anti-Rabbit) and Hoechst 
nuclear stain were added and incubated at room temperature for one hour protected from light. 
After a third wash step, the immunofluorescence buffer was added and plates were read at the 
following excitation/emission wavelengths 360/460, 480/535, 585/600.  Results were normalized 
to number of cells and expressed as a percentage of 0 mg/L control.   
In study 2, the CellTiter 96 AQueous non-radioactive cell proliferation assay (G5421, 
Promega, Madison, WI) was utilized to assess cell proliferation.  The assay utilizes the soluble 
compound 3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-3-(4-sulfophenyl)-2H-
tetrazolium (MTS) with an electron coupling reagent, phenazine methosulfate (PMS).  MTS is 
bioreduced by actively proliferating cells into a formazan product which is measured at 490nm 
absorbance and is directly proportional to the number of living cells in culture.   Proliferation 
was measured by the MTS assay as described by the manufacturer.  Briefly, 96 well plates were 
seeded with HT-29 or CaCo-2Bbe cells at a density of 1500 cells/well and allowed to adhere for 
24 hours followed by incubation with HMO treatments for 72 hours.  During the last hour of the 
incubation period, MTS/PMS was added and plates continued to incubate at 37
o
C at 5% CO2.  
Absorbance was then measured at 490 nm.  Results are expressed as a percent of control (0 
mg/L).  
Cellular differentiation 
HT-29 cells and CaCo-2Bbe cells were seeded separately in 75 cm
2
 tissue culture flasks 
at a density of 10
4
 cells/cm
2
 and maintained for either 48 hours (pre-confluent HT-29 and pre-
confluent CaCo-2Bbe cells) or 19 days (post-confluent CaCo-2Bbe cells).  Following the 
adherence period, media were changed and HMO treatments applied and allowed to incubate for 
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72 hours in the incubator.  After the 72 hour incubation period, cells were trypsinized, pelleted 
by centrifugation at 500 x g for 5 minutes and washed two times with PBS.  Cell pellets were 
flash frozen in liquid nitrogen and stored at -80
o
C until analysis.  Cellular differentiation was 
measured by alkaline phosphatase (AP) activity.  AP activity was measured by commercially 
available fluorometric and colorimetric assay kits (K422 and K412, BioVision, Mountain View, 
CA).  AP activity in HT-29 cells was determined fluorometrically following homogenization of 
cells in Assay Buffer then centrifuging for 3 minutes at 13,000 x g to remove insoluble material.  
Cell supernatants will then be added to black 96 wells plate and incubated with 4-
methylumbelliferyl phosphate disodium salt (MUP) substrate for 3 hours at room temperature 
protected from light.  The reaction was stopped by the addition of Stop Solution and read at 
excitation=360nm and emission=440nm.  Background controls were used for all samples by 
adding Stop Solution to the wells prior to addition of MUP.  Final AP activity was determined by 
subtracting background control values and quantifying activity based on standard curve 
methodology.  AP activity was normalized to protein content as measured by the Lowry assay.   
AP activity in CaCo2-Bbe cells was quantified in a similar manner with the following 
exceptions: p-nitrophenyl phosphate was used as a phosphatase substrate and measured 
colorimetrically in clear 96 wells plates at 405 nm in a plate reader after 30 minutes incubation at 
room temperature.  Results are expressed as AP activity units per milligram protein.   
Apoptosis 
Caspase-3 activity was used as a marker of cellular apoptosis and measured by enzymatic 
assay.  The caspase-3 colorimetric assay utilizes the hydrolysis of the peptide substrate acetyl-
Asp-Glu-ValAsp p-nitroanilide (Ac-DEVD-pNA) by caspase-3, resulting in the release of the p-
nitroaniline (pNA) moiety which can be measured at an absorbance of 405 nm and calculated 
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using standard curve methodology.  The caspase-3 assay kit (CASP-3-C, Sigma) was used 
according to manufacture directions.  Briefly, CaCo-2Bbe cells were seeded at a density of 10
4
 
cells/cm
2
 in 75 cm
2
 tissue culture flasks, maintained for 19 days, then media containing HMO 
treatments were applied.  After the 72 hour incubation period, cells were washed three times with 
ice-cold PBS then removed by scraping with a plastic cell scraper into 3.5 ml of PBS.  Following 
centrifugation at 500 x g for 5 minutes, PBS was removed and cell pellets flash frozen in liquid 
nitrogen and stored at -80
o
C until analysis.  Caspase-3 activity was quantified following cells 
lysis and centrifugation at 20,000 x g for 15 minutes at 4
o
C.  Cell lysate was added in triplicate to 
a 96 well plate.  Assay buffer and caspase-3 substrate were added to each well and incubated at 
37
o
C for 90 minutes.  Absorbance was read at 405 nm and results calculated based on a p-
nitroaniline calibration curve.  Positive and negative controls were included on each plate.  
Caspase-3 activity was normalized to protein content measure by BCA assay. Results are 
expressed as caspase-3 activity units per milligram protein.       
Cell cycle analysis 
HT-29 cells and CaCo-2Bbe cells were seeded separately in 75 cm
2
 tissue culture flasks 
at a density of 10
4
 cells/cm
2
 and allowed to adhere for 48 hours.  Thereafter, media were 
changed, HMO treatments applied, and cells were then allowed to grow for an additional 72 
hours.   At the end of the treatment period, pre-confluent HT-29 and pre-confluent CaCo-2Bbe 
cells were trypsinized, pelleted by centrifugation at 500 x g for 5 minutes, and washed two times 
with PBS.  Cells were fixed by adding 1 x 10
6
 cells to 9 ml of ice cold 90% ethanol and stored at 
-20
o
C until analysis.  For cell cycle analysis, cells fixed in ethanol were pelleted by 
centrifugation at 200 x g for 15 minutes at 4
o
C then washed two times with cold PBS.  Cells 
were resuspended in propidium iodide (PI)/Triton X-100 staining solution containing DNAse-
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free RNAse and strained through nylon filter capped Falcon tubes.  Following incubation at 
room temperature for 30 minutes, tubes were transfer to ice and protected from light until data 
acquisition by a Epics XL benchtop flow cytometer.  Data are expressed as the distribution of 
cell populations in different cell cycle stages.     
Sucrase and Lactase Activity 
CaCo-2Bbe cells were seeded in 75 cm
2
 tissue culture flasks at a density of 10
4
 cells/cm
2
 
and maintained for 19 days.  Following the adherence period, media was changed and treatments 
applied.  After the 72 hour incubation period, cells were washed three times with ice-cold PBS 
then removed by scraping with a plastic cell scraper into 3.5 ml of PBS.  Following 
centrifugation at 500 x g for 5 minutes, PBS was removed and cell pellets flash frozen in liquid 
nitrogen and stored at -80
o
C until analysis.  For measurement of disaccharidase activity, cell 
pellets were suspended in 1 mL of homogenization buffer (0.9% saline solution containing 1 uM 
phenylmethylsulfonyl fluoride and 223 uM of iodoacetic acid) and homogenized for 30 seconds 
on setting 5 on a homogenizer.  Homogenates were incubated with either sucrose or lactose 
buffers for 1 hour in a 37
o
C water bath.  Enzyme activity was stopped by the addition of 
Ba(OH)2 and ZnSO4.  Background control tubes were immediately stopped with Ba(OH)2  and 
ZnSO4 prior to incubation to quantify non-specific disaccharidase activity.  Samples were 
centrifuged for 20 minutes at 3000 rpm at 4
o
C.  Supernatants were added in triplicate to a clear 
96 well plates, glucose oxidase reagent (Sigma) was added and allowed to incubate at room 
temperature for 10 minutes in order to detect the amount of glucose released from the hydrolysis 
of the disaccharides.  The plates were read at 500 nm in a spectrophotometer and quantified 
using standard curve technique.  Disaccharidase activity was normalized to cellular protein 
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content of the same homogenate as measured by the Lowry assay and expressed as the amount of 
glucose release per hour per milligram protein.          
Transepithelial barrier function and electrogenic nutrient transport 
CaCo-2Bbe cells were seeded at a density of 1 x 10
5
 cells/cm
2
 into polyester, 0.4 micron 
pore size, 1.12 cm
2
 Transwell Snapwell inserts (Sigma) and maintained in an incubator for 18 
days with twice weekly medium renewal.  On day 18, media were replaced and cells were 
exposed to media containing HMO treatments.  On day 21, Transwell Snapwell inserts were 
mounted in modified Ussing chambers connected to dual channel voltage/current clamps 
interfaced with a computer system allowing for real-time data acquisition and analysis 
(Physiologic Instruments, Inc, San Diego, CA).  Chambers containing 4 milliliters of modified 
Kreb’s solution on both the apical chamber and basolateral chamber were maintained at 37oC by 
a circulating water bath (Fischer Scientific, Ithasca, IL).  Basal transepithelial resistance, short-
circuit current, and potential differences were measured after a 10 to 15 minute equilibration 
period.  Sodium-dependent nutrient transport was quantified by measuring changes in the short 
circuit current induced following the addition of 10 mmol/L glucose, glutamine, arginine or 
glysar.   
Statistical Analysis 
Statistical differences between treatments were determined using a one-way analysis of 
variance (ANOVA) with paired comparisons versus the 0 mg/L control.  Normality was tested 
using the Shapiro-Wilk statistic.  Logarithmic transformations were utilized as needed.  
Computations were conducted using a mixed model in SAS (Version 9.1; SAS Institute, Cary, 
NC).  Statistical significance was defined as p ≤ 0.05, and trends were reported at p<0.01.  Data 
are reported as mean ± SEM.  
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RESULTS 
Study 1 
The first study determined the time course of impact of a model HMO, LNnT.  We found 
that LNnT significantly reduced proliferation in pre-confluent HT-29 cells following incubation 
for 24 (p=0.021), 48 (p=0.012), and 72 hours (p=0.0039) (Figure 5.2); however, a consistent 
dose effect was not seen until 72 hours of incubation.  After 72 hours of incubation with 100, 200 
and 400 mg/L LNnT, cellular proliferation was reduced to 67.5%, 68.3% and 70.6% (SEM 
10.4%), respectively, as compared to the 0 mg/L control.   Pre-confluent CaCo-2Bbe cell 
proliferation was significantly reduced after 24 hours (p<0.001) and 72 hours (p=0.005); 
however, no significant effect was seen during the 48 hour incubation period (p=0.12) likely 
related to higher variation at this time point (Figure 5.3).   LNnT did not affect markers of 
proliferation in the slowly proliferating confluent and post-confluent cells at any time point (data 
not shown).    
Cellular differentiation, measured by AP activity, was not significantly affected by 
incubation with LNnT in the pre-confluent, confluent, or post-confluent CaCo-2Bbe cells at any 
time point.  The ability to detect significant differences was limited by the high variability in AP 
activities.  Although treatment did not affect differentiation, time and cell type (pre-confluent, 
confluent and post-confluent) did have significant effects (Figure 5.4).  
The conclusion of study 1 was that incubation with LNnT for 72 hours most efficaciously 
reduced proliferation in both CaCo-2Bbe and HT-29 cells and was therefore used as the 
incubation period for the second trial.    
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Study 2 
In the second study, dependent variables were assessed at one time point, 72 hours of incubation, 
with 3 different HMOs at 3 different levels each.  The effects of treatment with each of the three 
individual HMO on proliferation were assessed by MTS assay in the second preliminary study 
(Table 5.2).  Treatment with LNnT reduced proliferation (p=0.041) in pre-confluent HT-29 cells 
with significant treatment effects seen at 200 and 2000 mg/L as compared to 0 mg/L control.  
Treatments of 200 and 2000 mg/L LNnT resulted in proliferation rates of 94.4% and 92.1%, 
respectively, as compared to the 0 mg/L control.  Incubation with 2000 mg/L 2'FL decreased 
proliferation (p<0.001) in pre-confluent HT-29 cells to 75.3% as compared to 0mg/L control and 
6'SL decreased proliferation (p=0.024) at 400 mg/L and 4000 mg/L to 92.3% and 88.3%, 
respectively, as compared to the 0 mg/L control.  
 Pre-confluent CaCo-2Bbe cells were less sensitive to treatment with HMOs.  
Proliferation was significantly reduced in the highest doses of LNnT, 2'FL or 6'SL (Table 5.2).  
Energy controls within each HMO treatment group in both cell types were not significantly 
different from 0 mg/L controls suggesting that the reductions in proliferation were related to the 
presence of the HMOs and not the terminal lactose plus n-acetyllactosamine, fucose, or sialic 
acid.   
Cell cycle analysis by flow cytometry was conducted in pre-confluent HT-29 (Figures 
5.5, 5.6, and 5.7) and CaCo-2Bbe cells (Figure 5.8).  Treatment with 200 mg/L LNnT in pre-
confluent HT-29 cells induced changes in all three cell cycle phases as compared to 0 mg/L with 
cells exhibiting G0/G1 (p=0.026) and G2/M arrest (p=0.027) in coordination with a significant 
decrease (p<0.001) in the percentage of gated cells in the S phase (Figure 5.5).  Additionally, 
treatment with 2000 mg/L of LNnT also resulted in G2/M arrest (p=0.003) and tended to 
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decrease (p=0.085) the proportion of cells in G0/G1 as compared to 0 mg/L controls (Figure 
5.5).  Similar to the effects of the neutral LNnT treatment, 2'FL treatment at 2000 mg/L induced 
cell cycle arrest (p=0.021) in the G2/M phase which was balanced by a decrease (p=0.034) in the 
proportion of cells in the G0/G1 phase (Figure 5.6).  Treatment with the acidic HMO fraction 
6'SL revealed arrest (p<0.001) in the S phase at the highest dose of 4000 mg/L with a 
corresponding decrease (p=0.003) in the proportion of cells in the G2/M phase (Figure 5.7).  
Interestingly, a significant decrease (p=0.001) in the proportion of cells in the S phase was 
observed in the 400 mg/L 6'SL treatment group with cell arrest tending (p=0.058) to occur in the 
G2/M phase (Figure 5.7).   
A significant treatment effect was also observed at the 4000 mg/L 6'SL in the CaCo-2Bbe 
cells with cell cycle arrest (p=0.016) in the G2/M phase and decreased (p=0.0013) proportion of 
gated cells in the G0/G1 phase (Figure 5.8).  Conversely, the effect of 400 mg/L 6'SL on pre-
confluent CaCo-2Bbe cells resulted in accumulation (p=0.013) of cells in the G0/G1 phase.  This 
was balanced with a decrease (p=0.035) in the percentage of gated cells in the G2/M phase.  
Neither LNnT nor 2'FL affected the cell cycles in the pre-confluent CaCo-2Bbe cells (date not 
shown).  As with proliferation, cell cycle kinetics were not affected by the energy controls within 
any HMO treatment group in either cell type suggesting that progression through the cell cycle is 
related to the presence of the respective HMOs and not the terminal lactose plus n-
acetyllactosamine, fucose, or sialic acid. 
Cellular differentiation was measured via AP activity in post-confluent CaCo-2Bbe cells 
and pre-confluent HT-29 cells.  Of the three HMOs, only 2'FL had a significant effect or tended 
to significantly affect differentiation.  Pre-confluent HT-29 cells (Figure 5.9) exhibited a 30.9% 
(SEM 6.8%) increase (p=0.030) in AP activity as compared to 0 mg/L control while post-
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confluent CaCo-2Bbe cells (Figure 5.10) tended to exhibit a 33.1% (SEM 13.7%) increase  
(p=0.071) in AP activity at 2000 mg/L 2'FL.   
Cellular apoptosis, measured by caspase-3 activity, was determined in post-confluent 
CaCo-2Bbe cells.  In cells treated with LNnT (Figure 5.11) and 6'SL (Figure 5.12), a significant 
increase in apoptosis was exhibited in the positive energy control groups (lactose + n-
acetyllactosamine and lactose + sialic acid) and the highest treatment doses (2000 mg/L LNnT 
and 4000 mg/L 6'SL).  In the cells treated with LNnT, caspase-3 activity increased (p=0.036) by 
79.6% (SEM 13.6%) in the 2000 mg/L treatment group and increased (p=0.010) by 101.0 % 
(SEM 12.1%) in the energy control group (lactose + n-acetyllactosamine).  Treatment with 6'SL 
resulted in an increase (p=0.033) of 71.4% (SEM 14.1%) in the 4000 mg/L treatment group 
while the energy control group (sialic acid + lactose) increased (p=0.034) by 76.3% (SEM 
16.7%) as compared to the 0 mg/L control.  2'FL did not affect caspase-3 activity in post-
confluent CaCo-2Bbe cells.  
Functional indices were also assessed in post-confluent CaCo-2Bbe cells including 
sucrase and lactase activity, transepithelial resistance, and nutrient transport.  Cells treated with 
2000 mg/L of 2'FL (Figure 5.13) exhibited a 53.5% (SEM 6.6%) increase (p=0.036) in sucrase 
activity as compared to 0 mg/L control.  There were no other significant treatment effects with 
regard to HMO treatments as compared to 0 mg/L controls for either sucrase or lactase activity.  
Interestingly, there was a significant treatment effect of the positive energy control (Figure 
5.14), lactose + sialic acid, in which sucrase activity was enhanced (p=0.042) by 48.5% (SEM 
15.4%) as compared to the 0 mg/L control.  Of the outcomes measured in modified Ussing 
chambers, transepithelial resistance (Figure 5.15) significantly increased (p=0.002) by 21.1% 
(SEM 3.3%) in post-confluent CaCo-2Bbe cells treated with 200 mg/L LNnT and tended to 
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increase (p=0.059) by 12% (SEM 3.6%) in the 2000 mg/L treatment group as compared to 0 
mg/L control.  Treatment with LNnT, 2'FL or 6'SL did not alter basal short-circuit current, 
potential difference or electrogenic nutrient transport.    
Table 5.3 provides a summary of all epithelial cytokinetic and epithelial function results 
for each cell type.   
 
DISCUSSION 
 
The GI tract undergoes numerous structural and functional changes as it adapts to extra-
uterine life (Carver and  Barness, 1996).  Only recently have HMOs been identified as dietary 
components which may aid in maturation of the developing infant’s GI tract.  Studies by Kuntz 
and colleagues (2008) demonstrated that neutral and acidic HMO fractions and individual 
oligosaccharides affect proliferation, differentiation, and apoptosis in vitro in non-transformed 
fetal intestinal crypt cell line, HIEC, and in transformed human intestinal cell lines, HT-29 and 
CaCo-2 (Kuntz et al., 2008).  The present study investigated the effects of three individual 
HMOs (2'FL, LNnT, and 6'SL) on epithelial cell differentiation utilizing a more comprehensive 
model of the crypt-villus axis consisting of pre-confluent HT-29 cells and CaCo-2Bbe cells at 
pre-confluent, confluent, and post-confluent states.  A cell culture model was the most 
appropriate model for assessing the effects of HMOs on specific regions along the crypt-villus 
axis.  Utilizing a well-controlled, reproducible in vitro model allowed for characterization of 
cellular kinetics following treatment with specific HMOs.    Further, it allowed us to overcome 
the obstacle of limited availability of the HMOs of interest.     
With regard to selection of HMOs studied, although nearly 200 oligosaccharides are 
present in human milk, the neutral and acidic oligosaccharide fractions of human milk are 
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primarily made up of fourteen neutral and six acidic oligosaccharides (Thurl et al., 2010).  The 
three HMOs investigated in this trial were selected based on their predominance in human milk, 
with 2'FL and LNnT being dominant oligosaccharide within the neutral fraction and 6'SL 
representing the largest proportion of the acidic fraction.    
We demonstrated that each of the three individual HMOs dose-dependently inhibited 
proliferation in pre-confluent HT-29 cells with an associated cell cycle arrest primarily within 
the G2/M phase, with 2'FL also increasing differentiation.  AP activity, a marker of cell 
differentiation was enhanced with treatment of the physiologically relevant dose of 2000 mg/L 
2'FL.  Our cell proliferation and cell cycle results were similar to those of Kuntz and colleagues.  
We differed though in that we found a single neutral oligosaccharide to enhance differentiation 
where they found the total acidic HMO fraction as well as 6'SL to have the greatest stimulatory 
effect on AP activity.  A potential explanation for our differing results in HT-29 cell 
differentiation may relate to the medium.  While we cultured our HT-29 cells in the ATCC 
recommended McCoy’s 5A, Kuntz et al. used RPMI 1640.  As culture conditions such as 
limiting glucose and supplementing galactose have been shown to enhance HT-29 cell 
differentiation it is possible that their use of RPMI 1640 was more conducive to enhancing 
differentiation (Lindley et al., 2012).  Further, while we utilized HT-29 cells between passages 5 
and 15, they utilized later passages (40 to 50) which have been shown in some case to have 
enhanced differentiation when compared to early passages (Chantret et al., 1994).   
We found pre-confluent Caco-2Bbe cells to be less sensitive to inhibition of proliferation 
with only the highest doses of the individual HMO having a significant effect and only 6'SL 
effecting progression through the G2/M phase.  Differentiation was assessed in CaCo-2BBe cells 
at 21 days post-confluence and similar to above, 2'FL tended to have a stimulatory effect on AP 
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activity.  We also quantified disaccharidase activities in the post-confluent CaCo-2Bbe cells and 
found sucrase activity to be a more sensitive and specific measure of differentiation within these 
cells, demonstrating a statistically significant 50% increase in activity with 2000 mg/L 2'FL.  
Our proliferation results were again similar to Kuntz and colleagues (Kuntz et al., 2008).  As 
they reported cell cycle differences in fractions at 15 g/L after 24 hours, it is likely that the 
timing of our treatments allowed for changes to be detected in cell cycle at such low doses as 
6'SL at 4000 mg/L for 72 hours was found to arrest pre-confluent Caco-2Bbe cells within the 
G2/M phase.  To the best of our knowledge, this is the first time that an individual human milk 
oligosaccharide has been shown to enhance sucrase activity in vitro.       
 Cellular caspase-3 activity, a measure of apoptosis, increased in post-confluent Caco-
2Bbe cells treated with 2000 mg/L LNnT.  Interestingly, LNnT also enhanced transepithelial 
resistance in post-confluent CaCo-2Bbe cells.  The increase in apoptosis paralleled enhancement 
of transepithelial resistance leading us to conclude that LNnT may have stimulated maturation of 
these cells to enhance an especially important intestinal characteristic in developing neonates.  
This is further evidenced by the increase in apoptosis in post-confluent CaCo-2Bbe cells treated 
with lactose + sialic acid and their subsequent enhancement in sucrase activity.  These 
enhancements in intestinal maturation in vitro are important findings when one considers the 
protective effects of human milk in premature infants, a population with an especially immature 
gut.  It is well established that human milk decreases the incidence of necrotizing enterocolitis 
(NEC) in infants when compared to infant formula (Sisk et al., 2007).  Recently Jantscher-Krenn 
and co-workers demonstrated that a single human milk oligosaccharide, disialyllactos-N-tetraose 
(DSLNT), increased survival in a rat pup model of NEC (Jantscher-Krenn et al., 2011).  While 
the etiology of NEC remains undefined, impaired intestinal epithelial barrier function is often 
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implicated in the pathogenesis. Taken together, the enhancement of transepithelial resistance 
following treatment with LNnT in our trial and the increased NEC survival following treatment 
with DSLNT demonstrated by Jantscher-Krenn et al suggest that HMOs may specifically have a 
role in the overall protective effects of human milk against NEC.  More in vivo research is 
needed to determine if our in vitro effects of LNnT will translate into pre-clinical models.       
In summary, we observed that 2'FL, LNnT, and 6'SL individually inhibited proliferation 
in pre-confluent transformed small intestinal cell lines HT-29 and Caco-2Bbe with associated 
G2/M cell cycle arrest.  More importantly, within our model of the crypt-villus axis, the 
inhibition of proliferation was associated with increased in epithelial differentiation within HT-
29 cells treated with a physiologically relevant dose of 2'FL.  Post-confluent CaCo-2Bbe cells 
used to model the well differentiated villus enterocytes demonstrated greater digestive and 
barrier function following treatment with doses of 2'FL and LNnT that reflect concentrations 
found in human milk.  Further study is needed to assess whether synergist effects occur 
following concomitant administration of HMOs as these results indicate that HMOs may 
promote maturation of the small intestine.  In vivo research is needed to determine if these in 
vitro effects on epithelial cytokinetics and epithelial function continue within the complex milieu 
of the GI tract.   
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FIGURES AND TABLES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. In vitro model of the crypt-villus axis consisting of individually cultured pre-
confluent HT-29 cell, pre-confluent CaCo-2Bbe, confluent CaCo-2Bbe, and post-confluent 
CaCo-2Bbe cells to represent the increasing levels of differentiation progressing from crypt to 
villus tip. 
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Table 5.1. Study 2 treatment groups.  2'FL, 2'-fucosyllactose; LNnT, lacto-N-neotetraose; 6'SL, 
6’-sialyllactose.   160 mg/L lactose plus 94 mg/L of other sugar. 
  
Treatment Groups Concentration 
(mg/L) 
LNnT Control 0 
LNnT Energy Control
1
  
(lactose + n-acetyllactosamine) 
154 
LNnT – low 20 
LNnT – physiological 200 
LNnT – high 2000 
  
2'FL Control 0 
2'FL Energy Control (lactose + fucose) 154 
2'FL – low 20 
2'FL – low 200 
2'FL – physiological 2000 
  
6'SL Control 0 
6'SL Energy Control (lactose + sialic acid) 154 
6'SL – low 40 
6'SL – physiological 400 
6'SL – high 4000 
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Figure 5.2. Effect of incubation with lacto-N-neotetraose (LNnT) for 24, 48 or 72 hours on 
proliferation in pre-confluent HT-29 cells.  Proliferation significantly decreased following 
incubation with LNnT for 24 (p=0.021), 48 (p=0.012) and 72 (p=0.0039) hours, with the most 
consistent effect at 72 hours.   Energy references to lactose + n- acetyllactosamine.Values are 
mean + SEM.  Asterisks denote statistically significant difference in treatment means as 
compared to 0 mg/L control within each time period by one-way ANOVA and paired-
comparisons (*p<0.05, **p<0.01).     
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Figure 5.3.  Effect of incubation with lacto-N-neotetraose (LNnT) for 24, 48 or 72 hours on 
proliferation in pre-confluent CaCo-2Bbe cells.  Proliferation significantly decreased 
following incubation with LNnT for 24 (p<0.001) and 72 (p=0.0054) hours, with the most 
consistent effect at 72 hours.   No treatment effect was seen at 48 hours (p=0.12).  Energy 
references to lactose + n- acetyllactosamine.Values are mean + SEM.  Asterisks denote 
statistically significant difference in treatment means as compared to 0 mg/L control within each 
time period by one-way ANOVA and paired-comparisons (*p<0.05, **p<0.01).   
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Figure 5.4. Effect of incubation with lacto-N-neotetraose (LNnT) for 24, 48 or 72 hours on 
differentiation in pre-confluent, confluent, and post-confluent CaCo-2Bbe cells.  
Differentiation was not altered by treatment (p=0.47); however, alkaline phosphatase (AP) 
activity significantly increased with time (p<0.001), cell type (p<0.001) and in the interaction 
between cell type and time (p=0.001).  Values are pooled means of all LNnT treatments (0 mg/L, 
100 mg/L, 200 mg/L, 400 mg/L, and lactose +n-acetylglucosamine) for the respective time point 
and cell type.  Values are means + SEM.  Means that do not share a common letter are 
significantly different as determined by a three-way ANOVA and paired-comparisons.   
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  HT-29  CaCo-2 
Treatment Groups Concentration 
(mg/L) 
Mean 
% 
SEM 
% 
 Mean 
% 
SEM 
% 
LNnT Control 0 100.0% 2.0  100.0% 2.3 
LNnT Energy (lactose + n-acetyllactosamine) 154 96.0 2.0  93.8 2.3 
LNnT 20 94.8 2.0  102.4 2.3 
LNnT 200 94.4* 2.0  101.3 2.3 
LNnT 2000 92.1** 2.0  87.13** 2.3 
 2'FL Control 0 100% 2.3  100% 2.1 
2'FL Energy (lactose + fucose) 154 101.1 2.3  95.6 2.1 
2'FL 20 99.5 2.3  105.2 2.1 
2'FL 200 97.1 2.3  101.8 2.1 
2'FL 2000 75.3*** 2.3  89.7* 2.1 
 
6'SL Control 0 100% 2.9  100% 2.2 
6'SL Energy (lactose + sialic acid) 154 95.1 3.0  103.2 2.6 
6'SL 40 96.7 2.9  107.1* 2.2 
6'SL 400 92.3* 2.9  105.4 2.2 
6'SL 4000 88.3** 3.0  83.0*** 2.2 
Table 5.2. Effects of HMO treatments on proliferation in pre-confluent HT-29 and pre-
confluent CaCo-2Bbe cells.  Values represent the percent proliferation as compared to 
respective 0 mg/L controls (set at 100.0%).  HT-29 cells were more sensitive to reduction in 
proliferation with significant reductions seen at 200 and 2000 mg/L LNnT, 2000 mg/L 2’FL and 
400 and 4000 mg/L 6'SL.  Significant reductions were seen at 2000 mg/L LNnT, 2000 mg/L 
2'FL, and 4000 mg/L 6'SL in the CaCo-2Bbe cells.  Values are mean + SEM.  Asterisks denote 
statistically significant difference in treatment means as compared to 0 mg/L control within each 
treatment group by one-way ANOVA and paired-comparisons (*p<0.05, **p<0.01, 
***p<0.001).  2'FL, 2'-fucosyllactose; LNnT, lacto-N-neotetraose; 6'SL, 6'-sialyllactose.    
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Figure 5.5. Effect of incubation with lacto-N-neotetraose (LNnT) for on cell cycle events in 
pre-confluent HT-29 cells.  Treatment with 200 mg/L of LNnT resulted in both G0/G1  
(p=0.026) and G2/M arrest (p=0.027) in coordination with a decreased (p<0.001) proportion of 
cells in the S phase.  Treatment with 2000 mg/L of LNnT resulted in G2/M arrest (p=0.0033) and 
tended to decrease (p=0.085) the proportion of cells in G0/G1 as compared to 0 mg/L controls.  
Energy refers to lactose + n-acetyllactosamine.  Values are mean + SEM.  Asterisks denote 
statistically significant difference in treatment means as compared to 0 mg/L control within each 
cell cycle event by one-way ANOVA and paired-comparisons (*p<0.05, ***p<0.001).   
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Figure 5.6. Effect of incubation with 2'-fucosyllactose (2'FL) on cell cycle events in pre-
confluent HT-29 cells.  Treatment of 2000 mg/L 2'FL resulted in cell cycle arrest (p=0.021) in 
the G2/M phase and a decreased (p=0.034) proportion of cells in the G0/G1 phase.  Energy refers 
to lactose + fucose.  Values are mean + SEM.  Asterisks denote statistically significant difference 
in treatment means as compared to 0 mg/L control within each cell cycle event by one-way 
ANOVA and paired-comparisons (*p<0.05).   
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Figure 5.7. Effect of incubation with 6'-sialyllactose (6'SL) on cell cycle events in pre-
confluent HT-29 cells.  Treatment with 4000 mg/L 6'SL resulted in cell cycle arrest (p<0.001) in 
the S phase and a decreased (p=0.0035) proportion of cells in the G2/M phase.  Treatment with 
400 mg/L 6'SL resulted in a significant decrease (p=0.0013) in the proportion of cells in the S 
phase with cell arrest tending (p=0.058) to occur in the G2/M phase.  Energy refers to lactose + 
sialic acid.  Values are mean + SEM.  Asterisks denote statistically significant difference in 
treatment means as compared to 0 mg/L control within each cell cycle event by one-way 
ANOVA and paired-comparisons (#p<0.1;**p<0.01, ***p<0.0001).   
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Figure 5.8. Effect of incubation with 6'-sialyllactose (6'SL) on cell cycle events in pre-
confluent CaCo-2Bbe cells.  Treatment with 4000 mg/L 6'SL resulted in cell cycle arrest 
(p=0.016) in the G2/M phase and a decreased (p=0.0013) proportion of cells in the G0/G1 phase.  
Treatment with 400 mg/L 6'SL resulted in arrest (p=0.013) in the G0/G1 phase with a 
corresponding decrease (p=0.035) in the percentage of cells in the G2/M phase.  Energy refers to 
lactose + sialic acid.  Values are mean + SEM.  Asterisks denote statistically significant 
difference in treatment means as compared to 0 mg/L control within each cell cycle event by 
one-way ANOVA and paired-comparisons (**p<0.01, ***p<0.0001).   
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Figure 5.9. Effect of incubation with 2'-fucosyllactose (2'FL) on differentiation in pre-
confluent HT-29 cells.  A 30.9% (SEM 6.8%) increase (p=0.030) in alkaline phosphatase (AP) 
activity occurred in cells treated with 2000 mg/L 2'FL as compared to 0 mg/L control.   Energy 
refers to lactose + fucose.  Values are mean + SEM.  Asterisks denote statistically significant 
difference in treatment means as compared to 0 mg/L control by one-way ANOVA and paired-
comparisons (*p<0.05).   
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Figure 5.10. Effect of incubation with 2'-fucosyllactose (2'FL) on differentiation in post-
confluent CaCo-2Bbe cells.  Treatment with 2000 mg/L 2'FL tended to increase (p=0.071) 
alkaline phosphatase (AP) activity by 33.1% (SEM 13.7%) as compared to 0 mg/L control.  
Energy refers to lactose + fucose.  Values are mean + SEM.  There was no statistically 
significant difference in treatment means as compared to 0 mg/L control by one-way ANOVA 
and paired-comparisons.   
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Figure 5.11. Effect of incubation with lacto-N-neotatraose (LNnT) on apoptosis in post-
confluent CaCo-2Bbe cells.  Treatment with 2000 mg/L LNnT increased (p=0.036) caspase-3 
activity 79.6% (SEM 13.6%).  Lactose plus sialic acid (energy) increased (p=0.010) caspase-3 
activity 101.0 % (SEM 12.1%) as compared to the 0 mg/L control.  Values are mean + SEM.  
Asterisks denote statistically significant difference in treatment means as compared to 0 mg/L 
control by one-way ANOVA and paired-comparisons (*p<0.05). 
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Figure 5.12. Effect of incubation with 6'-sialyllactose (6'SL) on apoptosis in post-confluent 
CaCo-2Bbe cells.  Treatment with 6'SL increased (p=0.033) caspase-3 activity 71.4% (SEM 
14.1%) in the 4000 mg/L treatment while the energy control group (sialic acid plus lactose) 
increased (p=0.034) by 76.3% (SEM 16.7%) as compared to the 0 mg/L control.   Values are 
mean + SEM.  Asterisks denote statistically significant difference in treatment means as 
compared to 0 mg/L control by one-way ANOVA and paired-comparisons (*p<0.05). 
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Figure 5.13. Effect of incubation with 2'fucosyllactose (2'FL) on sucrase activity in post-
confluent CaCo-2Bbe cells.  Cells treated with 2000 mg/L of 2'FL had a 53.5% (SEM 6.6%) 
increase (p=0.036) in sucrase activity as compared to 0 mg/L controls.  Energy refers to lactose + 
fucose.  Values are mean + SEM.  Asterisks denote statistically significant difference in 
treatment means as compared to 0 mg/L control by one-way ANOVA and paired-comparisons 
(*p<0.05).   
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Figure 5.14. Effect of incubation with 6'sialyllactose (6'SL) on sucrase activity in post-
confluent CaCo-2Bbe cells.   Energy (lactose + sialic acid) increased (p=0.042) sucrase activity  
by 48.5% (SEM 15.4%) as compared to the 0 mg/L control.  Values are mean + SEM.  Asterisks 
denote statistically significant difference in treatment means as compared to 0 mg/L control by 
one-way ANOVA and paired-comparisons (*p<0.05). 
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Figure 5.15. Effect of incubation with lacto-N-neotetraose (LNnT) on transepithelial 
resistance in post-confluent CaCo-2Bbe cells.  Transepithelial resistance increased (p=0.002) 
by 21.1% (SEM 3.34%) in cells treated with 200 mg/L LNnT and tended to increase (p=0.059) 
by 12% (SEM 3.61%) in the 2000 mg/L treatment group as compared to 0 mg/L control.  Energy 
refers to lactose + n-acetyllactosamine.  Values are mean + SEM.  Asterisks denote statistically 
significant difference in treatment means as compared to 0 mg/L control by one-way ANOVA 
and paired-comparisons (#p<0.1; *p<0.05). 
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Table 5.3.  Summary of HMO effects in each cell type.  2'FL, 2'-fucosyllactose; LNnT, lacto-
N-neotetraose; 6'SL, 6'-sialyllactose. 
 
 
 
  
 LNnT 6'SL 2'FL 
Pre-confluent HT-29 
     Proliferation Decreased Decreased Decreased 
     Cell Cycle G2/M arrest G2/M & S arrest G2/M arrest 
     Differentiation   Increased 
Pre-confluent CaCo-2Bbe 
     Proliferation Decreased Decreased Decreased 
     Cell Cycle  G2/M arrest  
     Differentiation   Increased 
Post-confluent CaCo-2Bbe 
     Differentiation   Increased 
     Apoptosis Increased   
     Barrier Function Increased   
     Sucrase   Increased 
     Lactase    
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CHAPTER 6 
CONCOMITANT ADMINISTRATION OF HUMAN MILK OLIGOSACCHARIDES 
INFLUENCES INTESTINAL MATURATION IN VITRO 
 
 
ABSTRACT 
Human milk oligosaccharides (HMOs) are abundant in human milk (> 15 g/L) and are 
associated with enhanced intestinal maturation in vitro (Kuntz et al., 2008; Kuntz et al., 2009).  
Therefore, we aimed to assess the induction of epithelial differentiation by individual and 
concomitant administration of three HMOs, 2'-fucosyllactose (2'FL), 3'sialyllactose (3'SL), and 
6’-sialyllactose (6'SL), using an in vitro epithelial model of the crypt-villus axis made up of pre-
confluent HT-29, pre-confluent CaCo-2Bbe and post-confluent CaCo-2Bbe cells.  Cells were 
randomized to 1 of 18 treatments for 72 hours of incubation:  individual HMO treatments at low 
and high doses (3'SL at 0.2 and 1.0 g/L, 6'SL at 0.4 and 1.0 g/L, 2'FL at 0.2 and 2.0 g/L), 
concomitant treatments of the previous HMOs at both low and high doses, and controls (0 g/L, 
media, 4 g/L total HMO, and lipopolysaccharide (LPS)).   Pre-confluent HT-29 cells had reduced 
proliferation (p<0.05) with individual high dose treatments of 6'SL and 2'FL.  Additionally, 
concomitant administration of the high doses of HMOs (p<0.05) significantly reduced 
proliferation as did the total pooled HMO (p<0.001).  Pre-confluent CaCo-2Bbe cells were less 
sensitive to reduction in proliferation where only high dose concomitant treatments containing 
2'FL (p<0.01) significantly reduced proliferation in addition to the total HMO (p<0.001).  
Interestingly, 2'FL did not enhance differentiation in HT-29 cells as we had previously shown; 
however, it did increase (p<0.05) differentiation in pre-confluent Caco-2Bbe cells.  HMO 
treatments did not enhance alkaline phosphatase (AP) activity, a general marker of 
differentiation, nor did it increase disaccharidase activity in post-confluent Caco-2Bbe cells.  
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Disaccharidase activity was only affected by time (p<0.05) in that lactase activity was higher at 
12 days as compared to 21 days and the opposite was found for sucrase activity.  Apoptosis and 
necrosis were both significantly decreased (p<0.001) in post-confluent CaCo-2Bbe cells treated 
with 4.0 g/L total pooled HMO as compared to 0 g/L control.  In summary, HMO treatments 
consistently inhibit proliferation with some associated enhancement of epithelial differentiation.  
Although total pooled HMO reduced apoptosis and necrosis, it is less clear if this is associated 
with functional outcomes.  Further study is needed to determine if these effects translate in vivo, 
however, results of our in vitro model of the crypt-villus axis suggest addition of HMO to infant 
formula may promote intestinal maturation.   
 
INTRODUCTION 
Human milk, a complex physiological fluid, is nutritionally adequate to meet the needs of 
the developing neonate and promotes maturation of the neonatal gastrointestinal (GI) tract 
(Carver and  Barness, 1996).  Human milk oligosaccharides (HMOs) are the third most abundant 
solid component in human milk making up nearly 15 grams per liter in mature milk (Coppa et 
al., 1999; Chaturvedi et al., 2001a; Ninonuevo et al., 2006; German et al., 2008b; Thurl et al., 
2010; Wu et al., 2010).   Human milk is unique in its oligosaccharide complexity and 
composition, containing up to 200 unique oligosaccharides (Coppa et al., 2001).   In contrast, 
bovine milk is nearly completely lacking in free complex oligosaccharides (Kunz et al., 2000).  
Infant formula also essentially lacks oligosaccharides except in cases where plant derived or 
synthetic prebiotic oligosaccharides are supplemented (Tungland and  Meyer, 2002; Kunz and  
Rudloff, 2006).  
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As a large portion of U.S. infants are solely fed formula during the key period of neonatal 
development, more research is needed to determine potential ingredients which can aid in 
narrowing the compositional gap between formula and human milk in order to impart some of 
the benefits of human milk on to formula-fed infants.  Recent studies have sparked interest in 
HMOs as potential ingredients for supplementation to infant formula.  Kuntz and colleagues 
showed that neutral and acidic HMO fractions in effect cell dynamics and promote maturation of 
the small intestine in vitro (Kuntz et al., 2008) 
To our knowledge, this is the first study to investigate in vitro small intestinal effects as 
related to concomitant administration of specific HMOs which are of interest for use as infant 
formula ingredients.  As such, the results of this study will help fill the gap in knowledge 
surrounding synergistic effects of some of the most prevalent HMOs within the immature small 
intestine in vitro.  
In this study, we aimed to assess the induction of epithelial differentiation by individual 
and concomitant administration three HMOs, 2'-fucosyllactose (2'FL), 3'-sialyllactose (3'SL), 
and 6'-sialyllactose (6'SL), using an in vitro epithelial model of the crypt-villus axis consisting of 
pre-confluent HT-29 cells, pre-confluent CaCo-2Bbe cells, and post-confluent CaCo-2Bbe cells.    
 
 
MATERIALS AND METHODS 
Study Design 
 Our model consisted of pre-confluent HT-29 cells, pre-confluent CaCo-2Bbe cells and 
post-confluent CaCo-2Bbe cells cultured individually to provide an in vitro model of the small 
intestinal crypt-villus axis and simulate the varying levels of differentiation within the constantly 
renewing villus in vivo (Figure 5.1).  HT-29 cells are a low differentiated phenotype reflective of 
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crypt colonocytes—these cells are not able to differentiate even in post-confluent states under 
normal culture conditions (Lesuffleur et al., 1990).   HT-29 cells have properties of chloride 
secreting cells related to a chloride channel that can also be found within human intestinal 
epithelial cells (Kreusel et al., 1991).   CaCo-2Bbe cells, a well characterized model of intestinal 
absorptive epithelium, exhibit moderate differentiation in a pre-confluent state and in a post-
confluent state exhibit a process of differentiation similar to that seen in a villus enterocyte 
(Peterson and  Mooseker, 1992).  CaCo-2Bbe cells will grow as a monolayer, continuing to 
differentiate and form cylindrical polarized morphology with tight junctions between cells 
(Peterson and  Mooseker, 1992).  Additionally, CaCo-2Bbe cells have apical microvilli with 
associated brush-border enzymes (sucrase and lactase) in post-confluent states which are similar 
to human fetal enterocytes (Peterson and  Mooseker, 1992).   Furthermore, CaCo-2 cells grown 
as a monolayer are also a well-established model of intestinal absorptive function and provide an 
avenue by which transepithelial resistance and nutrient transport can be assessed (Delie and  
Rubas, 1997).       
Overall, our model allowed us to assess relevant outcomes along the length of the crypt-
villus axis in vitro as pre-confluent HT-29 cells model secretory crypt cells, pre-confluent CaCo-
2Bbe cells model proliferating absorptive enterocytes as they migrate up the villus, and post-
confluent CaCo-2Bbe cells model well differentiated functional absorptive villus cells.  The in 
vitro model as a whole simulates the neonatal infant’s maturing gastrointestinal epithelium 
(Kuntz et al., 2008).  Furthermore, incubation of the cells with HMOs provides a simulation of 
the suckling infant’s nearly continuous enteral feedings of human milk.   As such, our model will 
proved an avenue for novel insight into the synergistic effects of concomitant HMO 
administration on small intestinal cellular dynamics and function in vitro.      
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Treatments 
In order to decipher synergism effect of concomitant administration of HMOs, each 
treatment replicate included the individual HMO at the levels that will be tested in the 
concomitant groups.  HMOs were provided by Abbott Nutrition.  Thus, the treatment group 
included 3'SL, 6'SL and 2'FL individually at their physiologically relevant levels, 0.2 g/L, 0.4 
g/L and 2.0 g/L, respectively.  Additionally, each HMO was provided at a second dose of 1.0 g/L 
3'SL, 1.0 g/L 6'SL, and 0.2 g/L 2'FL.  Concomitant treatment groups included pairs of the HMOs 
at two levels each and all three HMOs at two levels.   Positive and negative controls were also 
included in each experiment.  Total HMO (donated by Lars Bode, University of San Diego) at 
4g/L acted as the positive control.  The 4g/L level was selected to match the highest concomitant 
treatment group tested (1.0 g/L 3'SL + 1.0 g/L 6'SL + 2.0 g/L 2'FL= 4.0 g/L).  
Lipopolysaccharide (LPS) control groups were utilized to match the remaining endotoxin units 
measured in the respective total HMO fraction following one passage through the endotoxin 
removal column.  The media control group was utilized to determine the potential effects of the 
endotoxin column on the 0 g/L.  The 0 g/L control contained the matched volume of medium 
passed through the endotoxin removal columns needed to make the 4 g/L concomitant treatment 
and pooled HMO treatment.   
Prior to treatment, each of the HMOs as well as the energy controls were added to either 
Dulbecco’s Modified Eagle Medium (DMEM) or McCoy’s 5A cell culture media at a 
concentration of 20 mg/mL, passed through a Detoxi-Gel endotoxin removing column (Pierce), 
and stored at -80
o
C until use.  The columns utilize immobilized polymixin B to remove pyrogens 
by binding their lipid A domains.  Solutions were tested prior to use to ensure endotoxin levels 
were below a detectable level using the Limulus Amebocyte Lysate (LAL) Endotoxin test kit 
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(Roche) according to manufacture guidelines.  3'SL, 6'SL, and 2'FL solutions did not contain 
detectable levels of endotoxin after passage through the endotoxin removal columns.  The total 
pooled HMO sample in DMEM contained 2050 endotoxin units and the total pooled HMO 
sample in McCoy’s 5A contained 2600 endotoxin units following one passage through the 
columns.  Thus, LPS controls were created by adding the respective amounts of endotoxin units 
to complete media prior to treatment.       
Cell Culture 
To model the crypt-villus axis and investigate the effects of incubation with HMOs, pre-
confluent HT-29, pre-confluent CaCo-2Bbe, confluent CaCo-2Bbe and post-confluent CaCo-
2Bbe cells were utilized.  The CaCo-2Bbe cell line was obtained from American Type Culture 
Collection (CRL-2102, ATCC, Manassas, VA) clone of CaCo-2 (ATCC: ATB-37).  They were 
used between passages 55 and 65.  The transformed human intestinal cells, HT-29 cells, were 
obtained were obtained from American Type Culture Collection (ATCC, Manassas, VA).  They 
were used between passages 5 and 15.  Both cell lines were separately maintained in 75 cm
2 
tissue culture flasks (TP90075, Midwest Scientific, St. Louis, MO) and maintained in a 
humidified atmosphere of 37
o
C and 5% CO2.  HT-29 cells were maintained in McCoy’s 5A 
media formulation supplemented with 10% fetal bovine serum (Atlanta Biological, 
Lawrenceville, GA).  CaCo-2Bbe cells were maintained in DMEM supplemented with 10% fetal 
bovine serum (Atlanta Biological) and 0.01 mg/ml human apotransferrin (Sigma).  Growth 
medium was replaced as needed, but no fewer than twice per week. Cell lines were subcultured 
weekly at pre-confluent densities with 0.25% trypsin-EDTA (25200, Invitrogen, Carlsbad, CA).   
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Cell Proliferation  
The CellTiter 96 AQueous non-radioactive cell proliferation assay (G5421, Promega, Madison, 
WI) was utilized to assess cell proliferation.  The assay utilizes the soluble compound 3-(4,5-
dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-3-(4-sulfophenyl)-2H-tetrazolium (MTS) 
with an electron coupling reagent, phenazine methosulfate (PMS).  MTS is bioreduced by 
actively proliferating cells into a formazan product which is measured at 490nm absorbance and 
is directly proportional to the number of living cells in culture.   Proliferation was measured by 
the MTS assay as described by the manufacturer.  Briefly, 96 well plates were seeded with HT-
29 or CaCo-2Bbe cells at a density of 1500 cells/well and allowed to adhere for 24 hours 
followed by incubation with HMO treatments for 72 hours.  During the last hour of the 
incubation period, MTS/PMS was added and plates continued to incubate at 37
o
C at 5% CO2.  
Absorbance was then measured at 490 nm.  Results are expressed as a percent of control (0 
mg/L).     
Cellular differentiation  
HT-29 cells and CaCo-2Bbe cells were seeded separately in 75 cm
2
 tissue culture flasks 
at a density of 10
4
 cells/cm
2
 and allowed to adhere for 48 hours in the case of the pre-confluent 
HT-29 and pre-confluent CaCo-2Bbe cells and 18 days for the post-confluent CaCo-2Bbe cells.  
Following the adherence period, media were changed and HMO treatments applied.  After the 72 
hour incubation period, cells were trypsinized, pelleted by centrifugation at 500 x g for 5 minutes 
and washed two times with PBS.  Cell pellets were flash frozen in liquid nitrogen and stored at -
80
o
C until analysis.  Cellular differentiation was measured by alkaline phosphatase (AP) activity.  
AP activity was measured by commercially available fluorometric and colorimetric assay kits 
(K422 and K412, BioVision, Mountain View, CA).  AP activity in HT-29 cells was determined 
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fluorometrically following homogenization of cells in Assay Buffer then centrifuging for 3 
minutes at 13,000 x g to remove insoluble material.  Cell supernatants were added to black 96 
wells plate and incubated with 4-methylumbelliferyl phosphate disodium salt (MUP) substrate 
for 3 hours at room temperature protected from light.  The reaction was stopped by the addition 
of Stop Solution and read at excitation=360nm and emission=440nm.  Background controls were 
used for all samples by adding Stop Solution to the wells prior to addition of MUP.  Final AP 
activity was determined by subtracting background control values and quantifying activity based 
on standard curve methodology.  AP activity was normalized to protein content as measured by 
the BCA protein assay.   AP activity in CaCo2-Bbe cells was quantified in a similar manner with 
the following exceptions: p-nitrophenyl phosphate was used as a phosphatase substrate and 
measured colorimetrically in clear 96 wells plates at 405 nm in a plate reader after 30 minutes 
incubation at room temperature.  Results are expressed as AP activity units per milligram 
protein.   
Apoptosis and Necrosis 
Apoptosis and necrosis were quantified by the Cell Death Detection ELISA
PLUS
 (Roche), 
a photometric enzyme-immunoassay for in vitro determination of cytoplasmic histone-
associated-DNA-fragments according to manufacture directions.  Briefly, for quantification in 
pre-confluent cells, 96 well plates were seeded with HT-29 or CaCo-2Bbe cells at a density of 
1500 cells/well and allowed to adhere for 24 hours followed by incubation with HMO treatments 
for 72 hours.  For assessment in post-confluent CaCo-2Bbe cells, cells were seeded at a density 
of 1 x 10
4
 cells/cm
2
 into the 96 well plates and maintained in an incubator for 18 days with twice 
weekly medium renewal.  On day 18, media were removed and media containing HMO 
treatments applied.  At the end of the 72 hour treatment period, plates were centrifuged for 10 
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minutes at 200 x g and supernatant was collected and stored at 4
o
C until assay to quantify 
necrotic cells.  Lysis buffer was added to each well and incubated at room temperature for 30 
minutes followed by centrifugation for 10 minutes at 200 x g.  Supernatant was collected to 
measure cellular apoptosis.  Next, 20 ul of the cytoplasmic fractions collected following the two 
centrifugation phases were transferred to the streptavidin coated microplate and 80 ul of the 
immunoreagent, containing anti-histone-biotin and anti-DNA-peroxidase, was added.  During the 
incubation period, the anti-histone antibody binds the nucleosomes histone-component while the 
biotin simultaneously complexes with the streptavidin coating the microplate and the anti-DNA-
peroxidase antibody reacts with the nucleosomal DNA-component.   At the end of the 2 hour 
incubation period, the solutions were removed and the plate washed 3 times with incubation 
buffer.  The ABTS substrate was then added and allowed to incubate for 10 minutes prior to 
stopping the reaction.  The photometric color development was measured at 490nm.  Results are 
expressed as a percent of control (0 mg/L).       
Cell cycle analysis 
HT-29 cells and CaCo-2Bbe cells were seeded separately in 75 cm
2
 tissue culture flasks 
at a density of 10
4
 cells/cm
2
 and were grown in media for 48 hours.  Following the adherence 
period, media were changed, HMO treatments applied, and cells were then allowed to grow for 
an additional 72 hours.   At the end of the treatment period, cells were trypsinized, pelleted by 
centrifugation at 500 x g for 5 minutes, and washed two times with PBS.  Cells were then fixed 
by adding 1 x 10
6
 cells to 9 ml of ice cold 90% ethanol and stored at -20
o
C until analysis.  For 
cell cycle analysis, cells fixed in ethanol were pelleted by centrifugation at 200 x g for 15 
minutes at 4
o
C then washed two times with cold PBS.  Cells were resuspended in propidium 
iodide (PI)/Triton X-100 staining solution containing DNAse-free RNAse and strained through 
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nylon filter capped Falcon tubes.  Following incubation at room temperature for 30 minutes, 
tubes were transfer to ice and protected from light until data acquisition by a Epics XL benchtop 
flow cytometer.  Data are expressed as the distribution of cell populations in different cell cycle 
stages.   
Sucrase and Lactase Activity 
CaCo-2Bbe cells were seeded in 75 cm
2
 tissue culture flasks at a density of 10
4
 cells/cm
2
 
and maintained for 9 or 18 days.  Following the adherence period, media was changed and 
treatment applied and allowed to incubate for 72 hours in the incubator.  After the incubation 
period, cells were washed three times with ice-cold PBS then removed by scraping with a plastic 
cell scraper into 3.5 ml of PBS.  Following centrifugation at 500 x g for 5 minutes, PBS was 
removed and cell pellets flash frozen in liquid nitrogen and stored at -80
o
C until analysis.  For 
measurement of disaccharidase activity, cell pellets were suspended in 1 mL of homogenization 
buffer (0.9% saline solution containing 1 uM phenylmethylsulfonyl fluoride and 223 uM of 
iodoacetic acid) and homogenized for 30 seconds on setting 5 on a homogenizer.  Homogenates 
were then incubated with either sucrose or lactose buffers for 1 hour in a 37
o
C water bath.  
Enzyme activity was stopped by the addition of Ba(OH)2 and ZnSO4.  Background control tubes 
were immediately stopped with Ba(OH)2  and ZnSO4 prior to incubation to quantify non-specific 
disaccharidase activity.  Samples were then be centrifuged for 20 minutes at 3000 rpm at 4
o
C.  
Supernatants were added in triplicate to a clear 96 well plates, glucose oxidase reagent (Sigma) 
was then added and allowed to incubate at room temperature for 10 minutes in order to detect the 
amount of glucose released from the hydrolysis of the disaccharides.  The plates were read at 500 
nm in a spectrophotometer and quantified using standard curve technique.  Disaccharidase 
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activity was normalized to cellular protein content of the same homogenate as measured by the 
BCA assay and expressed as the amount of glucose release per hour per milligram protein. 
Statistical Analysis 
Statistical differences between treatments were determined using a one-way analysis of 
variance (ANOVA) with Dunnett’s adjustment for multiple comparisons.  Source of variation 
were treatment (n=18) and replicate (n=3).  Contrast statements were also utilized: 1) to compare 
the pooled means of each of the individual HMO treatments verses the 0 g/L control; and, 2) to 
compare the pooled treatment means of each of the individual HMOs versus its respective 
concomitant HMO treatment group.  Normality was tested using the Shapiro-Wilk statistic.  
Logarithmic and reciprocal transformations were utilized as needed.  Computations were 
conducted using a mixed model in SAS (Version 9.1; SAS Institute, Cary, North Carolina).  
Statistical significance was defined as p ≤ 0.05, and trends were reported at p<0.01.  Data are 
reported as mean ± SEM. 
 
RESULTS 
In this trial, each dependent variable was assessed following a 72 hour incubation period 
with the HMO treatment groups discussed above.  The effect of each treatment on HT-29 cell 
proliferation is listed in Table 6.1.  Neither the media nor the LPS control groups were different 
from the 0 g/L control group.  Unless otherwise noted, all comparisons in proliferation rates were 
made to the 0 g/L control group.  Treatment with two of the individual HMOs, 6'SL and 2'FL, 
reduced proliferation in pre-confluent HT-29 cells.  Both 1.0 g/L 6'SL and 2.0 g/L 2'FL 
significantly reduced proliferation (p<0.05) by 8.7% and 9%, respectively as compared to 0 
mg/L control. Further, pooled treatment means of the high and low doses of the individual 
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HMOs reveals that both 3'SL and 2'FL reduced (p<0.05) proliferation as compared to 0 g/L 
control (Figure 6.1).  Thus, all three individual HMOs reduced proliferation in pre-confluent 
HT-29 cells.   
Concomitant treatments had a slightly additive effect on the reduction of proliferation in 
pre-confluent HT-29 cells.  Low dose and the high dose combinations of 3'SL + 6'SL resulted in 
proliferation rates of 90.1% and 86.6%, respectively, as compared to 0 g/L control.  Further, 
incubation with high dose combinations of 3'SL + 2'FL and 6'SL and 2'FL significantly reduced 
proliferation (p<0.05) to rates to 90.2% and 88.8% , respectively.  The low dose combination of 
the 3'SL + 6'SL + 2'FL did not significantly affect proliferation, however the high dose 
combination of the three reduced proliferation to 89.1% was significantly different from control 
(p<0.01).   The combined high dose combination of the three HMOs (totally 4 g/L) did not have 
as profound of an effect on proliferation as the total HMO treatment at 4 g/L.  Total HMO had 
the greatest effect, reducing (p<0.001) proliferation to 77.0% of the 0 g/L control.       
Pre-confluent CaCo-2Bbe cells were less sensitive to HMO treatments (Table 6.2).  
Again, there was no difference in proliferation between 0 g/L control and either the media or the 
LPS control groups.  Proliferation rates were not significantly reduced with individual HMO 
treatment.  Similar to the pre-confluent HT-29 cells, the high dose combinations of 3'SL + 2'FL 
and 6'SL + 2'FL reduced (p<0.01) proliferation rates in pre-confluent CaCo-2Bbe cells to 
91.90% and 92.18%, respectively.  Again, similar to above, the low dose combination of the 
3’SL + 6’SL + 2’FL did not significantly affect proliferation, however the high dose combination 
of the three reduced proliferation to 89.9% was significantly different from control (p<0.01).  
Interestingly, in these cells, the total pooled HMO (4 g/L) had a similar effect on the proliferation 
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rate as the 4g/L concomitant high dose group, significantly reducing (p<0.001) proliferation to 
89.5%.     
     No changes were detected in cell cycle kinetics in pre-confluent HT-29 cells in any 
treatment group (Table 6.3).  In pre-confluent CaCo-2Bbe cells (Table 6.4), treatment with 1.0 
g/L 6'SL, 0.2 g/L 2'FL and 2.0 g/L 2'FL each resulted in arrest (p<0.01) within the G1 phase and 
a corresponding significant decrease in the percentage of cells in the G2 phase.  Both the high 
and low dose combinations of 3'SL + 6'SL and 3'SL + 2'FL also resulted in arrest within the G1 
phase and a subsequent decrease in the percentage of cells in the G2 phase.  Only the high dose 
combinations of  3'SL + 6'SL and 3'SL + 2’FL resulted in a reduced (p<0.01) proportion of cells 
within the S phase.  The low dose combination of 6'SL + 2'FL resulted in a significant decrease 
(p<0.05) in the percentage of cells in the G2 phase with no other changes noted in the other 
phases.  The high dose combination of 6'SL + 2'FL has associated with accumulation of cells 
within the G1 phase.  The low dose combination of 3'SL + 6'SL + 2'FL significant decreased 
(p<0.01) in the proportion of cells in the G2 phase; however, no differences were detected in cell 
cycle kinetics at the high dose level when the three HMOs were combined.  Interestingly, the 
total pooled HMO treatment had the opposite effect of the other HMO treatments in that there 
was a significant decrease in the proportion of cells in the G1 phase (p<0.001) and a 
corresponding significant increase in the proportion of cells arrested in the S phase (p<0.001). 
AP activity of pre-confluent HT-29 cells is detailed in Table 6.5, pre-confluent CaCo-
2Bbe cells in Table 6.6, and post-confluent CaCo-2Bbe cells in Table 6.7.   Of the three cell 
types, only pre-confluent CaCo-2Bbe cells were affected by treatment.  Within pre-confluent 
CaCo-2Bbe cells, the high dose (2.0 g/L) of 2’FL significantly increased (p<0.05) differentiation 
by 22.6% (SEM=7.4%) as compared to the 0 g/L control.  Additionally, the pooled treatment 
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mean of 0.2 and 2.0 g/L 2'FL was also significantly higher than 0 g/L control (Figure 6.2).  
Treatment with both the high and low doses of 3'SL + 6'SL tended (p=0.060 and p=0.054, 
respectively) to increase differentiation in pre-confluent CaCo-2Bbe cells.   
Cellular apoptosis and necrosis was measured in all cell types studied.  Both pre-
confluent HT-29 cells (Table 6.8) and pre-confluent CaCo-2Bbe cells (Table 6.9) had 
exceptionally low levels of apoptosis and necrosis.  In pre-confluent HT-29 cells, HMO 
significantly increased (p<0.001) apoptosis by 179.3% with a subsequent decreased in necrosis 
to 4.0% of that of 0 g/L control cells.  In pre-confluent CaCo-2Bbe cells, necrosis was again 
significantly reduced (p<0.001) by the total HMO fraction to 22.8 % of that of the 0 g/L control, 
but no differences were found in the levels of apoptosis in any treatment group.  Post-confluent 
CaCo-2Bbe cells (Table 6.10) treated with the pooled HMO treatment had significant reductions 
in both apoptosis (p<0.001) and necrosis (p<0.001), reaching levels of 60.5% and 31.7% of that 
of the 0 g/L control, respectively.  Similar to the total pooled HMO treatment, the matched LPS 
control also had decreased necrosis (p<0.01) as compared to 0 g/L control but to a much lesser 
extent.  The LPS group reduced necrosis by 33.4% versus the 68.3% reduction in necrosis in the 
total pooled HMO group.  Necrosis was also decreased by individual high and low dose of 3’SL 
and 2’FL.  The low dose combination of 3'SL + 6'SL also had a significantly lower (p<0.05) 
proportion of necrotic cells as compared to 0 g/L control while the low dose combination of 3'SL 
+ 2'FL tended to have a lesser proportion of necrotic cells.      
Surcrase and lactase activity was also assessed in post-confluent CaCo-2Bbe cells at two 
different time points, 12 days postconfluence and 21 days post confluence, however no treatment 
effects were detected (Table 6.11 and Table 6.12).  There was a difference in the two time 
points in their respective disaccharidase activities.  Lactase activity was found to be significantly 
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higher (p<0.05) in cells at day 12 as compared to day 21 and sucrase activity was higher 
(p<0.05) at day 21 as compared to day 12.   
Tables 6.13 and 6.14 provide a summary of the treatment effects following treatment 
with individual HMOs and concomitant administration of HMOs, respectively.   
 
DISCUSSION 
 
Beginning in the perinatal period and extending through the first year of life, the GI tract 
undergoes numerous morphological changes that influence its physiological functions (Carver 
and  Barness, 1996).  Human milk is known to provide trophic factors that influence maturation 
of the GI tract.   Recently, HMOs have been recognized as potential components within human 
milk which aid in the promotion of intestinal maturation.  In a study by Kuntz and colleagues, as 
well in the unpublished data from our laboratory group, it was found that neutral and acidic 
HMO fractions and some individual HMOs increased AP activity in pre-confluent HT-29 cells 
(Kuntz et al., 2008).   Additionally, our lab group has shown that incubation with 2'FL and LNnT 
enhances specific functional indices relevant to digestion and absorption in post-confluent CaCo-
2Bbe cells, a model of the well-differentiated intestinal villus cell.  To our knowledge, no data 
exists on the effects of specific HMO pairings and correlations between enhanced differentiation 
and digestive and absorptive functionality.  As such, these novel assessments will help to fill the 
gap in knowledge as it relates to understanding functional efficacy of HMO pairings in vitro.  
The present study investigated the effects of individual and concomitant administration of 2'FL, 
6'SL, and 3'SL on epithelial cell differentiation utilizing well established intestinal cell lines HT-
29 and Caco-2Bbe to model of the crypt-villus axis.   
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A cell culture model was the most appropriate model to assess the effects of HMOs on 
cellular kinetics along the crypt-villus axis.  Further, it allowed us to overcome the obstacle of 
limited availability of the HMOs of interest.   Although human milk contains as many as 200 
different oligosaccharides, one-tenth of those seem to make up nearly the entire 10-15g/L 
concentration present in human milk (Thurl et al., 2010).   The HMOs investigated in this trial 
were selected based on their predominance in human milk, with 2'FL being a dominant neutral 
oligosaccharide, and 6'SL and 3'SL comprising a large proportion of the acidic fraction.    
In this trial, we found that both individual and concomitant administration of HMOs 
inhibited proliferation in pre-confluent HT-29 cells.  Additionally, concomitant administration of 
the individual HMOs reduced proliferation in pre-confluent CaCo-2Bbe cells.  In both cell types, 
the total pooled HMO treatment at 4g /L reduced proliferation to levels equal to or slightly 
greater than the high dose concomitant group which also provided 4 g/L with 1 g/L from 3'SL, 
1g/L from 6'SL, and 2 g/L from 2'FL.  Overall, the reductions in proliferation were found to be 
additive when HMOs were added concomitantly.  Additionally, the high dose combination of the 
three individual HMOs (3'SL + 6'SL + 2'FL) affected proliferation to a similar extent of total 
pooled HMO sample.  This suggests that the three HMOs investigated in this trial were able to 
achieve close to the same effects of what was likely an excess of 100 different oligosaccharides 
in the total pooled HMO treatment group.  This novel finding is promising as it is very unlikely 
that infant formula can be supplemented with all oligosaccharides found in human milk, instead 
it is much more clinically and commercially feasible to determine a select few oligosaccharides 
that are able to promote close to the same effects as the whole.   
Interestingly, the inhibition of proliferation in the HT-29 cells was not associated with 
cell cycle arrest nor was differentiation enhanced as in our previous trial or that of Kuntz et. al 
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(2008).  AP activity, a marker of cell differentiation, was highly variable in HT-29 cells and no 
changes in cell cycle were noted between treatment groups.  Several factors should be considered 
in light of this.  First, research has shown that conditions such as limiting glucose and 
supplementing galactose promote HT-29 cell differentiation (Lindley et al., 2012) as does 
supplementation of HMOs (Kuntz et al., 2008).  It is possible that exposure of the 0 g/L control 
medium to the endotoxin removal columns may have introduced low levels of polymixin B from 
the column resin into the media.  The presence of low levels of polymixin B and/or the slight 
dilution of the culture media may have stimulated enhanced AP activity in the 0 g/L group.  As 
the 0g/L control received the same volume of medium passed through the columns as the 4 g/L 
pooled HMO group, it may be that the effects are more pronounced than the our previous HMO 
trial when the 0 mg/L controls received a volume matched to the 154 mg/L energy controls.  In 
this instance, utilizing the media group at the control instead of the 0 g/L group may add clarity 
to discrepancy between the current HMO trial and the previous trial in our laboratory.  Second, 
as there were no changes in the cell cycle kinetics in this trial, it may also be possible that the 
HMOs simply did not enhance differentiation in the pre-confluent HT-29 cells in this trial as 
they did previously.  As the levels of AP activity are 10 fold higher in in pre-confluent CaCo-
2Bbe cells and 40 fold higher in post-confluent CaCo-2Bbe cells, AP activity in the HT-29 cells 
may not be the best marker to assess differentiation within our in vitro model.  Translation into 
preclinical animal models is warranted to determine if HMO promote maturation within the GI 
tract. 
 Similar to our previous finding, pre-confluent Caco-2Bbe cells were less sensitive to 
inhibition of proliferation with only concomitant administration of HMOs having a significant 
effect.    Differentiation was however enhanced in the pre-confluent Caco-2Bbe cells with an 
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associated G0/G1 arrest.  These results are opposite those of Kuntz et al., where neutral and 
acidic HMO fractions arrested pre-confluent CaCo-2 cells in the G2/M phase.  However, it 
should be noted that they did not detect increased AP activity in pre-confluent CaCo-2 cells as 
compared to control.  Our results are in agreement with other trials in that the enhancement of 
differentiation in Caco-2Bbe cells is often associated with cell cycle arrest within the G0/G1 
phase (Houde et al., 2001).  As further evidence of enhanced differentiation occurring following 
G0/G1 arrest, we saw that the total pooled HMO sample significantly inhibited proliferation with 
associated cell cycle arrest in the S phase but there was not an associated enhancement of AP 
activity within the total HMO treatment group.   
Although 2'FL tended to enhance AP activity in 21 days post-confluent Caco-2Bbe cells 
in our previous trial, no effect was observed with any treatments in this trial.  Mirroring this, 
disaccharidase activities were also unchanged due to treatment.  Sucrase and lactase activity 
were however affected by time in culture.  Similar to other trials, it was found that lactase 
activity is higher in 12 day post-confluent cells as compared to 21 days and the opposite for 
sucrase activity (Olsen et al., 1996).    
 Finally, we reported that that treatment with HMOs did not increase apoptosis as has 
been previously reported by our laboratory and Kuntz and co-workers.  On the contrary, total 
HMO at 4g/L decreased apoptosis as compared to control.  Necrosis was also decreased in the 
total HMO group.  In light of this, the means by which apoptosis and necrosis were quantified in 
each trial should be discussed.  In both our lab and that of Kuntz and co-workers, caspase-3 was 
utilized as a marker of apoptosis in previous trials.  In this study, we quantified histone-
complexed DNA fragments from cell cytoplasm both before and after cell lysis to quantify both 
apoptosis and necrosis within the same cell population.  As genomic DNA fragmentation is 
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considered the hallmark of apoptosis, it is possible that utilizing caspase-3 activity as a marker of 
apoptosis in these post-confluent CaCo-2Bbe cells may have resulted in a falsely inflated 
proportion of apoptotic cells.  Or, it may also be possible that in this trial the lack of activation of 
apoptosis explains why there was no enhancement of functional indices, i.e. sucrase activity, as 
was observed in our previous trial.         
In summary, we observed that individual and concomitant administration of 2’FL, 3’SL 
and 6'SL inhibited proliferation in pre-confluent transformed small intestinal cell lines HT-29 
and Caco-2Bbe.  In the pre-confluent CaCo-2Bbe cells, the inhibition of proliferation was 
associated with cell cycle arrest within the G0/G1 phase and an enhancement of differentiation.  
No enhancement in differentiation was found in the pre-confluent HT-29 cells nor were there any 
changes in cell cycle.  Further, treatment did not affect post-confluent CaCo-2Bbe 
differentiation.  The combination of inhibition of proliferation and induction of differentiation 
suggests that HMOs promote maturation of the GI tract.  However, the physiological relevance 
of these maturational changes should be investigated within in vivo models.  As the availability 
of synthetic human milk oligosaccharides has improved over the last few years, pre-clinical and 
clinical trials utilizing targeted oligosaccharides are becoming more feasible.      
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TABLES AND FIGURES 
 
 
 
 
 
 
 
Table 6.1.  Effects of treatment on pre-confluent HT-29 cell proliferation.  Values represent 
the percent proliferation as compared to 0 mg/L control (set at 100%).  Control (0mg/L) cells: 
0.776 + 0.038.  Values are mean + SEM expressed as percentages.  Asterisks denote statistically 
significant decrease in treatment means as compared to 0 mg/L control by one-way ANOVA 
followed by Dunnett’s multiple comparison test (*p<0.05, **p<0.01, ***p<0.001).  2'FL, 2'-
fucosyllactose; 3'SL, 3'-sialyllactose; 6'SL, 6'-sialyllactose; LPS, Lipopolysaccharide; HMO, 
human milk oligosaccharide.     
  
Treatment 
3'SL 
(g/L) 
6'SL 
(g/L) 
2'FL 
(g/L) 
Mean 
(% of control) 
SEM 
(%) 
Control: 0 g/L    100.0 4.9 
Media       95.7 4.9 
LPS      99.4 4.9 
4 g/L total HMO             77.0 *** 4.9 
3'SL 0.2     95.4 4.9 
3'SL 1.0     94.0 4.9 
6'SL  0.4  101.0 4.9 
6'SL  1.0       91.3 * 4.9 
2'FL   0.2    94.9 4.9 
2'FL   2.0       91.0 * 4.9 
3'SL + 6'SL 0.2 0.4        90.1 * 4.9 
3'SL + 6'SL 1.0 1.0         86.6 ** 4.9 
3'SL + 2'FL 0.2  0.2    95.2 4.9 
3'SL + 2'FL 1.0  2.0      90.2 * 4.9 
6'SL + 2'FL  0.4 0.2    98.0 4.9 
6'SL + 2'FL  1.0 2.0         88.8 ** 4.9 
3'SL + 6'SL + 2'FL 0.2 0.4 0.2    97.9 4.9 
3'SL + 6'SL + 2'FL 1.0 1.0 2.0        89.1 ** 4.9 
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Figure 6.1. Effects of individual HMO on pre-confluent HT-29 cell proliferation.  Values 
represent the percent proliferation as compared to 0 mg/L control (set at 100%).  Control 
(0mg/L) cells: 0.776 + 0.038.  Values are mean + SEM expressed as percentages.  Bars with 
asterisks denote statistically significant decrease in pooled treatment means of the combined high 
and low treatments of individual HMO compared to 0 g/L control by one-way ANOVA 
(*p<0.05).  Both 3'SL and 2'FL significantly reduced pre-confluent HT-29 cell proliferation.  
2'FL, 2'-fucosyllactose; 3'SL, 3'-sialyllactose; 6'SL, 6'-sialyllactose.    
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Table 6.2.  Effects of HMO on pre-confluent CaCo-2Bbe cell proliferation.  Values represent 
the percent proliferation as compared to 0 mg/L control (set at 100%).  Control (0mg/L) cells: 
0.583 + 0.0174.  Values are mean + SEM expressed as percentages.  Asterisks denote 
statistically significant decrease in treatment means as compared to 0 mg/L control by one-way 
ANOVA followed by Dunnett’s multiple comparison test (**p<0.01, ***p<0.001).  2'FL, 2'-
fucosyllactose; 3'SL, 3'-sialyllactose; 6'SL, 6'-sialyllactose; LPS, Lipopolysaccharide; HMO, 
human milk oligosaccharide.  
Treatment 
3'SL 
(g/L) 
6'SL 
(g/L) 
2'FL 
(g/L) 
Mean 
(% of Control) 
SEM 
(%) 
Control: 0 g/L      100.0 3.0 
Media      103.5 3.0 
LPS      102.9 3.0 
4 g/L total HMO             89.5*** 3.0 
3'SL 0.2       98.9 3.0 
3'SL 1.0       97.6 3.0 
6'SL  0.4      97.9 3.0 
6'SL  1.0    100.6 3.0 
2'FL   0.2   103.5 3.0 
2'FL   2.0     97.6 3.0 
3'SL + 6'SL 0.2 0.4      98.6 3.0 
3'SL + 6'SL 1.0 1.0      94.7 3.0 
3'SL + 2'FL 0.2  0.2     99.8 3.0 
3'SL + 2'FL 1.0  2.0         91.9** 3.0 
6'SL + 2'FL  0.4 0.2     96.2 3.0 
6'SL + 2'FL  1.0 2.0        92.2** 3.0 
3'SL + 6'SL + 2'FL 0.2 0.4 0.2   100.3 3.0 
3'SL + 6'SL + 2'FL 1.0 1.0 2.0        89.9** 3.0 
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Table 6.3. Effects of treatment on pre-confluent HT-29 cell cycle kinetics.  Treatment did not affect cell cycle kinetics compared to 
control (0 mg/L) as analyzed by one-way ANOVA followed by Dunnett’s multiple comparison test. Values are mean + SEM.  2'FL, 
2'-fucosyllactose; 3'SL, 3'-sialyllactose; 6'SL, 6'-sialyllactose; LPS, Lipopolysaccharide; HMO, human milk oligosaccharide.   
  
Treatment 
3'SL 
(g/L) 
6'SL 
(g/L) 
2'FL 
(g/L) 
% G1      
Mean 
% G1 
SEM 
% S         
Mean 
%S 
SEM 
%G2       
Mean 
%G2 
SEM 
Control: 0 g/L       65.0 3.0 26.9 4.1 8.1 1.5 
Media       68.2 4.6 17.7 6.2 14.1 2.4 
LPS       67.3 4.6 18.2 6.2 14.5 2.4 
4 g/L total HMO       73.2 2.9 18.4 4.0 8.4 1.5 
3'SL 0.2     66.3 3.0 24.0 4.1 9.7 1.5 
3'SL 1.0     65.9 3.0 24.6 4.1 9.6 1.5 
6'SL   0.4   66.6 3.0 23.4 4.1 10.0 1.5 
6'SL   1.0   66.4 3.0 24.4 4.1 9.2 1.5 
2'FL     0.2 65.5 3.0 24.7 4.1 9.8 1.5 
2'FL     2.0 67.0 3.0 24.0 4.1 9.0 1.5 
3'SL + 6'SL 0.2 0.4   67.9 3.0 22.7 4.1 9.4 1.5 
3'SL + 6'SL 1.0 1.0   67.8 3.0 23.9 4.1 8.2 1.5 
3'SL + 2'FL 0.2   0.2 67.6 3.0 23.6 4.1 8.8 1.5 
3'SL + 2'FL 1.0   2.0 67.6 3.0 24.8 4.1 7.7 1.5 
6'SL + 2'FL   0.4 0.2 68.2 3.0 22.7 4.1 9.1 1.5 
6'SL + 2'FL   1.0 2.0 66.8 3.0 24.5 4.1 8.6 1.5 
3'SL + 6'SL + 2'FL 0.2 0.4 0.2 67.7 3.0 22.9 4.1 9.4 1.5 
3'SL + 6'SL + 2'FL 1.0 1.0 2.0 68.1 3.0 24.9 4.1 7.0 1.5 
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Table 6.4.  Effects of treatment on pre-confluent CaCo-2Bbe cell cycle kinetics.  Values are mean + SEM.  Asterisks denote 
statistically significant differences in treatment means as compared to 0 mg/L control by one-way ANOVA followed by Dunnett’s 
multiple comparison test (*p<0.05; **p<0.01; ***p<0.0001).  2'FL, 2'-fucosyllactose; 3'-SL, 3'sialyllactose; 6'SL, 6'-sialyllactose; 
LPS, Lipopolysaccharide; HMO, human milk oligosaccharide.  
  
Treatment 
3'SL 
(g/L) 
6'SL 
(g/L) 
2'FL 
(g/L) 
% G1     
Mean 
%G1 
SEM 
% S        
Mean 
%S 
SEM 
%G2      
Mean 
%G2 
SEM 
Control: 0 g/L     51.4 1.5 34.2 1.4 14.4 0.4 
Media       59.4* 2.0 29.7 1.9      10.9*** 0.5 
LPS      60.5* 2.0 28.1 1.9     11.4** 0.5 
4 g/L total HMO          46.1*** 1.5      37.7*** 1.4 16.2 0.4 
3'SL 0.2    52.7 1.5 34.5 1.4 12.8 0.4 
3'SL 1.0    54.0 1.5 33.8 1.4    12.2** 0.4 
6'SL  0.4   52.9 1.5 34.6 1.4   12.6* 0.4 
6'SL  1.0      54.7** 1.5 34.2 1.4      11.2*** 0.4 
2'FL   0.2     55.1** 1.5 33.5 1.4      11.4*** 0.4 
2'FL   2.0      57.1*** 1.5 32.3 1.4      10.1*** 0.4 
3'SL + 6'SL 0.2 0.4     54.3* 1.5 34.0 1.4    11.7** 0.4 
3'SL + 6'SL 1.0 1.0      55.4** 1.5   32.2* 1.4   12.3* 0.4 
3'SL + 2'FL 0.2  0.2   54.6* 1.5 33.3 1.4    12.2** 0.4 
3'SL + 2'FL 1.0  2.0     55.7** 1.5   32.0* 1.4    12.3** 0.4 
6'SL + 2'FL  0.4 0.2 53.9 1.5 33.5 1.4   12.6* 0.4 
6'SL + 2'FL  1.0 2.0   54.5* 1.5 32.5 1.4  13.1 0.4 
3'SL + 6'SL + 2'FL 0.2 0.4 0.2 53.8 1.5 33.5 1.4   12.6* 0.4 
3'SL + 6'SL + 2'FL 1.0 1.0 2.0 53.5 1.5 32.7 1.4  13.7 0.4 
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Table 6.5.  Effects of treatment on pre-confluent HT-29 cell differentiation.  Treatment did 
not increase differentiation compared to control (0 mg/L) as analyzed by one-way ANOVA 
followed by Dunnett’s multiple comparison test. Values are mean + SEM.  2’FL, 2’-
fucosyllactose; 3’SL, 3’-sialyllactose; 6’SL, 6’-sialyllactose; LPS, Lipopolysaccharide; HMO, 
human milk oligosaccharide.    
  
Treatment 
3'SL 
(g/L) 
6'SL 
(g/L) 
2'FL 
(g/L) 
Alkaline Phosphatase 
Activity (U/mg protein) 
SEM 
Control: 0 g/L    1.32 0.99 
Media    0.36 0.04 
LPS    0.34 0.04 
4 g/L total HMO    0.47 0.06 
3'SL 0.2   0.90 0.29 
3'SL 1.0   0.64 0.12 
6'SL  0.4  0.55 0.09 
6'SL  1.0  0.58 0.10 
2'FL   0.2 0.56 0.09 
2'FL   2.0 0.53 0.08 
3'SL + 6'SL 0.2 0.4  0.52 0.08 
3'SL + 6'SL 1.0 1.0  0.46 0.06 
3'SL + 2'FL 0.2  0.2 0.51 0.07 
3'SL + 2'FL 1.0  2.0 0.51 0.07 
6'SL + 2'FL  0.4 0.2 0.53 0.08 
6'SL + 2'FL  1.0 2.0 0.44 0.06 
3'SL + 6'SL + 2'FL 0.2 0.4 0.2 0.42 0.05 
3'SL + 6'SL + 2'FL 1.0 1.0 2.0 0.43 0.05 
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Table 6.6. Effects of treatment on pre-confluent CaCo-2Bbe cell differentiation. A 22.6% 
increase increase (p=0.049) in AP activity occurred in cells treated with 2.0 g/L 2'FL as 
compared to 0 g/L control.   The combinations of 3'SL and 6'SL tended (#) to increase 
differentiation (p=0.0595 and p=.0535).  Values are mean + SEM.  Asterisks denote statistically 
significant difference in treatment means as compared to 0 mg/L control by one-way ANOVA 
followed by Dunnett’s multiple comparison test (#p<0.01, *p<0.05).  2'FL, 2'-fucosyllactose; 
3'SL, 3'-sialyllactose; 6'SL, 6'-sialyllactose; LPS, Lipopolysaccharide; HMO, human milk 
oligosaccharide.   
  
Treatment 
3'SL 
(g/L) 
6'SL 
(g/L) 
2'FL 
(g/L) 
Alkaline Phosphatase 
Activity (U/mg protein) SE 
Control: 0 g/L    2.57 0.19 
Media    2.47 0.22 
LPS    2.30 0.22 
4 g/L total HMO    2.56 0.22 
3'SL 0.2   2.92 0.20 
3'SL 1.0   2.77 0.20 
6'SL  0.4  2.78 0.22 
6'SL  1.0  2.98 0.22 
2'FL   0.2 3.05 0.20 
2'FL   2.0    3.15 * 0.19 
3'SL + 6'SL 0.2 0.4     3.15 # 0.20 
3'SL + 6'SL 1.0 1.0     3.13 # 0.19 
3'SL + 2'FL 0.2  0.2 2.93 0.20 
3'SL + 2'FL 1.0  2.0 2.72 0.19 
6'SL + 2'FL  0.4 0.2 2.97 0.20 
6'SL + 2'FL  1.0 2.0 2.79 0.20 
3'SL + 6'SL + 2'FL 0.2 0.4 0.2 2.72 0.19 
3'SL + 6'SL + 2'FL 1.0 1.0 2.0 2.56 0.19 
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Figure 6.2. Effects of individual HMO on pre-confluent Caco-2Bbe cell differentiation.  
Values are mean + SEM.  Bars with asterisks denote statistically significant increase in pooled 
treatment means of the high and low dose treatments of individual HMO as compared to 0 mg/L 
control by one-way ANOVA (*p<0.05).  2’FL significantly increased pre-confluent Caco-2Bbe 
cell differentiation.  Pooled treatments of 3'SL, 6'SL, and 2'FL vs 0g/L control; *p=0.0059.  2'FL, 
2'-fucosyllactose; 3'SL, 3'-sialyllactose; 6'SL, 6'-sialyllactose. 
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Table 6.7.  Effects of treatment on post-confluent CaCo-2Bbe cell differentiation.  
Treatment did not increase differentiation compared to control (0 mg/L) as analyzed by one-way 
ANOVA followed by Dunnett’s multiple comparison test. Values are mean + SEM.  2'FL, 2 '-
fucosyllactose; 3'SL, 3'-sialyllactose; 6'SL, 6'-sialyllactose; LPS, Lipopolysaccharide; HMO, 
human milk oligosaccharide.
Treatment 
3'SL 
(g/L) 
6'SL 
(g/L) 
2'FL 
(g/L) 
Alkaline Phosphatase Activity 
(U/mg protein) SEM 
Control: 0 g/L    12.04 1.36 
Media    10.69 1.31 
LPS      8.37 1.36 
4 g/L total HMO    10.12 1.27 
3'SL 0.2   13.59 1.27 
3'SL 1.0   12.65 1.27 
6'SL  0.4  13.27 1.44 
6'SL  1.0  13.42 1.31 
2'FL   0.2 11.32 1.31 
2'FL   2.0 12.82 1.27 
3'SL + 6'SL 0.2 0.4  13.75 1.27 
3'SL + 6'SL 1.0 1.0  12.89 1.27 
3'SL + 2'FL 0.2  0.2 13.40 1.27 
3'SL + 2'FL 1.0  2.0 12.67 1.27 
6'SL + 2'FL  0.4 0.2 14.27 1.27 
6'SL + 2'FL  1.0 2.0 11.92 1.31 
3'SL + 6'SL + 2'FL 0.2 0.4 0.2 11.94 1.27 
3'SL + 6'SL + 2'FL 1.0 1.0 2.0 11.77 1.31 
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Table 6.8.  Effects of treatment on pre-confluent HT-29 Cell Apoptosis and Necrosis.  Values represent the percent apoptosis or 
necrosis as compared to 0 mg/L control (set at 100%).  Control (0mg/L) cell apoptosis: 0.127 + 0.0166.  Control (0mg/L) cell necrosis: 
0.145 + 0.0118.  Values are mean + SEM expressed as percentages.  Asterisks denote statistically significant differences either 
apoptosis or necrosis in treatment means as compared to 0 mg/L control by one-way ANOVA followed by Dunnett’s multiple 
comparison test (#p<0.1, *p<0.05, **p<0.01, ***p<0.001).  There was a significant increase in apoptois in the HMO treatment group 
(p<0.001).  There was a significant reduction is necrosis compared to the 0g/L control for HMO (p<0.001) and LPS (p=0.0439) and a 
trend for 2g/L of 2'FL (p=0.065).  2'FL, 2'-fucosyllactose; 3'SL, 3'-sialyllactose; 6'SL, 6'-sialyllactose; LPS, Lipopolysaccharide; 
HMO, human milk oligosaccharide.  
Treatment 
3'SL 
(g/L) 
6'SL 
(g/L) 
2'FL 
(g/L) 
Apoptosis 
(% of control) 
SEM 
(%) 
Necrosis 
(% of control) 
SEM 
(%) 
Control: 0 g/L    100.0 13.1 100.0 8.2 
Media    121.7 10.1   85.9 8.2 
LPS     138.2 13.1    69.5* 8.2 
4 g/L total HMO          279.3*** 10.7          4.0*** 7.0 
3'SL 0.2   118.1 13.1 105.6 8.2 
3'SL 1.0     86.7 13.1 102.1 8.8 
6'SL  0.4  111.5 13.1 116.2 8.2 
6'SL  1.0                         82.6 13.1  99.7 8.2 
2'FL   0.2   91.1 13.1  95.7 8.2 
2'FL   2.0   94.4 13.1     71.1 # 8.2 
3'SL + 6'SL 0.2 0.4  123.1 13.1  96.8 8.2 
3'SL + 6'SL 1.0 1.0  132.4 13.1  87.1 8.2 
3'SL + 2'FL 0.2  0.2   87.5 13.1  96.6 8.2 
3'SL + 2'FL 1.0  2.0   94.6 13.1  84.4 8.2 
6'SL + 2'FL  0.4 0.2   89.9 13.1 100.5 8.2 
6'SL + 2'FL  1.0 2.0 110.0 13.1  77.8 8.8 
3'SL + 6'SL + 2'FL 0.2 0.4 0.2 129.4 13.1 102.3 8.2 
3'SL + 6'SL + 2'FL 1.0 1.0 2.0 130.8 13.1   75.8 8.2 
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Table 6.9.  Effects of treatment on pre-confluent CaCo-2Bbe cell apoptosis and necrosis.  Values represent the percent apoptosis 
or necrosis as compared to 0 mg/L control (set at 100%).  Control (0mg/L) cell apoptosis: 0.0645 + 0.0114.  Control (0mg/L) cell 
necrosis: 0.0899 + 0.0204.  Values are mean + SEM expressed as percentages.  Asterisks denote statistically significant differences in 
apoptosis or necrosis in treatment means as compared to 0 mg/L control by one-way ANOVA followed by Dunnett’s multiple 
comparison test (***p<0.001).  There was a significant decrease in necrosis in the HMO treatment group (p<0.001). 2'FL, 2 '-
fucosyllactose; 3'SL, 3’-sialyllactose; 6'SL, 6'-sialyllactose; LPS, Lipopolysaccharide; HMO, human milk oligosaccharide.  
  
Treatment 
3'SL 
(g/L) 
6'SL 
(g/L) 
2'FL 
(g/L) 
Apoptosis 
(% of Control) 
SEM 
(%) 
Necrosis 
(% of Control) 
SEM 
(%) 
Control: 0 g/L      100.0 17.7   100.0 22.7 
Media      153.2 17.7   119.5 22.7 
LPS      144.9 17.7   109.6 22.7 
4 g/L total HMO        68.5 14.4          22.8*** 21.3 
3'SL 0.2     108.1 17.7   137.2 22.7 
3'SL 1.0       92.4 17.7   111.7 22.7 
6'SL  0.4    121.6 17.7  109.3 22.7 
6'SL  1.0    109.0 17.7  117.1 22.7 
2'FL   0.2   154.1 17.7    89.7 22.7 
2'FL   2.0   103.6 17.7   108.1 22.7 
3'SL + 6'SL 0.2 0.4    128.6 17.7   100.8 22.7 
3'SL + 6'SL 1.0 1.0    100.7 17.7   103.5 22.7 
3'SL + 2'FL 0.2  0.2   121.8 17.7   102.2 22.7 
3'SL + 2'FL 1.0  2.0   109.8 17.7     98.6 22.7 
6'SL + 2'FL  0.4 0.2     86.7 17.7   107.3 22.7 
6'SL + 2'FL  1.0 2.0   153.7 17.7     92.1 22.7 
3'SL + 6'SL + 2'FL 0.2 0.4 0.2   118.8 17.7   114.6 22.7 
3'SL + 6'SL + 2'FL 1.0 1.0 2.0   126.7 17.7     94.2 22.7 
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Table 6.10.  Effects of treatment on post-confluent CaCo-2Bbe cell apoptosis and necrosis.  Values represent the percent 
apoptosis or necrosis as compared to 0 mg/L control (set at 100%).  Control (0mg/L) cell apoptosis: 1.11 + 0.105.  Control (0mg/L) 
cell necrosis: 0.561 + 0.158.  Values are mean + SEM expressed as percentages.  Asterisks denote statistically significant differences 
in apoptosis or necrosis in treatment means as compared to 0 mg/L control by one-way ANOVA followed by Dunnett’s multiple 
comparison test (p<0.05; **p<0.01; ***p<0.001).  There was a significant decrease in necrosis in the HMO treatment group 
(p<0.001). 2'FL, 2'-fucosyllactose; 3'SL, 3'-sialyllactose; 6'SL, 6'-sialyllactose; LPS, Lipopolysaccharide; HMO, human milk 
oligosaccharide.    
  
Treatment 
3'SL 
(g/L) 
6'SL 
(g/L) 
2'FL 
(g/L) 
Apoptosis 
(% of Control) 
SEM 
(%) 
Necrosis 
(% of Control) 
SEM 
(%) 
Control: 0 g/L    100.0 9.4   100.0 28.2 
Media       91.5 8.7         65.7** 18.6 
LPS       94.2 9.1         67.6** 19.1 
4 g/L total HMO            60.5*** 5.8           31.7*** 8.9 
3'SL 0.2   105.4 10.0     76.7 21.6 
3'SL 1.0   109.3 10.4     80.9 22.8 
6'SL  0.4  105.8 10.0       72.8* 20.5 
6'SL  1.0     96.9 9.2         69.4** 19.6 
2'FL   0.2 104.6 9.9         68.9** 19.4 
2'FL   2.0 104.8 9.9         71.1** 20.0 
3'SL + 6'SL 0.2 0.4  106.0 10.0       75.4* 21.2 
3'SL + 6'SL 1.0 1.0  107.2 10.2     85.7 24.1 
3'SL + 2'FL 0.2  0.2 103.0 9.8        77.2# 21.7 
3'SL + 2'FL 1.0  2.0 106.7 10.1     82.9 23.4 
6'SL + 2'FL  0.4 0.2 100.1 9.5     80.8 22.8 
6'SL + 2'FL  1.0 2.0 103.0 9.8     85.2 24.0 
3'SL + 6'SL + 2'FL 0.2 0.4 0.2 104.4 9.9     80.6 22.7 
3'SL + 6'SL + 2'FL 1.0 1.0 2.0 105.5 10.0     85.4 24.1 
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Table 6.11. Effects of treatment on post-confluent CaCo-2Bbe cell sucrase activity at day 12 and day 21.  Treatment did not 
increase sucrase activity compared to control (0 mg/L) as analyzed by one-way ANOVA followed by Dunnett’s multiple comparison 
test. Values are mean + SEM. 2'FL, 2'-fucosyllactose; 3'SL, 3'-sialyllactose; 6'SL, 6'-sialyllactose; LPS, Lipopolysaccharide; HMO, 
human milk oligosaccharide.  
  
Treatment 
3'SL 
(g/L) 
6'SL 
(g/L) 
2'FL 
(g/L) 
Sucrase Activity 
(10
-2 
U/mg protein) 
Day 12 
SEM 
Sucrase Activity 
(10
-2 
U/mg protein) 
Day 21 
SEM 
Control: 0 g/L    1.78 0.13 2.53 0.22 
Media    1.82 0.25 1.95 0.33 
LPS    1.71 0.19 1.92 0.33 
4 g/L total HMO    1.58 0.10 1.96 0.22 
3'SL 0.2   1.93 0.15 2.47 0.22 
3'SL 1.0   1.85 0.14 2.29 0.21 
6'SL  0.4  1.91 0.15 2.37 0.23 
6'SL  1.0  1.75 0.13 2.39 0.23 
2'FL   0.2 1.72 0.12 2.28 0.22 
2'FL   2.0 1.61 0.11 2.43 0.22 
3'SL + 6'SL 0.2 0.4  1.86 0.14 2.37 0.22 
3'SL + 6'SL 1.0 1.0  1.67 0.12 2.51 0.22 
3'SL + 2'FL 0.2  0.2 1.85 0.14 2.49 0.22 
3'SL + 2'FL 1.0  2.0 1.68 0.12 2.40 0.22 
6'SL + 2'FL  0.4 0.2 1.58 0.10 2.42 0.22 
6'SL + 2'FL  1.0 2.0 1.49 0.09 2.31 0.23 
3'SL + 6'SL + 2'FL 0.2 0.4 0.2 1.98 0.16 2.46 0.22 
3'SL + 6'SL + 2'FL 1.0 1.0 2.0 1.70 0.12 2.45 0.23 
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Table 6.12. Effects of treatment on post-confluent CaCo-2Bbe cell lactase activity at day 12 and day 21.  Treatment did not 
increase lactase activity compared to control (0 mg/L) as analyzed by one-way ANOVA followed by Dunnett’s multiple comparison 
test. Values are mean + SEM.  2'FL, 2'-fucosyllactose; 3'SL, 3'-sialyllactose; 6'SL, 6'-sialyllactose; LPS, Lipopolysaccharide; HMO, 
human milk oligosaccharide.  
Treatment 
3'SL 
(g/L) 
6'SL 
(g/L) 
2'FL 
(g/L) 
Lactase Activity          
(10
-3 
U/mg protein)     
Day 12 
SEM 
Lactase Activity         
(10
-3 
U/mg protein)    
Day 21 
SEM 
Control: 0 g/L    7.59 0.67 6.86 0.55 
Media    9.72 2.13 6.22 0.70 
LPS    9.54 2.04 6.22 0.64 
4 g/L total HMO    7.98 0.74 6.78 0.51 
3'SL 0.2   7.39 0.63 7.01 0.55 
3'SL 1.0   7.32 0.62 6.61 0.55 
6'SL  0.4  8.06 0.75 6.40 0.60 
6'SL  1.0  7.91 0.73 5.17 0.60 
2'FL   0.2 7.32 0.62 5.41 0.55 
2'FL   2.0 6.84 0.54 6.94 0.55 
3'SL + 6'SL 0.2 0.4  8.49 0.84 6.23 0.55 
3'SL + 6'SL 1.0 1.0  8.10 0.76 6.56 0.55 
3'SL + 2'FL 0.2  0.2 8.76 0.90 7.01 0.55 
3'SL + 2'FL 1.0  2.0 9.64 1.09 6.93 0.55 
6'SL + 2'FL  0.4 0.2 7.04 0.57 6.78 0.55 
6'SL + 2'FL  1.0 2.0 8.05 0.75 6.79 0.60 
3'SL + 6'SL + 2'FL 0.2 0.4 0.2 9.62 1.09 5.85 0.55 
3'SL + 6'SL + 2'FL 1.0 1.0 2.0 9.20 0.99 7.71 0.60 
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Table 6.13.  Summary of individual HMO effects in each cell type.  2'FL, 2'-fucosyllactose; 
3'SL, 3'-sialyllactose; 6'SL, 6'-sialyllactose. 
 
 3’SL 6’SL 2’FL 
Pre-confluent HT-29 
     Proliferation  Decreased Decreased 
     Cell Cycle    
     Differentiation    
     Apoptosis    
     Necrosis   Decreased 
Pre-confluent CaCo-2Bbe 
     Proliferation    
     Cell Cycle    
     Differentiation   Increased 
     Apoptosis    
     Necrosis    
Post-confluent CaCo-2Bbe 
     Differentiation    
     Apoptosis    
     Necrosis  Decreased Decreased 
     Sucrase    
     Lactase    
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Table 6.14.  Summary of concomitant HMO effects in each cell type.  2'FL, 2'-fucosyllactose; 3'SL, 3'-sialyllactose; 6'SL, 6'-
sialyllactose. 
  
 3’SL + 6’SL 3’SL + 2’FL 6’SL + 2’FL 3’SL + 6’SL + 2’FL HMO 
Pre-confluent HT-29 
     Proliferation Decreased Decreased Decreased Decreased Decreased 
     Cell Cycle      
     Differentiation      
     Apoptosis     Increased 
     Necrosis     Decreased 
Pre-confluent CaCo-2Bbe 
     Proliferation  Decreased Decreased Decreased Decreased 
     Cell Cycle      
     Differentiation Increased Increased    
     Apoptosis      
     Necrosis     Decreased 
Post-confluent CaCo-2Bbe 
     Differentiation      
     Apoptosis     Decreased 
     Necrosis Decreased Decreased   Decreased 
     Sucrase      
     Lactase      
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CHAPTER 7 
 
GENERAL DISCUSSION, CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
It is well established that human milk is the optimal source of nutrition for the developing 
infant.  Human milk contains both microbes and oligosaccharides.  Research has shown that 
bifidobacteria predominate the microbiota of breast-fed infants.  Human milk oligosaccharides 
contribute to the bifidogenic properties of human milk, provide immune enhancing effects, and 
may enhance intestinal maturation.  However, research is still lacking on specific ingredients 
which may be added to infant formula to impart some of the benefits of breast feeding onto the 
formula fed infant.  Therefore, the specific aim of this thesis research was to assess 1) the effects 
of the probiotic Bifidobacterium animalis subspecies lactis, 2) the prebiotics galacto- and fructo-
oligosaccharides, and 3) the individual and combined effects of specific human milk 
oligosaccharides (HMOs) as means to narrow the compositional gap between human milk and 
infant formula.  This was explored through two clinical trials investigating the individual effects 
of the addition of a pro- or prebiotic to infant formula as well as through in vitro studies on the 
effects of human milk oligosaccharides on intestinal maturation.     
 
Hypothesis 1:  Consumption of an infant formula containing Bifidobacterium animalis 
subspecies lactis for 6 weeks will positively impact the intestinal-associated immune system and 
resident microbiota of formula-fed infants.   
 
Human milk contains a multitude of components including bacteria, nutrients that 
stimulate colonization of bifidobacteria within the intestine, and immunoglobulins (Goldman et 
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al., 1982; Heikkila and Saris, 2003; Martín et al., 2003; German et al., 2008a).  Thus, we 
investigated the effects of infant formula containing B. lactis and found it to be well tolerated by 
health infants and to stimulate intestinal immunity.  We found both enhanced fecal secretory IgA 
(sIgA) and vaccine-specific IgA following immunization in supplemented infants. 
Although the mechanism of the stimulation of sIgA by bifidobacteria remains largely 
unknown, there is speculation that the Gram-positive cell walls, which are rich in 
peptidoglycans, may have a role in the immune stimulation (Bakker-Zierikzee et al., 2006).  
Research from our lab group as well as others, suggests that induction of inflammation may play 
a role in immune maturation and enhanced IgA production (Kukkonen et al., 2010; Holscher et 
al., 2012a).  In addition to stimulating antibody production from B cells, probiotic 
supplementation has also been shown to induce regulatory dendritic cells and T cells (Kwon et 
al., 2010).  Bifidobacteria in particular have been found to stimulate maturation of dendritic cells, 
characterized by the release of tumor necrosis factor-a, interleukin (IL-10) and IL-12 (Hart et al., 
2004).  Overall, the low level production of cytokines stimulated by probiotic supplementation is 
thought to be beneifical as it is an immunoregulatory response, rather than an aggressive immune 
response.  It seems likely that a combined response from dendritic cells, T and B cells is 
necessary for induction of IgA production.  Further research is needed to clarify the mechanism 
by which B. lactis supplementation stimulates antibody production.   
While we have shown that B. lactis supplementation results in detectable levels of fecal 
B. lactis and increases fecal immunoglobulins with an enhanced effect in cesarean-section 
delivered infants, it would be beneficial to further investigate the composition of the fecal 
microbiota utilizing more sophisticated techniques such as pyrosequencing.  Specifically, 
investigation of the effects of supplementation on bifidobacteria species would be of interest due 
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to their association with enhanced sIgA.  A recent study by Hascoet and coworkers showed that a 
whey/casein ratio of 70/30 along with supplementation of Bifidobaceterium longum BL999 
resulted in similar fecal bifidobacteria counts between formula fed infants and breast fed infants 
along with a numeric increase in fecal secretory IgA in the formula fed groups (Hascoët et al., 
2011).  As the probiotic formula utilized in our study was whey based and enhanced fecal sIgA, it 
is possible that it also stimulated an increased proportion of fecal bifidobacteria.  However, in 
light of the findings by Hascoet and colleagues, it is possible that the lower phosphate, whey 
based formulas we investigated promoted bifidobacteria regardless of probiotic supplementation.  
Even so, it remains likely that delivery method in combination with feeding method resulted in 
differences in the respective microbiota of each group thus further study will better our 
understanding of the influence of diet and delivery method on the microbiota.    
Further, assessment of the fecal microbiota of our infant stool samples may add clarity to 
the effects seen in infants fed probiotic formula in our research trial.  Utilizing pyrosequencing to 
assess the fecal microbioata would allow for quantification of bacteria at the species and 
subspecies level.  These data are needed so that we may better understand the compositional 
differences between breast-fed and formula-fed infants as well as the impact of delivery method 
and probiotic feeding.   
In addition to exploring the microbial composition, it would also be interesting to follow-
up with the infants in the trial to see if the immune enhancing effects persist after cessation of 
study formula.  A study by Kuitunen and co-workers showed that infants supplemented with 
probiotics until 6 months of age and delivered by cesarean section had lower IgE-associated 
allergies at 5 years of age (Kuitunen et al., 2009).  A follow-up study in our infant population 
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would allow us to broaden our understanding of the potential long term effects of probiotic 
supplementation.     
 
Hypothesis 2:  Consumption of the galacto- and fructo-oligosaccharide-containing formula for 
six weeks will be well-tolerated and increase fecal bifidobacteria proportions in formula-fed 
infants.   
 
Infant formulas are often supplemented with prebiotic galacto- (GOS) and fructo-
oligosaccharides (FOS) in an effort to mimic the neutral oligosaccharide content of human milk 
which is known to contribute to the higher proportion of bifidobacteria within the microbiota of 
breastfed infants (Sela and  Mills, 2010).  A large number of clinical trials in infants have shown 
that supplementation of infant formula with GOS and FOS at varying concentrations and blends 
increases fecal bifidobacteria (Moro et al., 2002; Moro et al., 2003; Schmelzle et al., 2003; Ben 
et al., 2004; Boehm et al., 2004; Bakker-Zierikzee et al., 2005; Haarman and  Knol, 2005; Knol 
et al., 2005a; Knol et al., 2005b). Our laboratory has also demonstrated that infant formula 
containing GOS and FOS was well-tolerated by formula fed infants, increased the abundance and 
proportion of fecal bifidobacteria, and reduced fecal pH after six weeks of feeding (Holscher et 
al., 2012b).  
To expand on these findings, it would be beneficial to analyze the fecal bacterial 
populations of our infants using more sophisticated techniques such as pyrosequencing. Much of 
the research detailing the microbiota composition of infants is based on culture-based techniques.  
Although we utilized FISH, a culture-independent method, we were unable to discriminate many 
of the bacteria at the species level.  Pyrosequencing would allow us to further characterize the 
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bacteria present within the infant’s microbioita.  Assessment of the microbiome along with 
metagenomics analysis would also help us to better interpret the modifications in the SCFA 
profiles seen in the formula-fed and breastfed infant groups.   Utilizing the most up-to-date 
technologies to detail both microbes and microbial gene expression will help us to better 
understand the impact of diet on the human infant’s gastrointestinal tract.    
In addition to further characterization of the microbioita, the impact of prebiotic 
supplementation on immunity should also be assessed.  Recent infant formula trials have 
demonstrated that prebiotic supplementation enhances fecal secretory IgA levels, thus further 
assessment of immune enhancing effects of the GOS/FOS provided in our trial would add to this 
body of literature (Bakker-Zierikzee et al., 2006; Scholtens et al., 2008).   
  
Hypothesis 3:  Three individual HMO, 2'-fucosyllactose (2'FL), lacto-N-neotetraose (LNnT), 
and 6'-sialyllactose (6'SL), will induce epithelial differentiation in an in vitro epithelial model of 
the crypt-villus axis consisting of pre-confluent HT-29 cells, pre-confluent CaCo-2Bbe cells, and 
post-confluent CaCo-2Bbe cells.  
 
Human milk has both high structural diversity and concentration of oligosaccharides—
HMOs constitute up to 20 g/L of human milk, making them the third largest solid component 
(Coppa et al., 1999; Chaturvedi et al., 2001a; Ninonuevo et al., 2006; German et al., 2008; Thurl 
et al., 2010; Wu et al., 2010).  Infant formula completely lacks HMOs and milk based formulas 
provide only negligible amounts of free complex bovine oligosaccharides (Kunz et al., 2000).  
Previous studies have shown that HMOs influence maturation of intestinal epithelial cells 
making them an ingredient of interest for supplementation in infant formula (Kuntz et al., 2008).  
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Although greater than 200 different oligosaccharides structures are present in human milk, the 
neutral and acidic fractions are primarily made up of fourteen neutral and six acidic 
oligosaccharides with 2'FL and LNnT being dominant neutral oligosaccharides and 6’SL 
representing a large proportion of the acidic fraction (Thurl et al., 2010).  Thus, using an in vitro 
model of the crypt-villus axis we investigated the effect of the three individual HMO (2'FL, 
LNnT, and 6'SL) and found that they promoted intestinal cell maturation in vitro.   HMOs 
inhibited cellular proliferation, with 2'FL also providing stimulation for associated enhancement 
of epithelial differentiation in pre-confluent HT-29 cells.  Furthermore, this trial demonstrated 
that well differentiated Caco-2Bbe cells have greater digestive and barrier function when treated 
with physiological levels of 2'FL and LNnT, respectively.  In light of these findings, we 
investigated the synergistic effects of specific human milk oligosaccharides in our fourth 
hypothesis.        
  
Hypothesis 4:  Concomitant administration of HMO, 2'-fucosyllactose (2'FL), 3'-sialyllactose 
(3'SL) , and 6'-sialyllactose (6'SL), will induce epithelial differentiation and enhance maturation 
of the small intestine in vitro in an epithelial model of the crypt-villus axis consisting of pre-
confluent HT-29 cells, pre-confluent CaCo-2Bbe cells, and post-confluent CaCo-2Bbe cells.   
 
In this trial, we investigated the effects of concomitant administration of human milk 
oligosaccharides 2'FL, 3'SL, and 6'SL within our in vitro model of the small intestine.   It was 
again demonstrated that individual HMO inhibit cellular proliferation.  Further, combinations of 
HMO were shown to have with additive effects on the reduction in proliferation in both pre-
confluent HT-29 and CaCo-2Bbe cells.  Inhibition of proliferation was associated with cell cycle 
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arrest within the G0/G1 phase and an enhancement of differentiation in pre-confluent CaCo-
2Bbe cells, however there was no enhancement in differentiation in the pre-confluent HT-29 
cells nor were there any changes in cell cycle contrary to our previous findings.  Further, 
treatment did not affect post-confluent CaCo-2Bbe differentiation.  Apoptosis and necrosis were 
reduced in post-confluent CaCo-2Bbe cells treated with the 4 g/L pooled HMO sample, but this 
physiological change was not associated with a functional outcome.  The combination of 
inhibition of proliferation and induction of differentiation do suggests that HMOs promote 
maturation of the gastrointestinal (GI) tract in vitro.  However, the physiological relevance of 
these changes should be investigated within in vivo models.  Pre-clinical animal models, such as 
the short bowel syndrome (SBS) piglet model utilized by our laboratory group would allow for 
assessments to be made on structural and functional outcomes associated with enteral 
supplementation of HMO.  The piglet intestinal failure model has been shown to resemble the 
complications associated with short-bowel syndrome in human infants including the ability of 
the remaining residual bowel to adapt at both the cellular and tissue level (Heemskerk et al., 
1999; Bartholome et al., 2004).  Further, it has been shown that piglets recovering from intestinal 
resection fed polymeric infant formula supplemented with colostrum protein concentrate had 
improved intestinal adaption and overall growth as compared to control animals (Nagy et al., 
2004).  Additionally, unpublished data from our laboratory group has demonstrated that piglets 
provided 20% of their needs as colostrum had enhanced structural and functional outcomes 
within the GI tract as compared to piglets receiving sow-replacer formula during the first week 
of life.  As colostrum contains the richest source of human milk oligosaccharides (>20 g/L), it is 
possible that the oligosaccharides also played a role in stimulating the intestinal adaption.   
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Summary 
 
In summary, this thesis research has provided insight into the roles of probiotics, 
prebiotics, and HMOs in infant formulae.  It further substantiated the safety and efficacy of 
supplementation of pro- and prebiotics in infant formulae as well as provided valuable insight 
into novel infant formula ingredients, HMOs.  Thus, the information gained from this research 
strengthens our understanding of specific ingredients which may play a role in narrowing the 
functional and compositional gap between human milk and infant formula.    
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